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There is no doubt that without the ability of nature to form very stable aggregates of 
small molecules, or to form well-defined secondary, tertiary and even quaternary structures 
of macromolecules, life as we know it could not exist. The folding of polypeptide chains into 
secondary and eventually a bewildering array of tertiary structures results in protein 
molecules that are responsible for most of the biological interactions and functions found in 
nature.  
A logical next step is to mimic nature and to create nonbiological structures, involving 
intramolecular folding of unnatural molecules that are capable of mimicking or antagonizing 
the biological action(s) of a natural parent peptide, the so called: PEPTIDOMIMETICS. 
The development of these chemical model systems provides valuable insights into 
biomolecular structure and interactions by allowing researchers to simplify, isolate, and 
manipulate aspects of the complex molecular machinery of living systems. 
This thesis reports our efforts towards the design and synthesis of new 
peptidomimetics that act as secondary structure inducing elements with respect to the 
growing peptide chain (such as the β-hairpin mimics, discussed in Chapter II) or that are able 
to establish a defined secondary structure with biological targets. (i.e. the molecular tongs 
discussed in Chapter III).  
In Chapter II, a practical synthesis of a new bifunctional diketopiperazine scaffold, 
formally derived from the cyclization of L-aspartic acid and (S)-2,3-diaminopropionic acid, is 
reported. The scaffold bears a carboxylic acid functionality and an amino functionality in a cis 
relationship, which were used to grow peptide sequences. Conformational analysis of these 
peptidomimetic sequences reveals the formation of β-hairpin mimics and a reverse turn of 
the peptide chain. 
Synthetic peptides and peptidomimetics, containing the arginine-glycine-aspartate 
(RGD) sequence, have been used as inhibitors of integrin-ligand interactions. In many cases, 
the RGD sequence is combined with a secondary structure inducing element to form cyclic 
peptidomimetics. Therefore, the diketopiperazine scaffold was used to synthesise a cyclic 
peptidomimetic containing the RGD sequence that was tested as a selective ligand for the 
αvβ3 integrin receptor. 
In Chapter III, new peptidomimetics were introduced in molecular tongs for inhibiting 
HIV-1 protease dimerization. 
HIV-1 protease (PR) is a homodimer of two identical 99-amino acid subunits in which 
the active site is generated by self-assembly of these subunits. Remarkably, the antiparallel 
β-sheet formed by interdigitation of N- and C-terminal strands of each protease monomer, 
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which contributes over 75% to the stabilization force of the dimer, is found relatively free of 
mutations. By targeting this highly conserved dimerization interface, we demonstrated that 
HIV-1 protease dimer is disrupted with loss of activity by constrained molecular tongs that 
are able to establish a stable β-sheet structure with the N- and C-terminal of one PR 
monomer, mimicking the 4-stranded β-sheet structure of the protease dimer. Herein, we 
describe the design, synthesis, and enzyme inhibitory activity against wild-type HIV-1 PR, of 
new molecular tongs containing hydrazide-based peptidomimetic fragments in both arms, as 




KEYWORDS: peptidomimetics, diketopiperazine, reverse turn mimic, β-turn, β-peptides, β-  
hairpin, RGD, integrin, inhibitors, dimerization, β-sheet, HIV-1 protease, 
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Ac    Acetyl 
AcCN   Acetonitrile  
AIDS    Acquired Immunodeficiency Syndrome 
APCI    Atmospheric Pressure Chemical Ionization 
BIV    Bovine Immunodeficiency Virus 
Bn    Benzyl 
Boc    tert-Butyloxycarbonyl 
Boc2O   Di-tert-butyldicarbonate 
Boc-ON  2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
Cbz    Benzyloxycarbonyl 
CD    Circular Dichroism 
CHA    Cyclohexylamine 
COSY   Correlation Spectroscopy 
DABCYL  4-(4-Dimethylaminophenylazo)-benzoic acid 
DIAD    Diethyl azodicarboxylate   
DIPEA  Diisopropylethylamine 
DMEDA  N,N’-Dimethylethylamine 
DMSO  Dimethylsulfoxide 
DMSO-d6  Deuterated dimethylsulfoxide 
DMF    N,N-Dimethylformamide 
DKP    Diketopiperazine 
ECM    Extracellular Matrix 
EDANS  5-[(2-Aminoethyl)amino]naphthalene-1-sulfonic acid 
EDC    N-Ethyl-N’-[3-(dimethylamino)propyl]-carbodiimide 
Equiv   Equivalents 
ESI    Electrospray Ionization 
Et    Ethyl 
EtOAc   Ethyl acetate 
FAB    Fast Atom Bombardment 
FRET   Fluorescence Resonance Energy Transfer 
HAART  Highly Active Antiretroviral Therapy 
HATU O-(7-Azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium 
hexafluorophosphate 
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NATURAL AMINO ACIDS: 
 
AMINO ACID ONE-LETTER CODE THREE-LETTER CODE 
Alanine A Ala 
Arginine  R Arg 
Asparagine  N Asn 
Aspartic acid  D Asp 
Cysteine  C Cys 
Glutamine  Q Gln 
Glutamic acid  E Glu 
Glycine  G Gly 
Histidine  H His 
Isoleucine  I Ile 
Leucine L Leu 
Lysine K Lys 
Methionine M Met 
Phenylalanine F Phe 
Proline P Pro 
Serine S Ser 
Threonine T Thr 
Tryptophan W Trp 
Tyrosine Y Tyr 
Valine V Val 
 
 
UNNATURAL AMINO ACIDS:  Dab  Diaminobutyric acid 
Orn  Ornithine 
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I.  PROTEIN  STRUCTURE:  OVERVIEW 
  
Proteins play crucial roles in virtually all biological processes. Their significance and the 
remarkable scope of their activity are exemplified in the following functions: enzymatic 
catalysis, transport and storage, coordinated motion, mechanical support, immune 
protection, generation and transmission of nerve impulses and growth control, and 
differentiation. 
Despite the enormous functional diversity, all proteins are built of a single repertoire of 
20 amino acids (“building blocks”), meaning that all proteins consist of a linear arrangement 
of these “building blocks” assembled together into a polypeptide chain. However the flat “two-
dimensional” representation of the polypeptide chain fails to convey the beautiful three-
dimensional arrangement of proteins. In fact, it is the formation of regular secondary 
structures into complicated patterns of protein folding that ultimately leads to the 
characteristic functional properties of proteins: function arises from conformation.  
 
Four levels of protein structure are commonly defined (Figure I.1): 
 
(a) Primary structure: is the amino acid sequence of the protein. It arises from covalent 
linkage of individual amino acids via peptide bonds. Every protein is defined by a 
unique sequence of residues and all subsequent levels of organization rely on this 
primary level of structure. 
(b) Secondary structure:  it is the local conformation of the polypeptide chain or the 
spatial relationship of amino acid residues that are close together in the primary 
sequence. In globular proteins the three basic units of secondary structure are the: α-
helix, β-sheet and turns. 
(c) Tertiary structure: it represents the folded polypeptide chain. It is defined as the 
spatial arrangement of amino acid residues that are widely separated in the primary 
sequence. The formation of stable tertiary folds relies on interactions that differ in 
their relative strengths and frequency in proteins, like: disulfide bonds, hydrophobic 
effect, charge-charge interactions, hydrogen bonding and Van der Waals interactions. 
(d) Quaternary structure:  it happens in proteins that have more than one polypeptide 
chain (also called, subunit). The interaction between these subunits underscores the 
quaternary structure. The interactions responsible for this kind of protein structure are 
exactly the same as those responsible for tertiary structure, with the exception that 
they occur between one or more polypeptide chain. 
 




Figure I.1.  Four levels of organization within proteins: a) primary, b) secondary, c) tertiary, and d) quaternary. 
 
 
II.  SECONDARY  STRUCTURES 
 
II.1  α-HELIX 
 
The α-helix is the most common structural motif found in proteins, in fact, in globular 
proteins over 30% of all residues are found in helices. 
The α-helix is a “rodlike” structure in which the tightly coiled polypeptide main chain 
forms the inner part of the rod, and the side chains extend outwards. The regular α-helix 
(Figure I.2) has 3.6 residues per turn with each residue offset from the preceding residue by 
0.15 nm (this parameter is called the translation per residue distance). With a translation 
distance of 0.15 nm and 3.6 residues per turn the pitch (translation distance between any two 
corresponding atoms on the helix) of the α-helix is simply 0.54 nm (i.e. 3.6 x 0.15 nm). 
The values of φ and ψ (torsion or dihedral angles) adopted in the α-helix allow the 
backbone atoms to pack close together with few unfavourable contacts. More importantly this 
arrangement allows some of the backbone atoms to form hydrogen bonds that occur 
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between the carbonyl oxygen (acceptor) of one residue and the amide hydrogen (donor) of a 
residue four ahead in the polypeptide chain. In a regular helix the H-bonds are 0.286 nm long 
from oxygen to nitrogen atoms, linear and lie parallel to the helical axis.  
 
 
Figure I.2. Regular α-helix.1 
 
Hydrogen bonds have directionality that reflects the intrinsic polarization of the H-bond 
due to the electronegative oxygen atom. In a similar fashion the peptide bond also has 
polarity and the combined effect of these two parameters gives α-helix pronounced dipole 
moments. On average the amino end is positive whilst the carbonyl end is negative. 
 
 
II.2.  β-STRAND  AND  β-SHEETS 
 
The β-strand is the second type of periodic secondary structure and is an extended 
conformation when compared with the α-helix. In this kind of “zig-zag” conformation (labelled 
E on the Ramachandran plot, Figure I.3) the translation distance between similar atoms in 
neighbouring residues is of 0.34 nm, which leads to a pitch of repeated distance of nearly 0.7 
nm in a regular β-strand.2 
 





Figure I.3.  Ramachandran plot.3 
 
A single β-strand (Figure I.4a) is not stable largely because of the limited number of 
local stabilizing interactions. However, the backbone of N–H and C=O groups are oriented 
approximately perpendicular to the direction of the chain and therefore these groups are 
available for interstrand hydrogen bonding. Consequently, hydrogen bonds can be formed 
between two or more β-strands leading to a stable sheet arrangement. These β-sheets result 
in significant increase in the overall stability and in the formation of backbone H-bonds 
between adjacent stands that may involve residues widely separated in the primary 
sequence. Adjacent strands can align in antiparallel or parallel arrangements with the 
orientation established by determining the direction of the polypeptide from the N- to the C-
terminal. Antiparallel association of β-strands leads to colinear N–H ••• O=C hydrogen bonds 
and, consequently, to a network of 10- and 14-membered H-bonded rings, while a parallel 
association of strands leads to deviation from colinearity and to a network of 12-membered 
H-bonded rings (Figure I.4b and I.4c, respectively). On average β-sheets containing 
antiparallel strands are more common than sheets made up entirely of parallel strands. 
Antiparallel sheets are often formed from just two β-strands running in opposite directions 
whilst it is observed that at least four β-strands are required to form parallel sheets. 
Another amazing characteristic of β-sheets is the ability to produce amphipathic 
structures. This ability arises from the fact that the residues side chains in β-strands point at 
right angles alternately above and below the plane of the propagating polypeptide chain. As 
a consequence, patterns in amino acid character in the primary sequence of a segment that 
CHAPTER I  INTRODUCTION 
 6 
adopts a β-structure can lead to sidedness in the character of a β-sheet. Alternating polar 
and nonpolar residues will create an amphipathic sheet.  
 
   β−strand 
 
 
Figure I.4.  a) β-strand, b) antiparallel β-sheet and c) parallel β-sheet.1 
 
 
II.3.  TURNS  AS  ELEMENTS  OF  SECONDARY  STRUCTURE 
 
Reverse turns constitute one of the most common structural features in globular 
proteins. Turns have the universal role of enabling the polypeptide to change direction and in 
some cases to reverse back on itself. Besides its structural role in the protein fold, turns play 
also a key role in many of the molecular recognition events in biological systems. These 
events include interactions between peptide hormones and their receptors, antibodies and 
antigens, and regulatory enzymes and their corresponding substrates.4 
Reverse turns comprise the widely distributed β-turns, as well as the less prevalent γ-
turns and α-turns, and may include well-defined loops, such as Ω-loops.5 In current practice, 
the classification of a turn is based on the preferred torsion angles (φ and ψ) of the backbone 
chain, the position of the stabilizing hydrogen bond, and the length of the chain where the 
turn occurs.6 Analysis of the amino acid composition of turns reveals that bulky or branched 
side chains occur at very low frequencies. Instead, residues with small side chains as: 
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A γ-turn (Figure I.5) contains three residues and frequently links adjacent stands of 
antiparallel β-sheets. This kind of turn is characterized by the fact that the middle residue 
(i+1) does not participate in H-bonding whilst the first and third residues can form the final 
and initial H-bonds of the antiparallel β-stands, resulting in a 7-membered hydrogen-bonded 
ring. The change in direction of the polypeptide chain caused by a γ-turn is reflected in the 
values of φ and ψ for the central residue. As result of the size and conformational flexibility, 






TURN TYPE φi+1 ψi+1 
CLASSIC γ-TURN 70º to 85º -60º to -70º 
INVERSE γ-TURN -70º to -85º 60º to 70º 
 
Figure I.5. Torsion angles of classic and inverse γ-turns.7 
 
 
More commonly found in proteins and both linear and cyclic peptides are four residue 
turns, meaning β-turns. According to the last revaluation of the β-turn classification, nine 
distinct structural types were suggested based on the φ and ψ torsion angles in residues i+1 
and i+2 (Figure I.6).8 β-turns, may (classical β-turn) or may not (open β-turn) be stabilised by 
an intramolecular H-bond formed between the C=O of the first residue (i) and the N–H of the 
fourth residue (i+3) (abbreviated as 4 → 1 H-bond), giving rise to a 10-membered H-bonded 
ring. 
Two major classes of β-turns meet the stereochemical criteria with all peptide bonds 
trans: type I and type II (Figure I.6).2 These turns differ in the orientation of the peptide bond 
between the i+1 and i+2 residues, and consequently in the preferred side chain dispositions 
in these positions. In a type I turn, both the i+1 and i+2 positions accommodate L-residues, 
however proline preferentially fits in the i+2 position. Type I turns are the most prevalent in 
naturally occurring proteins. In a type II turn, the i+1 position can accommodate an L-residue 
(usually proline) and the i+2 position favours a glycine, small polar L-residues, or a D-residue 
because of steric clash with a side chain in the L-configuration. Proline in the i+1 position is a 
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strong sequence determinant for either a type I or II turn because of the restriction on the 
φ angle from the cyclic side chain.2 
Other turn geometries are also found. For example, the mirror images of types I and II 
are known respectively as types I’ and II’, and are energetically equivalent if residues of the 
opposite chirality occupy corresponding sequence positions. This means that, for example, a 
D-Pro residue would be favoured in position i+1 of a type I’ turn or in position i+2 of a type II’ 
turn. On the other hand, the intervening peptide bond (between residue i+1 and i+2) can 
adopt a cis conformation and still allow the turn to form an i to i+3 hydrogen bond and link to 
two β-strands. The resulting turn is called a type VI turn. 
 







TURN TYPE φi+1 ψi+1 φi+2 ψi+2 
I -60 -30 -90 0 
I’ 60 30 90 0 
II -60 120 80 0 
II’ 60 -120 -80 0 
IV -61 10 -53 17 
VIa1 -60 120 -90 0 
VIa2 -120 120 -60 0 
VIb -135 135 -75 160 
VIII -60 -30 -120 120 
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II.4  β-HAIRPIN 
 
β-Hairpins (Figure I.7) are the simplest units that can be constructed from β-strands 
and β-turns. These occur widely in proteins and make up the fundamental building blocks of 
antiparallel β-sheet. They are also structures found in many naturally occurring bioactive 




Figure I.7. Ribbon representation of a β-hairpin.9 
 
β-hairpins are stabilised by virtue of turn propensities of amino acid residues as well 
cross-strand interactions between the sequences flaking the turn. Favourable energetic 
contributions to the stability of these structural features have been demonstrate to include 
cross-strand aromatic-aromatic, aromatic-polar, H-bonding and salt-bridge interactions in 
combination with loop conformational propensity and entropy terms dependent on loop 
length.10 
A tetrapeptide can adopt a “minimal β-hairpin” conformation (Figure I.8) with residues 
i+1 and i+2 involved in the β-turn. This structure is characterized by the presence of 10- and 




Figure I.8. Minimal β-hairpin. 
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III. PEPTIDOMIMETICS OF PROTEIN SECONDARY STRUCTURES IN THE β-REGION 
 
There is no doubt that without the ability of nature to form very stable aggregates of 
small molecules, or to form well-defined secondary, tertiary and even quaternary structures 
of macromolecules, life as we know it could not exist. The folding of polypeptide chains into 
secondary and eventually a bewildering array of tertiary structures results in protein 
molecules that are responsible for most of the biological interactions and functions found in 
nature.  
A logical next step is evidently to mimic nature and to create nonbiologically derived 
molecules that fold into well-defined structures. Since the early 1990’s, a great deal of 
literature has been devoted to these types of biomimetic structures,11-17 involving 
intramolecular folding of unnatural molecules that are capable of mimicking or antagonizing 
the biological action(s) of a natural parent peptide, the so called: PEPTIDOMIMETICS. 
The development of these chemical model systems provides valuable insights into 
biomolecular structure and interactions by allowing researchers to simplify, isolate, and 
manipulate aspects of the complex molecular machinery of living systems. 
 
 
III.1.  β-AMINO  ACIDS  AND  β-PEPTIDES 
 
Oligomers composed exclusively of β-amino acids (so-called β-peptides) are probably 
the most thoroughly investigated peptidomimetics.11,12,14,15,18-20 They have the advantage of 
being: (i) stable to metabolism (exhibit slow microbial degradation, and are inherently stable 
to proteases and peptidases) and (ii)  able to mimic α-peptides in peptide-protein and protein-
protein interactions; they also fold into well-ordered secondary structures (helices, turns, and 
sheets) in solution even with short chain lengths.21 
β-Amino acids represent the smallest step away from α-amino acids in “backbone 
space”, and they can be subdivided into β3-, β2-, and β2,3-amino acids, depending upon the 




Figure I.9. β-Amino acid classification. 
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The conformations of β-peptides can be analysed in terms of the main chain torsional 
angles, which are assigned the ω, φ, θ, and ψ angles (Figure I.10) in the convention of 
Balaram.22 Folded helical or turnlike conformations of β-peptides require a gauche 
conformation about the θ torsion angle defined by the C2−C3 bond. A trans rotamer leads to a 




Figure I.10.  Definition for torsion angles in β-peptides. 
 
 
The effects of substituents on the local conformation of a β-amino acid are summarised 
in Figure I.11. The unsubstituted β-amino acid, β-alanine, is highly flexible, analogous to Gly 
in the α-amino acids. Alkyl substituents at positions 2 and 3 favour a gauche conformation 
about the C2−C3 bond.23 C2,C3-disubstituted amino acids are even more conformationally 
constrained and favour gauche conformers when the substituents are anti (aldol convention). 
When substituents at C2 and C3 are syn, a trans conformation about the C2−C3 bond is 
favoured, which encourages the formation of sheet-like structures.23-25 It is interesting to 
consider C2,2- and C3,3-disubstituted β-amino acids in light of the well-known tendency of 
dialkyl α-amino acids such as α-aminoisobutyric acid to induce helical and turn-like 














































Figure I.11. Effect of substituents on the torsional angle, θ.15 
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β-SHEET-LIKE  CONFORMATIONS  OF  β-PEPTIDES 
 
Besides helical arrangements,29 β-peptides, like the α-peptidic prototypes, can also 
adopt non-aggregating extended-chain structures,30 can assemble to parallel25,31,32 (Figure 
I.12a) and antiparallel24,25,32-34 pleated sheets (the latter being inherently part of a hairpin turn, 









Figure I.12.  a) Parallel pleated sheet of a β-tripeptide,25 b) a β-octapeptide folded into a hairpin-like conformation 
with antiparallel β-sheet-type H-bonding interaction (Zn2+-enforced turn structure).33 
 
 
There are in principle two types of sheet secondary structure available to β-peptides, 
one in which each residue has an anti C2−C3 torsion angle and another in which each residue 
has a gauche C2−C3 torsion angle.24 The “anti” type of β-peptide sheet is distinctive since all 
backbone carbonyls are oriented in approximately the same direction, which would endow 
the resulting sheet with a net dipole, rendering the β-peptidic sheet polar. In contrast, β-
sheets formed by α-peptides have little or no net dipole because the backbone carbonyls 
alternate in direction along each strand. β-Peptide sheets formed by residues with gauche 
C2−C3 torsion angles would lack a net dipole for the same reason. 
In the last decade significant progresses have been made toward the goal of preparing 
β-peptides with sheet-like conformations. 
Initial studies performed in Gellman’s laboratory led to the identification of an optimal β-
amino acid substitution pattern for the strand residues in an antiparallel sheet through the 
use of hairpin-forming molecules containing non-β-peptide loop segments.24 It was 
demonstrated that disubstituted β-amino acid residues with syn configuration (syn β2,3-amino 
acids) favours anti C2−C3 torsion angles because the alkyl substituents at these positions can 
adopt an energetically favourable anti-orientation only when the N−C3−C2−C torsion angle is 
180°, and therefore these residues have the highest  sheet-forming propensity. Later on, the 
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same group has also described a loop segment containing a heterochiral dipeptide, 
composed of the Pro analogue nipecotic acid residues, that adopts a reverse turn 
conformation and promotes hairpin formation.35 The resulting tetrapeptide 1 (Figure I.13), 
contains exclusively β-amino acid residues, and represented the first autonomously folded β-
peptide sheet. It was also demonstrated that homochiral dinipecotic acid segments (i.e., both 
nipecotic acid residues with the same absolute configuration) prevented sheet interactions 
between the terminal residues. 
Seebach’s group used a similar strategy to stabilize the formation of β-peptide hairpins 
in organic solvent.25 They prepared hexapeptide 2 (also Figure I.13) with the first two and last 
two residues being syn-C2,C3-disubstituted β-amino acids. Significantly, Seebach et al. found 
that a dipeptide sequence containing a β2- followed by a β3-amino acid stabilised a reverse 
turn that is different from the reverse turn formed by Gellman’s heterochiral dinipecotic acid 
segment (10-membered ring hydrogen bond in the former vs 12-membered ring hydrogen 
bond in the latter).  
The availability of two distinct types of reverse turn among β-peptides highlights the 
greater conformational diversity in this foldamer family relative to α-peptides in which only a 










































Figure I.13.  Different hydrogen-bond patterns in β-peptide hairpins. 
 
Stable β-hairpins generated from hybrid peptide sequences containing both α- and β-
amino acids have also been reported.  
Balaram and co-workers were the first to describe hairpin-turn formation involving 
mixed α/β-peptides. They reported an α/β-hybrid octapeptide 3 containing the conventional 
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D-Pro-Gly α-peptidic turn motif and carrying β-amino acid residues (β3Val or β3Leu)i on 
opposite sides of the antiparallel sheet part of the hairpin.36 In this case, a hydrogen bond 
between the C=O of residue i and the N–H of residue i+3 of the β-turn is formed resulting in 
a 10-membered H-bonded ring (Figure I.14). 
Seebach and co-workers have also reported hairpin-turn secondary structures of mixed 
α/β-peptides containing novel types of turn structures with 9- and 10-membered H-bonded 
rings.37 The hexapeptide 4 consists of β3-homo-amino, β2-homo-amino, and α-amino acids 
with a central β2−β3 segment, whereas heptapeptide 5 is composed of β2-homo-amino and α-
amino acids in alternating positions. Despite their small size, these two peptides showed 
stable hairpin structures showing a turn with a 10-membered H-bonded ring induced by the 
β2/β3 unit, for 4, and a turn involving the β2Metii and Lys units with a (formally) 9-membered 
H-bonded ring, for 5 (also Figure I.14). 
  
 
Figure I.14. Schematic representation of hairpin structures involving mixed α/β-peptides. 
 
The enzymatic stability and the variety of secondary structures discovered push the 
door wide open for the application of β-peptides as peptidomimetics in medicinal chemistry. 
Once again, Seebach’s group synthesised cyclic β-tetrapeptide 638 (Figure I.15) that was 
able to mimic the α-peptide hormone somatostatin, a peptide responsible for several 
important biological functions, like the regulation of the release of growth hormone and 
insulin. Compound 6 also displayed biological activity and micromolar affinity for human 
receptors.38 
 
                                                 
i  β3Val: β3-(R)-homovaline and β3Leu: β3-(S)-homoleucine. 
ii β2Met: β2-(S)-homomethionine. 




Figure I.15.  a) The α-peptide hormone somatostatin and b) loop analogue, cyclic β-tetrapeptide 6.38 
 
 
III.2.  β-TURN  MIMETICS 
 
In the previous section the role of specific β-amino acids in the nucleation of secondary 
structure systems was discussed. However, this function may also be performed by synthetic 
organic templates. Molecular templates may be used in two distinct ways in generating 
folded polypeptides.39 First, the designed templates may provide a preorganized folding 
nucleus which can position hydrogen-bonding groups in a manner that permits propagation 
of a regular secondary structure. Second, templates may be used to organize prefabricated 
modules of secondary structure in order to generate compact tertiary folds. Regarding the 
first case, considerable efforts have been devoted towards the development of structures 
able to mimic or stabilize β-turns, either in linear or cyclic peptides.  
β-turn mimetics can be categorized into two distinct groups: internal and external.40 
Internal mimetics are constructed upon skeletons that lie within the pseudo 10-membered 
ring framework of the turn motif, and place an emphasis on side chain presentation as 
displayed by the pioneering structures of Kahn41 (7, Figure I.16). On the other hand, the 
external mimetics are often constructed on dipeptide isostere skeletons that do not display 
side chain functionality at the central i+1 and i+2 positions. These structures reduce the 
conformational flexibility of a peptide with a rigidified skeleton that lies outside of the turn’s 
general framework, and are primarily employed to orientate the surrounding peptide chain 
into a turn conformation. Structures 8 and 9 developed by Freidinger42 and Nagai,43 








Figure I.16.  Internal (7) and external (8 and 9) turn mimetics. 
 
In the last two decades a considerable amount or work has been published in terms of 
β-turn mimetics leading to an enormous structural diversity. Figure I.17 shows a 
representative set of these structures that can include: spirocyclic β-lactams 10,44,45 
spirobarbiturates 11,46 piperidinone derivatives 12,47 sugar amino acids (1348 and 1449), 
BTAa (Bicycles from Tartaric Acid and Amino acids) scaffolds 15,50 aza-, thiaza-, and oxaza-
bicycloalkane amino acids (16,51-53 17,54,55 and 18,56-58 respectively), other bicyclic lactams 
19,59,60 saturated (2061) and unsaturated (2162) 10-membered lactams, bicyclic 




Figure I.17.  Examples of β-turn mimetics (Part I). 
 




Figure I.17.  Examples of β-turn mimetics (Part II). 
 
 
III.3.  β-STRAND  MIMETICS 
 
Mimicking β-strands to antagonize β-sheet formation or recognition may represent a 
viable therapeutic strategy toward the prevention or treatment of diseases associated with β-
sheet structures.  
With respect to conformational stability, the arrangement of peptides into β-strands for 
recognition by biomolecular targets is either a chance event in which the receptor captures 
the small percentage of peptide present in a β-strand conformation, or in alternative the 
receptor plays an active role in contorting the peptide into the preferred strand shape.65 It is 
known that molecules, which are conformationally preorganized or fixed into a shape that is 
recognized by a receptor, can have higher affinity for that receptor due to the reduced 
entropy penalty for adopting the receptor-binding shape. It is therefore surprising that, unlike 
the case for turns and helices, there are relatively few reported conformationally restricted, 
surrogates for the β-strand. 
One minimalist approach to conformational stability involves restricting peptide freedom 
though cyclization,66 either via side chain to side chain, side chain to main chain, or main 
chain to main chain linkages, to form macrocycles. Nature frequently uses cyclization to force 
peptides into bioactive conformations.67 Cyclic peptides also have the advantages over linear 
peptides of being more resistant to amide bond cleavage by proteolytic enzymes and of 
being more conformationally restrained or less flexible.65  
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Alternatively, conformational constraints can be incorporated in peptide sequences. 
Nature frequently moulds peptides into turn shapes by replacing amino acid components with 
a wide variety of constraints such as disulfides, double bonds, N-methyl amino acids, D-
amino acids, aromatic and heterocyclic rings, often in conjunction with cyclization.67,68 Similar 
conformational constraints could be used to synthetically mimic the peptide β-strand. For 
example, one or more amino acid residues could be replaced in a peptide sequence by one 
or more rigid organic units. 
Schrader et al. were the first to report an artificial template (3-aminopyrazole derivative) 
able to stabilize the β-sheet conformation in N/C-protected dipeptides by purely 
intermolecular interactions.69 In the complex reported (24, Figure I.18a). two aminopyrazole 
molecules laid exactly above and below the peptide backbone. Binding to the top face of the 
peptide is strongly favoured because it forms three cooperative hydrogen bonds 
simultaneously to the receptor molecule, whereas the bottom face has only two. Later on, 
they introduced an additional carboxylate into the aminopyrazole structure that allowed them 
to produce aminopyrazole oligomers (25, Figure I.18b), with a hydrogen pattern 
complementary to the top and bottom face of a peptide in β-sheet conformation.70,71 
 
 
Figure I.18.  a) First generation of 3-aminopyrazole derivatives, b) aminopyrazole oligomers for β-sheet 
stabilization of peptides. 
 
 
A single-strand mimic was introduced by Hirschmann and co-workers, based on the 
pyrrolinone scaffold, which mimics both the functionality and the side chain orientation of a 
peptide in the extended conformation (26, Figure I.19).72,73  
 




Figure I.19.  Design of a pyrrolinone-based peptidomimetic possessing the conformation of a β-strand. 
 
 
Bartlett and co-workers have developed a cyclic amino acid surrogate (1,2-dihydro-
3(6H)-pyridinone or “@”-unit, Figure I.20) that was designed to mimic the extended 
conformation of a peptide unit and to provide hydrogen bond donor and acceptor functions 
conducive to β-sheet formation.74,75 The “@”-unit has then incorporated into oligomers 
alternating with peptide units. The resulting “@-tides” (27, Figure I.20) revealed an enhanced 
propensity to dimerize in comparison to a related peptide.  
 
   
 
Figure I.20.  Dimerization of linear “@-tides”. 
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III.4.  β-HAIRPIN  AND  β-SHEET  MIMETICS 
 
Although β-sheets are key structural elements in the three dimensional structure and 
biological activity of proteins, the factors that contribute to β-sheet structure and stability are 
still not as well understood as in the case of α-helices. Unlike helices, where local 
conformational effects and amino acids not further apart than 3−4 residues play a decisive 
role in dictating structural stability, the β-sheet can be viewed partly as a tertiary structure, 
with complex geometry and interactions between residues far apart in primary sequence. 
This implies that a scale for the intrinsic sheet-forming propensities of residues is not as 
easily obtained as for the α-helices, and therefore it is difficult to predict the pattern of protein 
folding from the sequence of amino acids. 
Generally, preparation of chemical models of β-sheet is difficult due to the complexity 
of their folding and their propensity for self-association, therefore, several researchers have 
developed chimeric peptides that display β-hairpin-like or β-sheet-like conformations in which 
a strand or a loop is replaced by a peptidomimetic segment.  
In 1988, Kemp et al. reported the first example of antiparallel β-sheet formation with 
urea functionalized peptide conjugates of 2,8-diaminoepindolidione76 (Figure I.21). The 
presence of two D-Ala-Pro loops led to the three-stranded antiparallel 28 sheet in which two 




Figure I.21 . First example of β-sheet mimics containing a peptidomimetic strand by Kemp et al. 
 
 
In 1993, Kelly et al. reported the first model system in which a molecular scaffold was 
employed to create the β-sheet-like structure of attached peptide chains and serve as 
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substitute for the β-turn.78 The authors used a dibenzofuran-based amino acid 2979 to 
induced β-hairpin-like antiparallel pairing of two short peptide strands (30, Figure I.22) in 
aqueous solution. It is noteworthy that this achievement was coincident with the discovery by 

































Figure I.22. Kelly’s dibenzofuran peptidomimetic acting as β-hairpin inducer. 
 
Kelly’s studies on related peptides containing residue 29 suggested that 29 needs to be 
flanked by two α-amino acid residues bearing relatively large hydrophobic side chains (e.g. 
Leu, Val, Phe, etc.). In this case the aromatic template and the side chains of the flanking α-
amino acids form a hydrophobic cluster which appears to be sufficient to nucleate β-sheet 
folding in aqueous medium. Based on this conclusion, template 29 was used to create an 
acyclic β-sheet peptidomimetic 3181 with sufficient structural integrity to exhibit antimicrobial 
activity equivalent to that of gramicidin S (Figure I.23), a cyclic peptide that adopts an 





Figure I.23.  a) Gramicidin S and b) acyclic peptidomimetic analogue. 
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These initial studies push the door wide open for the application of peptidomimetics in 
chemical models of β-hairpins and β-sheets. Encouraged by the success of Kemp and Kelly, 
several research groups have dedicated their efforts to continue the development of such 
peptidomimetic systems. For example, König and co-workers have developed a model 
system containing Gellman’s β-turn fragment (D-Pro-Gly), a peptidic and a peptidomimetic β-
strand formed by methoxypyrrole amino acids - MOPAS83 (Figure I.24). System 32 adopts a 





Figure I.24.  Konig’s model system containing methoxypyrrole amino acids. 
 
 
Bartlett and co-workers have demonstrated that the presence of a 1,6-dihydro-3(2H)-
pyridinone moiety (the @-unit, previously described in Section III.3, page 19) as an amino 
acid replacement at the i-1 or i+4 positions relative to a β-turn (in this case, D-Pro-Ala) 
strongly stabilizes the β-hairpin conformation (33, Figure I.25) in a variety of short peptides in 
both nonpolar and hydroxylic solvents.84,85 Moreover, the vinylogous amide moiety of the @-
unit produces a distinctive CD signal at 280 nm that is sensitive to conformational changes, 
providing a convenient spectroscopic handle for investigating sequence and side-chain 
effects on β-hairpin folding.86 
 

























































Figure I.25.  Folding of @-tide-peptide into β-hairpin structures. 
 
 
Scolastico and co-workers have incorporated different bicyclic lactam in N-acetylated 
hexapeptide mimics. They have demonstrated that the nature of the bicyclic lactam 
determines not only the turn motifs but also the folding patterns of these constrained 
peptides. For example, the (5,6)-bicyclic lactam derivative 34 is characterized by a type-II’ β-
turn (C=O3 ••• H6–N) and is a very compact intramolecularly H-bonded structure (Figure 
I.26). On the other hand, the (5,7)-bicyclic lactam derivative 35 is characterized by an inverse 




Figure I.26.  Different hydrogen-bonding patterns in N-acetylated hexapeptide mimics. 
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In the last years two groups have reported the incorporation of a photoswitchable 
azobenzene as a turn mimic. Both groups found that the cis-azobenzene maintained a β-
hairpin structure, but that the trans isomer disrupted folding (Figure I.27). The system 
designed by Hilvert and co-workers88,89 was found to aggregate in the trans configuration, 
whereas no aggregation was observed for either isomer in the system designed by Renner 




Figure I.27.  Light-induced isomerisation of azobenzene-based peptides.90 
 
 
In a similar manner, Gogoll and co-workers developed a stilbene-type β-hairpin mimetic 
capable of light-triggered conformational changes between an unfolded structure and a 
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According to the authors, stilbene derivatives 36 are in many ways superior to 
azobenzenes compounds, which are known to undergo cis-trans isomerisation and are more 




In terms of cyclic β-hairpin peptidomimetics, a considerable amount of work has been 
developed by Robinson and co-workers. Since the end of the 90’s they have designed, 
synthesised, and studied the conformational preferences of several β-hairpin mimetics 
containing different templates, like, bicyclic diketopiperazine-based templates92,93 and the 
heterochiral D-Pro-L-Pro dipeptide unit.94-97  
In particular the mimetics containing the β-hairpin-inducing template, D-Pro-L-Pro 
dipeptide, revealed very interesting biological applications as: trypsin inhibitors,98 
antibacterial agents against Gram-positive and Gram-negative bacteria,95,99 BIV and HIV-1 
Tat−TAR RNA (Tat-Transactivator Response Element RNA) inhibitors,96 HIV-1 RRE (Rev 




Figure I.29.  a) Structure of the β-hairpin mimetic 37 (Val2 in red); b) BIV Tat peptide (yellow) adopts a β-hairpin 
conformation upon binding to the TAR RNA; c) model of the 37-TAR complex (green with Val2 in red), with β-
hairpin mimetic 37 bound in the major groove of BIV TAR RNA.96 
 
 
                                                 
iii CXCR4 is an α-chemokine receptor specific for stromal-derived-factor-1 (SDF-1). This receptor is one of several 
chemokine receptors that HIV isolates can use to infect CD4+ T-cells. 
a) b) c) 
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Finally, it is not possible to close this section without mentioning the enormous work 
developed by Nowick and co-workers in β-sheet mimetics field, during the last 16 years. 
Their first paper, published in 1992, described an intramolecularly hydrogen-bonded 
oligourea molecular scaffold that presents a series of amino acids or other groups in an 
orderly fashion.101 This achievement represented one of the first examples of synthetic 
“foldamers”. Later on, the attachment of two peptide strands to a urea-based scaffold led to 
Nowick’s first artificial β-sheet 38 (Figure I.30), which folded in chloroform solution to mimic 




Figure I.30. Nowick’s first artificial β-sheet showing the urea-based scaffold (blue box). 
 
 
Nowick and co-workers also developed a series of molecular templates based on 5-
amino-2-methoxybenzoic acid, and related hydrazine derivatives, to mimic and complement 
the hydrogen-bonding functionality of peptide strands and block unfilled hydrogen-bonding 
valences. The 2-methoxy group played the dual roles of blocking a H-bond donor group and 
providing organization through intramolecular hydrogen bonding within these β-strand 
mimics. By combining the urea-based molecular scaffold with these β-strand mimics, they 
created a variety of artificial β-sheets (e.g., 39, Figure I.31) that fold into well-defined 
structures in chloroform and other non-competitive organic solvents.103-107 Singly-templated 
structure 38 (Figure I.30) exhibits a parallel β-sheet, while doubly-templated structure 39 
(Figure I.31) mimics the structure and hydrogen-bonding pattern of an antiparallel β-sheet. 
 






































Figure I.31. Artificial β-sheet showing the 5-amino-2-methoxybenzoic hydrazide unit (red box). 
 
 
Aiming to create larger and more complex artificial β-sheets, Nowick and co-workers 
combined oligourea molecular scaffolds and β-strand mimics to make molecules that mimic 
the structure and hydrogen-bonding patterns of protein β-sheets. Three- and four-stranded 
artificial β-sheets were then created. These structures combine features of doubly-templated 
artificial β-sheet 39 (Figure I.31) with features of singly-templated artificial β-sheet 38 (Figure 
I.30), meaning that they are mixed β-sheets, exhibiting both parallel and antiparallel 




Figure I.32.  Three-stranded artificial β-sheets, exhibiting antiparallel and parallel H-bonding patterns. 
 
 
More recently, Nowick’s laboratory has developed a new class of cyclic models of 
protein β-sheets (41, Figure I.33). These “cyclic modular β-sheets” are 42-membered rings 
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that contain a pentapeptide in the “upper” strand, the amino acid Hao110,111 and two α-amino 
acids in the “lower” strand, and two δ-linked ornithine β-turn mimics.112 Hao is a relatively 
rigid tripeptide β-strand mimic that serves as a template for the folding of the upper strand 
and blocks the lower strand to minimize edge-to-edge aggregation. The two α-amino acids in 
the lower strand permit tuning the folding and solubility of the cyclic modular β-sheets without 
changing the upper strand. The two δ-linked ornithine (δOrn) residues form hairpin turns and 
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I.  DIKETOPIPERAZINES (DKPS) 
 
I.1.  INTRODUCTION 
 
Although diketopiperazines (DKPs) have been known since the beginning of the 
century, only now they have attracted considerable interest with respect to their biological 
properties.1 As result of the structural similarity of diketopiperazines to peptides, their 
appearance in biologically active natural products has inspired medicinal chemists to use 
DKPs to circumvent the limitations of peptides. Constraining the nitrogen atoms of an α-
amino amide into a DKP ring (Figure II.1) alters its physical properties, reduces the 
susceptibility to metabolic amide bond cleavage reactions and induce conformational rigidity. 
These changes in structural and physical properties, as well as the presence of groups that 
can act as donors and acceptors of hydrogen bonds enhance favourable interactions with 
biological targets. Moreover, diketopiperazines are simple heterocyclic scaffolds in which 
diversity can be introduced and stereochemically controlled at up to four positions and they 
can be prepared from readily available α-amino acids using conventional synthetic 
procedures. In view of all these properties it is understandable why DKPs are seen as 
privileged structures for the discovery of new lead compounds and they have been exploited 
in combinatorial chemistry strategies aimed at accelerating the drug discovery process.2 In 
addition, DKPs have been used as organic catalysts for asymmetric hydrocyanation of 
aldehydes3 and imines,4 and have been shown to be useful scaffolds for the rational design 




Figure II.1.  Diketopiperazine isomers. 
 
 
 Diketopiperazines, the smallest cyclic peptides known, are commonly biosynthesised 
from amino acids by different organisms, including mammals, and are considered to be 
secondary functional metabolites or side products of terminal peptide cleavage. Cyclic 
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dipeptides are extensively obtained by extraction from natural sources, but may be easily 
synthesised as it will be discussed in Section I.3.2 (page 40). 
 
 
 I.2.  BIOLOGICAL  ACTIVITIES 
 
Some of the most important biological activities of diketopiperazines are related to the 
inhibition of Plasminogen Activator Inhibitor-1 (PAI-1)8-11 and alteration of cardiovascular and 
blood-clotting functions.1  
 
PAI-1 is the main physiological inhibitor of serine proteases, urokinase plasminogen 
activator (uPA) and tissue plasminogen activator (tPA). The plasminogen-converting 
enzymes generate active plasmin, which proteolytically degrades fibrin and components of 
the extracellular matrix; while tPA is an essential element in the fibrinolytic system, regulating 
the formation and degradation of clots, uPA is linked to extracellular proteolytic homeostasis 
and consequently related to detachment and cell migration events inherent in metastasis, 
invasion and angiogenesis processes.8-11  
When PAI-1 is quantitatively disrupted, a variety of modulated functions are implicated 
in several pathological situations such as thromboembolic disease due to highly active PAI-
1,11 coronary heart disease, atherosclerosis, thrombosis10 and cancer progression8 
associated with increase levels of circulating PAI-1. The correlation between PAI-1 and 
cancer has been demonstrated in mice, by showing that the administration of exogenous 
PAI-1 leads to an increasing number of metastases in animals previously injected with 
malignant cells, while the introduction of monoclonal antibodies to this macromolecular 
inhibitor reduces the metastatic potential. 
The inhibitory capacity of PAI-1 is dependent on the conformation of the reactive centre 
loop (RCL) and on its availability to bind tPA or uPA, so its potential to be explored as a 
therapeutic macromolecular target for the treatment of cardiovascular diseases and cancer 
emphasises the importance of developing drugs as specific inhibitors.9 Diketopiperazines are 
the most potent PAI-1 inhibitors known,10 acting through a mechanism involving 
conformational changes, which inactivate PAI-1 RCL-complementarity, preventing its binding 
to the target protein. 
Metabolite 42 isolated from Streptomyces sp., as the first low-molecular-weight PAI-1 
inhibitor, was the model for designing structural changes in order to obtain more active 
products (Figure II.2). Using bioisosteric substitutions and combinatorial chemistry 
approaches, DKP 43 and 44 containing different side chains connected by exocyclic double 
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bonds were synthesised and showed both in vivo and in vitro PAI-1 inhibitory activity (IC50 
3.5 µM and 0.2 µM, respectively).11 Other strategies, such as introduction of structural 
rigidity, were also applied to metabolite 42, leading to compounds like 45 that also shows an 




Figure II.2.  Diketopiperazines as PAI-1 inhibitors. 
 
 
Tumour cell pro-coagulant activity has been considered to favour metastatic processes 
by encasing malignant cells in a fibrin coat, which protects them from the host immunological 
system. Thus, components of the blood-clotting system are potential targets for a new class 
of therapeutic agents designed to selectively inhibit tumour growth and prevent metastasis. 
Haematological studies showed that cyclo(L-His-L-Tyr) DKP 46 (Figure II.3) significantly 
increases clotting time and prevents platelet adhesion and aggregation induced by 
adenosine diphosphate.1 Cyclo(L-His-L-Phe) DKP 47 (Figure II.3) showed antitumour activity 
by significantly reducing the viability of HeLa, WHCO3 and MCF-7 cells, respectively from, 
cervical, oesophageal and mammary carcinoma.1 
In relation to cardiac effects, compound 46 increased the heart rate in isolated rodent 
hearts, while compound 47 decreased cardiac output and the level of coronary blood flow. In 
a similar manner to several cyclic dipeptides that display potential activity for the treatment of 
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cardiovascular dysfunctions, compounds 46 and 47 could be employed as antiarrhythmic 




Figure II.3.  DKPs which interfere in cardiovascular and blood-coagulation functions. 
 
 
Some DKP-based compounds show a different antitumor mechanism. Phenylahistin 48 
(Figure II.4), structurally similar to 47 (Figure II.3), is a metabolite isolated from Aspergillus 
ustus, which is involved in microtubule depolymerisation in human A549 lung carcinoma cells 
and is cytotoxic to several lines of tumour cells. Although structurally distinct from colchicine, 
compound 48 interacts at the same site in tubulin causing depolymerisation and inhibiting 
progression of the cellular cycle.12 
Diketopiperazine 49 (also Figure II.4), a synthetic non-chiral analogue of the natural 
product 48, also binds to microtubules, as colchicine, and shows antitumour activity in vitro 
against human tumour cell lines from prostate, breast, lung, leukaemia and colorectal 
tumours with IC50 values varying from 4.3 to 18 nM. A similar activity was reported against 
multidrug-resistant lines.13 More potent than colchicine and vincristine and active in 
concentrations as low as 10 nM, compound 49 was able to rapidly induce microtubule 
depolymerisation in proliferating human umbilical vein endothelial cells (HUVECs), an in vitro 
model for vascular endothelial tumour cells. Since these cells lack a well-developed actin 
filament structure, the microtubule network is essential to structure integrity and may thus be 
explored as a selective therapeutic target. Compound 49 at 20 nM was able to increase 
permeability in a proliferating HUVEC monolayer, eventually causing vascular collapse. 
Considering that vasculature is very important to tumour survival and growth, the property of 
selective rupture of tumour vessels makes compound 49 a promising agent for cancer 
treatment and, for this reason, it is being tested in preclinical studies.13 
Other compounds inhibiting cellular division were prepared from diketopiperazines with 
phenylalanine side chains. Some cyclic dipeptides were converted into dehydrogenated 
derivatives at the α-β positions of the amino acids generating exocyclic double bonds, using 
enzyme catalysis from strains of Streptomyces albulus. The unsaturated functions allow the 
molecule to assume a planar structure, important for the inhibition of cellular division. Among 
CHAPTER II    SYNTHESIS AND CONFORMATIONAL ANALYSIS OF PEPTIDOMIMETICS CONTAINING A NEW DKP SCAFFOLD 
 38 
the tetradehydro derivatives evaluated, compound 50 (also Figure II.4) was the most potent 




Figure II.4.  Cytotoxic diketopiperazines. 
 
 
Other examples in literature have also demonstrated that diketopiperazines show 
activities as antiviral,15 antifungal,16-18 antibacterial,19-24 and antihyperglycaemic25-27 agents 
and affinities for calcium channels and opioid,28 GABAergic,29 serotoninergic 5-HT1A
30
 and 
oxytocin31 receptors. Figure II.5 shows a representative set of DKP-based molecules 




Figure II.5.  Biological activities of 2,5-diketopiperazines (Part I). 




Figure II.5.  Biological activities of 2,5-diketopiperazines (Part II). 
 
 
I.3.  SYNTHESIS  OF  DIKETOPIPERAZINES  
 
I.3.1  MECHANISM  OF  DIKETOPIPERAZINE  FORMATION  
 
The planar backbone amide bonds in polypeptides are known to occur predominantly 
in the trans conformation. Planarity is maintained through a rotational energy barrier because 
of the partial double bond character of the peptide bond. On average, the energy difference 



















s-trans s-cis  
 
Scheme II.1  
 
Such isomerism is relevant to DKP formation because in a dipeptide derivative the 
intramolecular attack of the amino group on the terminal carboxylic group is possible only 
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The low abundance of cis peptide bonds in naturally occurring polypeptides is thought 
to be mostly due to steric conflict between neighbouring Cα-substituents in the cis 
conformation. However, the actual frequencies of occurrence of cis peptide bonds in known 
protein structures do not correlate well with residue side-chain bulk. In a similar way, the 
relative ease of DKP formation from a number of dipeptide derivatives can not be explained 
sufficiently by steric interactions between the side chains in the trans and cis isomers. 
Particularly noteworthy in this respect are dipeptides involving α-alkyl amino acid residues. 
For such compounds one would predict large energy differences between trans and cis 
isomers on the basis of steric crowding in the cis isomer, whereas in fact such peptides have 
been observed to cyclise quite readily. It is likely that the conformational constrains (on 
backbone torsional angles) introduced into a peptide by, for example Aib residues, result in 
amide bond isomerisation/cyclization mechanisms with low energy barriers that are favoured. 
Possibly such factors as overall proximity between terminal amino and carbonyl groups, as 
well as stabilizing intramolecular interactions may be involved.32 
 
 
I.3.2.  CONVENTIONAL  SYNTHETIC  PROCEDURES 
 
The 2,5-diketopiperazines, head-to-tail dipeptide dimers, are a common naturally 
occurring structural motif and consequently most biologically active DKPs are isolated from 
natural sources. They are also frequently generated as unwanted by-products or degradation 
products in the synthesis of oligopeptides.33 However, due to the relative structural simplicity 
of its basic nucleus, several synthetic methods are also available mainly based on reactions 
of dipeptides, easily prepared from α-amino acids by conventional methodology. 
Most symmetrical DKPs can be prepared simply by heating the free amino acid methyl 
esters in a sealed tube and this method can even be effective for DKPs derived from amino 
acids with reactive side chains. However, it is generally advisable to use protected 
precursors since for example, Dab, Orn, and Lys derivatives can give rise do the 
corresponding pyrrolidone, piperidone and homopiperidone by-products. In the case of 
unsymmetrical DKPs, the oldest synthetic procedure consists in the dipeptide ester treatment 
with methanolic ammonia, but the strongly basic conditions in this procedure can lead to 
epimerization. A method less prone to loss of chiral integrity consists of Boc-dipeptidyl methyl 
ester N-deprotection with formic acid, followed by reflux of the dipeptidyl ester formate salt in 
2-butanol/toluene and removal of formic acid through azeotropic distillation.34 However, for 
many DKPs, simple reflux of dipeptidyl methyl esters in low-boiling solvents, particularly 
methanol, is normally effective (Scheme II.3).35 




Scheme II.3.  Solution-layer synthesis: (i) MeOH, reflux, 14 h. 
 
 
Diketopiperazines can also be obtained by the Ugi reaction, a synthesis containing a 
small number of multicomponent steps, which allows substitutions on the secondary amino 
group.5 The stereospecific synthesis illustrated in Scheme II.4 was proposed as an 
alternative in the preparation of trisubstituted DKPs. However, it was not possible to control 




Scheme II.4.  Ugi reaction: (i) 1 equiv Et3N, MeOH; (ii) t-Bu-isonitrile, N-Boc-R-indanylglycine; (iii) 4 N 
HCl/dioxane, 4 h; (iv) Et3N. 
 
 
As an alternative, the glycine cyclic dipeptide has been used as the starting material for 
the solution-layer synthesis of substituted diketopiperazines. The protocol outlined in 
Scheme II.5 was used in the synthesis of several active compounds.11 A similar strategy was 
employed to generate olefin derivatives of N-acetylated diketopiperazines with exocyclic 
double bonds.35 
 




Scheme II.5.  Synthesis of substituted diketopiperazines starting from cyclo(Gly-Gly): (i) Ac2O, reflux; (ii) t-BuOH, 
t-BuOK, Ar1CHO, THF, r.t.; (iii) Ar2CHO, Cs2CO3, DMF, 80-100ºC. 
 
 
An innovating strategy employing microwave heating was used to couple peptides 
intramolecularly, resulting in symmetrical dimeric DKP, without epimerisation in the α-position 
of the amino acids. Nα-benzoyl-Arg(NO2)-Leu-NH2 71, a PAR-2 receptor antagonist, was 
prepared by classical solution-layer synthesis. To the C-terminal end of this dipeptide 
pharmacophore, a glycine residue was introduced and activated for auto-condensation, 
resulting in the DKP cyclo(Gly-Gly) 72 N-substituted by the selected dipeptide. The 
cyclization reaction is exemplified in Scheme II.6 and, compared to conventional heating, the 




Scheme II.6.  Dipeptide dimers obtained by microwave heating: (i) HBTU/DMAP, DMF, 5 min, 40 ºC, 400 W. 
 
A microwave-assisted stereoselective one-pot synthesis of symmetrical and 
unsymmetrical 2,5-DKPs from unprotected amino acids, through a phosphite-promoted one 
step coupling reaction (Scheme II.7), was recently reported. This method is characterized by 
overall good yields, scalability, and tolerance to several base-stable protecting groups. 
Simple filtration through a pad of silica provides the pure compounds.38 
 













i R1 = H; R2 = H, CH3, C3H7




Scheme II.7.  PIII-promoted coupling of amino acids: (i) MeOPCl2, Et3N, toluene, MW. 
 
 
DKP formation can also occur even when it is not desired. In fact, parallel DKP 
formation in reactions involving amino acids is a quite common side reaction. For example, 
attempts to perform nucleophilic substitutions in substituted pyrimidinic rings, by ethyl glycine 
chloride in the presence of a strong base, DABCO (1,4-diaza-bicyclo[2.2.2]octane), resulted 
in the glycine DKP produced by predominant auto-condensation of ethyl glycine.39 
Although solution-layer synthesis presents the advantage of requiring a smaller number 
of reaction steps, solid-layer synthesis has been the most used method to synthesise DKPs, 
with variations in the type of resin, protecting groups and type of cleavage among others. In 
multistep protocols, a dipeptide having the first peptide bond generated in situ is attached to 
the solid support, and it remains bound through the carboxylic extremity up to the cycling 
step, that is then followed by separation from the matrix or release of the N-protective group 
of the amino acid (cyclative cleavage).40-42 A generic solid-layer protocol is shown in Scheme 
II.8 for obtaining DKPs under mild conditions, using the phenacyl ester (O-Pac) bond to 
attach the carboxylic amino acid terminal to the resin. Deprotection of the Boc-amino group 
and coupling with the next amino acid afforded dipeptide 77, which was subsequently 




Scheme II.8.  Solid-layer synthesis: (i) BrCH2COBr, AlCl3, nitrobenzene/DCM (1:1); (ii) Boc-AA’-OH, Et3N, DMF; 
(iii) 3.5 N HCl/AcOH; (iv) Boc-AA’’-OH, HOBt, DCC, NMM, DMF; (v) 10% DIPEA/EtOAc; (vi) 5% Et3N/THF-H2O. 
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Solid-layer synthesis of unsaturated 3-substituted DKP, employing a carbamate bond 
between the dipeptide N-terminal and the resin, was also described.40 
Notwithstanding the successful use of activated ligands such O-Pac, the bond 
susceptible to nucleophilic attack requires amino acid side-chain group protection. Small 
losses of the elongating peptides are usually associated with this relative lability. Peptide 
attachment to the resin by the safety-catch technique circumvents this problem, because the 
stable bond is conveniently activated only after ending the peptide synthesis, allowing 
cleavage and cyclization. The strategy outlined in Scheme II.9 permits the removal of 
protecting groups before cleavage, facilitating further workup.5 The use of safety-catch 
ligands allowed the solid-layer generation of bicyclic and tricyclic DKP, which show even 




Scheme II.9.  Solid-layer synthesis by safety-catch approach: (i) Boc-AA’-OH, DIC, DIPEA; (ii) Boc-based solid-
layer peptide synthesis; (iii) TFMSA, TFA; (iv) DIPEA. 
 
 
II. DKPS  AS  TEMPLATES  THAT INDUCE  A  DEFINED SECONDARY  STRUCTURE 
 
II.1.  DKP-BASED  TEMPLATES  IN  LITERATURE 
 
A relevant application of DKPs, which has gained importance in the last decade, is its 
use as templates capable of inducing a defined secondary structure in peptide sequences. In 
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these cases, advantage can be taken from the synthesis of symmetrical and unsymmetrical 
DKP bearing reactive functionalities in the lateral chains of the amino acids. 
For instance, Wennemers and co-workers have prepared a few symmetrical 
diketopiperazine two-armed receptors derived from 4-amino-proline where the two amino 
groups (with a cis disposition) were functionalized with two tripeptide side chains (84, Figure 
II.6). The resulting two-armed receptors were screened towards a tripeptide library and 
showed highly selective binding properties which were attributed to the specific turn 
geometry of the receptor.43-46 Later on, the same group reported the synthesis of water 
soluble diketopiperazine receptors (85, Figure II.6) and their selective binding properties to 
arginine containing peptides in aqueous solution.47 To provide for arginine binding sites and 
water solubility the authors equipped the receptor arms of the DKP receptors with aspartic 
acids. The termini of the arms were either acetylated (receptor 85a) or functionalized with 
succinic acid which provided for an additional carboxylic acid functional group (receptor 85b).  
 
 
Figure II.6.  a) General structure of diketopiperazine receptors and b) water-soluble DKP receptors. 
 
 
Alternatively, two different functionalities can be created in the lateral chains of the two 
amino acids forming the DKP core, such as an amine (e.g. derived from Lys, Orn or 
diaminobutyric acid) and a carboxylic acid (e.g. derived from Asp or Glu). In this case, a new 
peptidomimetic structure is formed, possessing a fixed conformation (due to the cyclic DKP 
core and the configuration of the two amino acids), and which can now be used as molecular 
templates, scaffolds or spacers in molecular design.48  
Davies and co-workers reported the synthesis of diketopiperazine scaffold 86 (Figure 
II.7), capable of mimicking a β-turn, although no synthesis or conformational studies of 
peptides containing scaffold 86 have been reported.49 




Figure II.7.  Diketopiperazines as β-turn mimetics. 
 
 
Golebiowski and co-workers have developed a high-throughput organic synthesis 
protocol for the efficient preparation of bicyclic DKP-containing systems (87, Figure II.8).that 
could be seen as a β-turn mimetic.50 In a similar way, Kahn and co-workers have also 






































Figure II.8. Bicyclic diketopiperazines as β-turn mimetics. 
 
 
Robinson and co-workers have synthesised a novel bicyclic template (88, Figure II.9), 
comprising a diketopiperazine derived from L-aspartic acid and (2S,3R,4R)-diaminoproline,52 
that was then incorporated by solid-layer peptide synthesis into a cyclic loop mimetic 
containing the sequence [-Ala1-Asn2-Pro3-Asn4-Ala5-Ala6-template-] (89, Figure II.9). It was 
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Figure II.9.  DKP-based template 88 stabilizes loop conformations in cyclic peptides. 
 
 
II.2.  CONCEPTION  OF  OUR  DKP-BASED  MOLECULES 
 
II.2.1.  CONCEPTION  OF  THE  DKP  SCAFFOLD  90  (DKP-90) 
 
Capitalizing on the interesting properties of diketopiperazines discussed above, we 
decided to synthesise a new bifunctional DKP scaffold 90 (DKP-90, Figure II.10), formally 
derived from L-aspartic acid and (S)-2,3-diaminopropionic acid, bearing a carboxylic acid and 
an amino functionalities. As a consequence of the absolute configuration of the two α-amino 
acids forming the cyclic dipeptide unit, the two reactive functionalities (amino and carboxylic 
acid) are locked in a cis configuration. Furthermore, these functionalities allow the 
introduction of peptide or peptidomimetic sequences and, therefore, we can foresee the use 






Figure II.10. DKP scaffold 90 as a reverse turn inducer. 
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II.2.2.  CONCEPTION  OF  PEPTIDOMIMETICS  CONTAINING  DKP-90 
 
Although DKP scaffold 90 is derived from α-amino acids, it can be seen as a 
conformationally constrained β-peptide formed by two β-amino acids (Figure II.11), in 
particular a β2- and a β3-amino acids (according to Seebach’s nomenclature, the 
superscripted number after β specifies the position of the side-chain in the corresponding β-
amino acid).54  
 
 
Figure II.11.  Structure of the bifunctional diketopiperazine scaffold 90 (DKP-90) highlighting the conformationally 
constrained β2-β3 dipeptide sequence. 
 
As it was extensively described in Chapter I (Section III.1, page 10), investigation on β-
peptides indicated that these are able to adopt stable secondary structures such as helices 
and sheets. The stabilization of β-peptide-hairpins sequences was also studied, and in 
particular Seebach and co-workers described the formation of turn-like secondary structures 
in oligo-β-peptides containing a dipeptide sequence formed by a β2-amino acid (C2-
substituted) followed by a β3-amino acid (C3-substituted)55 (2, Figure II.12). Gellman and co-
workers reported the formation of a hairpin conformation when a heterochiral dinipecotic acid 




Figure II.12. Different hydrogen-bond patterns in β-peptide hairpins. 
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The intramolecular hydrogen bonding pattern in these two cases is different (Figure 
II.12): in the first case a 10-membered H-bonded ring is formed involving the C=O of the β3-
amino acid and the NH of the β2-amino acid, while, in the second case a 12-membered H-
bonded ring can be identified, which is a two-term homolog of the β-turn structure formed by 
α-amino acids. β-Hairpins containing both α- and β-amino acids have also been reported to 
be very stable.57  
 
In view of these potential properties, we decided to study the ability of DKP-90 to form 
well-defined folded structures, when introduced in peptide sequences. Therefore, several 

















































































































Figure II.13. Peptidomimetics containing DKP-90. 
 
 
II.3.  SYNTHESIS  OF  THE  DKP-BASED  MOLECULES 
 
II.3.1.  SYNTHESIS  OF  THE  DKP  SCAFFOLD  90 
 
The synthetic procedure to obtain DKP-90 involved the cyclization of the corresponding 
dipeptide, bearing a tertiary amide (namely the central one), in turn prepared starting from 
two α-amino acids namely, (2S)-aspartic acid and (S)-serine (Figure II.14). 




Figure II.14.  Strategy designed to obtain DKP scaffold 90. 
 
 
The success of the strategy designed hinged on the availability of an ester protecting 
group which would be orthogonal to the Boc and methyl ester. We decided, therefore, to 
protect the β-carboxylic acid group of the (2S)-aspartic acid as its allyl ester. Accordingly, 
(2S)-aspartic acid was esterified by treatment with acetyl chloride in allyl alcohol to give (2S)-
aspartic acid β-allyl ester hydrochloride 98 (Scheme II.10). In this procedure, the reaction of 
acetyl chloride with an alcohol (allyl alcohol here) is used to generate HCl in situ leading to 
allyl acetate formation that, if necessary, can be removed by evaporation under reduced 
pressure. This procedure is reported to be selective for the β-carboxylic group esterification 
but some bis-allylation can still take place.58 In order to minimize the α-carboxylic acid 
esterification the reaction was performed at low temperature (0–10 ºC). The amino group 
was then protected as its N-tert-butoxycarbonyl derivative, under standard conditions, to give 
N-(tert-butoxycarbonyl)-(2S)-aspartic acid β-allyl ester 99 (Scheme II.10). 
On the other hand, the OH group in the (S)-serine side-chain does not interfere with the 
subsequent coupling reaction, therefore, it is only necessary to protect the α-carboxylic acid 
group, in this case, as its methyl ester. (S)-serine methyl ester hydrochloride 100 was 
obtained by esterification of the corresponding free amino acid in refluxing methanol, in the 
presence of acetyl chloride. The serine α-amino group was then alkylated because, as we 
noted previously (see Section I.3.1, page 39), the presence of a tertiary amine decreases the 
energy difference between cis and trans peptide bond isomers and, therefore, facilitates the 
cyclization step and DKP formation. The (S)-N-benzylserine methyl ester 101 was then 
obtained through a reductive amination. The hydrochloride salt 100 was treated with 
benzaldehyde in methanol, in the presence of triethylamine to obtain the corresponding 
imine, that was subsequently reduced with sodium borohydride (Scheme II.10). In order to 
minimize racemisation during this last step, special attention should be given to both 
temperature and reaction time.59 




Scheme II.10.  (i) CH3COCl, CH2=CHCH2OH: 90%; (ii) Et3N, Boc2O, H2O/Dioxane: 96%; (iii) CH3COCl, CH3OH: 
82%; (iv) Et3N, PhCHO, CH3OH, then NaBH4: 86% over two steps. 
 
The suitably protected amino acids were then coupled to form dipeptide 101. However, 
this coupling step proved to be difficult, possibly because it involves the formation of a 
tertiary amine. Different coupling reagents (EDC, HOAt, HATU) and reaction conditions 
(solvent, temperature, inert atmosphere) were tried. The best yield (72%) was obtained using 
HATU as coupling reagent and DIPEA as base in dichloromethane under nitrogen 
atmosphere (Scheme II.11). Dipeptide 101 was fully characterized and it was possible to 
observe two set of signals in the 13C spectrum due to the presence of two rotational isomers 




Scheme II.11.  (i) HATU, DIPEA, CH2Cl2: 72%. 
 
Intramolecular aminolysis of dipeptide esters with DKP formation is thermodynamically 
favoured due to the 6-membered ring formation and, in this particular case, also due to the 
presence of the tertiary amide that favours the folded conformation containing a cis peptide 
bond necessary in the ring-closing step. In order to proceed to the cyclization step, dipeptide 
101 was deprotected with neat TFA and its trifluoroacetate salt cyclized, in good yield, to 
diketopiperazine 102 (Scheme II.12), in a basic biphasic system (NaHCO3 aq / EtOAc).
60 
These conditions were selected to minimize the epimerization of the serine methyl ester and 
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the formation of the diastereomeric trans-DKP 103 (< 10%), which could, however, be 




Scheme II.12.  (i) TFA and (ii) saturated aqueous. NaHCO3/EtOAc (1:1, v/v): 81% over two steps. 
 
These reaction conditions represent the final step of a long series of tests to optimize 
the cyclization step both in terms of yield as well as proportion of epimeric trans-DKP 103. 
Table 2.1 summarizes the conditions tried. 
 
Table II.1 - Optimization of the cyclization step. 
REACTION CONDITIONS TOTAL YIELD  RATIO 
cis : trans 
DIPEA (4 equiv), CH2Cl2, 48 h, r.t. 47 % 8 : 2 
DIPEA (6 equiv), CH2Cl2, 48 h, r.t. 63 % 7 : 3 
DIPEA (6 equiv), CH2Cl2, 24 h, reflux 80 % 3 : 7 
Sat. aq. NaHCO3/EtOAc (0.1 M, 1:1, v/v), 24-48 h, r.t. 90 % 9 : 1 
 
A single crystal X-ray structure of DKP 102 was obtained, confirming its relative 
stereochemistry (Figure II.15). 
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Figure II.15.  X-ray crystallographic data of 102: Crystal data: C17H20N2O5; MW = 332.35 g.mol
-1; T = 293 K; λ(Mo, 
Kα) = 0.71073 Å, monoclinic, space group P21, a = 7.394(4) Å, b = 10.764(19) Å, c = 10.800(5) Å, β = 99.71(4)°, 
V = 847(2) Å3, ρcalc = 1.303 g.cm
-3, Z = 2; µ(Mo, Kα) = 1.0 cm-1. R and wR2 0.086 and 0.155, respectively, for 
1230 unique data collected in the 3 - 25.3° 2 θ range. 
 
 
The introduction of the nitrogen functionality (the amino group precursor) proved to be 
the most difficult step of the synthetic strategy. Several methodologies were tested but they 
were always hampered by the concurrent elimination reaction yielding the unsaturated 
diketopiperazine with the exocyclic double bond. Initial trials involved the activation of the 
hydroxyl group of 102 in the form of a mesylate.61  
 
 
Scheme II.13.  (i) Et3N, CH3SO2Cl, CH2Cl2, 0 ºC: quantitative yield; (ii) NaN3 (2 equiv), DMF: 30%. 
 
Reaction of alcohol 102 with methanesulfonyl chloride, in the presence of triethylamine 
led to the corresponding mesylate 104 in quantitative yield (Scheme II.13). However the 
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subsequent reaction with sodium azide at room temperature resulted to be quite 
disappointing. The desired azide 105 was obtained, but in a low yield (30%) and, the 
elimination product 106 was obtained as the major product (44 %). Similar results were 
obtained even when the reaction was performed at low temperature (0 ºC). 
 
On the other hand, when the hydroxyl group was activated as its triflate, the concurrent 
elimination reaction did not occur (Scheme II.14). The same observation had been already 
reported in literature, using the same reaction conditions.62 Nonetheless, the yield of isolated 
azide 105 was in the same range (31%), probably due to decomposition of the triflate 
derivative prior to substitution. The same reaction in different solvents (THF and THF/DMF, 




Scheme II.14.  (i) Pyridine, (CF3SO2)2O, CH2Cl2, -20 ºC; (ii) NaN3 (4 equiv), DMF, 0 ºC to r.t.: 31%. 
 
Finally, the introduction of the azide group was attempted through a Mitsunobu-type 
reaction using a solution of hydrazoic acid (HN3) in toluene.
63. This procedure has been 
reported for the successful synthesis of 2,3-diamino propionic acid starting from serine 
derivatives.64,65 Unfortunately, in our case even the Mitsunobu-type conditions led to 
significant amounts of elimination product. By decreasing the temperature reaction it was 
possible to increase the yield of the desired product and reduce the formation of the 
elimination product. Eventually, it was necessary to change solvent due to the insolubility of 
DKP 102 in toluene at temperatures lower than 0 ºC. Scheme II.15 summarizes the 
optimized Mitsunobu-type conditions which afforded azide 105 in a moderate yield (48%). 
 
 




Scheme II.15.  (i) PPh3, DIAD, HN3·Tol, Toluene/CH2Cl2 (2/1), -20 ºC: 48%. 
 
The same Mitsunobu-HN3 reaction run on dipeptide 101 gave a higher yield of the 
azide derivative, but, unfortunately, all attempts to cyclise this derivative met with no 
success.  
The next step involved a one pot Staudinger – Boc protection. The Staudinger reaction, 
a very mild azide reduction, involves the reaction of the azide with a phosphine to generate a 
phosphazide, which loses N2 to form an iminophosphorane. Hydrolysis of this intermediate 




Scheme II.16.  Mechanism of the Staudinger reaction. 
 
In our case the intermediate iminophosphorane reacted directly with 2-(t-
butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON),66 present in the reaction medium, 
affording the desired Boc-protected amine in very good yield (Scheme II.17). Finally the DKP 
scaffold allyl ester 108, was de-allylated in the presence of a catalytic amount of palladium 
tetrakis(triphenylphosphine) [Pd(PPh3)4] and pyrrolidine, i.e. a nucleophile acting as an allyl 
scavenger to give the amino acid derivative 90 in quantitative yield (Scheme II.17). Such 
methodology is of special interest for peptide synthesis because the deprotection conditions 
are usually mild enough to be compatible with the presence of acid labile t-Bu and Boc 
protections.67 








II.3.2.  SYNTHESIS  OF  THE  PEPTIDOMIMETICS  CONTAINING  DKP-90 
 
Several peptidomimetics: di- (Ac-DKP-NH-CH2Ph), tri- (AA
1-DKP), tetra- (AA1-DKP-
AA2), penta- (AA1-AA2-DKP-AA3) and hexa-peptide mimics (AA1-AA2-DKP-AA3-AA4), were 
synthesised by solution layer peptide synthesis (Boc strategy) starting from the C-terminus.68 
Good yields were obtained in the coupling of the amino acids to the N-terminus of DKP-90, 
using HOBt [N-hydroxybenzotriazole] / EDC [N-ethyl-N’-(3-
(dimethylamino)propyl)carbodiimide] in dichloromethane (Procedure A) or HATU [O-(7-
azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate] in 
dimethylformamide (Procedure B), always in the presence of a tertiary amine (in this case, 
N,N-diisopropylethylamine).68 
 
SYNTHESIS  OF  THE  DIPEPTIDE  MIMIC  91 
In a first instance dipeptide 109 was synthesised by coupling benzylamine to the C-
terminus of DKP-90, using general procedure A. The N-terminus was deprotected using TFA 





































Scheme II.18.  (i) PhCH2NH2, HOBt, DIPEA, DMF then EDC, 0 ºC to r.t.: 90%; (ii) TFA/CH2Cl2 (1:1, v/v)  and (iii) 
Ac2O, DIPEA, CH2Cl2: 92% over two steps. 
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SYNTHESIS  OF  THE  TETRAPEPTIDE  MIMICS  92  AND  93 
Tetrapeptide mimics 92 and 93, were obtained by initially coupling the TFA salt of 110 
to the C-terminus of DKP-90, using general procedure A. Boc-(S)-Ala-OH was then coupled 
to the N-terminus of the tripeptide mimic 111, yielding the N-Boc-tetrapeptide mimic 92. 
Alternatively, when Ac-(S)-Ala-OH was reacted, the N-Ac-tetrapeptide mimic 93 was 
obtained (Scheme II.19). In both cases general procedure B was used for the attachment of 




Scheme II.19.  (i) PhCH2NH2, HOBt, DIPEA, DMF then EDC, 0 ºC to r.t.: quantitative yield; (ii) TFA/CH2Cl2 (1:1, 
v/v) and (iii) DKP-90, HOBt, DIPEA, DMF then EDC, 0 ºC to r.t.: 92% over two steps; (ii) and (iv) Boc-(S)-Ala-OH, 
HATU, DIPEA, CH2Cl2, 0 ºC to r.t.: 82% over two steps; (ii) and (v) Ac-(S)-Ala-OH, HATU, DIPEA, CH2Cl2, 0 ºC to 
r.t.: 76% over two steps. 
 
SYNTHESIS  OF  THE  PENTAPEPTIDE  AND  HEXAPEPTIDE  MIMICS  95  AND  96 
The synthesis of the longer hexapeptide mimics was obtained starting form the 
dipeptide fragment 113 (Scheme II.20), which was then attached to the C-terminus of DKP-
90. Dipeptide 113 was synthesised from Boc-(S)-Ala-OnBu 112 and Boc-(S)-Val-OH, using 
procedure A. According to the same general procedure, coupling of the deprotected 
dipeptide 113 to the C-terminus of DKP-90, afforded compound 114. After Boc deprotection 
with TFA, another Ala residue was coupled to the N-terminus of DKP-90. In this case general 
procedure B was necessarily used to obtain the pentapeptide mimic 94 in good yield (85%). 
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Finally, coupling of either Boc-(S)-Val-OH or Ac-(S)-Val-OH to the N-terminus of 94 (again 
with general procedure B), afforded the N-Boc-hexapeptide mimic 95 and N-Ac-hexapeptide 




Scheme II.20.  n-BuNH2, HOBt, DIPEA, DMF then EDC, 0 ºC to r.t.: 95%; (ii) TFA/CH2Cl2 (1:1, v/v) and (iii) Boc-
(S)-Val-OH, HOBt, DIPEA, DMF then EDC, 0 ºC to r.t.: 96% over two steps; (ii) and (iv) DKP-90, HOBt, DIPEA, 
DMF then EDC, 0 ºC to r.t.: 80% over two steps; (ii) and (v) Boc-(S)-Ala-OH, HATU, DIPEA, CH2Cl2, 0 ºC to r.t.: 
85% over two steps; (ii) and (vi) Boc-(S)-Val-OH, HATU, DIPEA, CH2Cl2, 0 ºC to r.t.: 70% over two steps; (ii) and 
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II.4.  CONFORMATIONAL STUDIES 
 
II.4.1.  CONFORMATIONAL  STUDIES  OF  CONSTRAINED  PEPTIDES:  AN  OVERVIEW 
 
The conformational preferences of peptides are commonly carried out by means of 
NMR spectroscopy, IR spectroscopy, as well as, molecular modelling techniques.  
Characteristic differences in the NMR spectral parameters for unstructured peptides and 
peptides in extended and intramolecularly hydrogen bonded conformations have been widely 
reported in organic solvents.69-72 Chemical shifts and coupling constants for the Cα hydrogens 
reflect the average conformations of individual amino acid residues, while the chemical shifts 
of the amide protons and their temperature dependence reveal whether they are solvent 
exposed or intramolecularly hydrogen bonded. 
Insights into hydrogen bonding can be gained from the chemical shifts of amide NHs: 
signals of protons that are H-bonded, either intramolecularly or to the solvent, appear 
downfield of those that are not H-bonded. In solvents that do not form strong hydrogen bonds 
(e.g. CDCl3), significantly deshielded amide protons often indicate that they are involved in 
intramolecular hydrogen bonding.73 However, the same conclusion is not true in the case of 
strongly H-bonding solvents (e. g. MeOD, DMSO-d6). In, such cases each amide proton is 
either locked in an intramolecular H-bond or engaged in an intermolecular H-bonding with the 
solvent. 
Peptide amide protons involved in H-bonding, or otherwise shielded from solvent, can 
be identified by their relatively slow rate of H/D exchange. It is generally accepted that 
intramolecular hydrogen-bonds in proteins must break before exchange with the solvent can 
occur.74 Therefore, amide proton-deuterium exchange rates permit the identification of amide 
protons that are involved in intramolecular hydrogen-bonding. The ∆δ(NH) upon addition of a 
solvent able to compete for the formation of H-bonds (MeOH, DMSO) can also provide 
information regarding the possible participation of an amide proton in a stable intramolecular 
H-bond. 
On the 1H-NMR timescale, equilibration between hydrogen-bonded and non-hydrogen-
bonded states for a given amide proton is rapid; therefore the observed amide resonances 
are weight averages of the contributing states. IR spectroscopy is, in principle, more useful 
for detecting amide H-bonding equilibrium, as the much shorter timescale of IR 
measurements permits the observation of distinct N-H stretching absorptions for equilibrating 
H-bonded and non-H-bonded states.75 However, the use of this technique to elucidate H-
bonding behaviour in peptides is limited, because the presence of multiple NH groups 
(specially, the resulting band overlap) often renders IR data inconclusive in such cases. 
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Another powerful tool for understanding the extent of H-bonding is the temperature 
dependence of the chemical shifts of amide protons [∆δ(NH)/∆T]. In non-competitive solvents 
(like CDCl3), different ways of interpreting these data have been proposed. According to 
some authors, peptide NH protons that are either non-H-bonded or locked in a H-bonded 
conformation exhibit a small temperature dependence (typically 0 to -3 ppb/K), while protons 
that participate in an equilibrium between a H-bonded and a non-H-bonded state exhibit a 
large temperature dependence (typically -4 to -8 ppb/K).76,77 However, other authors consider 
that NH protons with a ∆δ(NH)/∆T smaller in absolute value than -2.6 ppb/K are 
intramolecularly H-bonded, irrespective of the chemical shift value or other parameters, while 
protons with a ∆δ(NH)/∆T  larger in absolute value than -2.6 ppb/K are non-H-bonded.78 In 
the case of competitive solvents, like water and DMSO, the consensus is higher and, it is 
generally accepted that solvent-exposed protons exhibit a large temperature dependence, 
while intramolecular H-bonded (solvent-shielded) protons exhibit only a small temperature 
dependence. 
Finally, molecular mechanics calculations are usually performed to corroborate NMR 
data. Monte Carlo conformational search and molecular dynamics calculations are often 
carried out to investigate the conformational preferences of peptides and peptidomimetics. 
 
 
II.4.2.  CONFORMATIONAL  STUDIES  OF  PEPTIDOMIMETICS  CONTAINING  DKP-90 
 
The tendency of the DKP-90-containing peptidomimetics 91−96 to adopt a defined 
secondary structure was then evaluated by a combination of 1H-NMR spectroscopy, IR 
spectroscopy, CD spectroscopy, and computer modelling. 
The dipeptide mimic 91, in CDCl3, showed some degree of concentration dependence 
and a strong temperature dependence of the chemical shifts of all the NH’s (> 20 ppb/K) at a 
2 mM concentration, while the chemical shift values were only slightly deshielded (6.25–7.02 
ppm) with respect to the average values for non-hydrogen-bonded NH protons (ca 6.0 ppm). 
These data are in agreement with an equilibrium between a non-hydrogen-bonded and an 
intermolecularly H-bonded status (aggregation). 
In the case of the longer peptidomimetics (tetra-, penta-, and hexa-peptides), the 
chemical shift of the amide protons was essentially invariant over the concentration range 0.5 
– 10 mM at 298 K, indicating an absence of significant aggregation in this concentration 
range, and 0.5 – 2 mM solutions were employed for all conformational analysis. In all cases, 
all the proton resonances could be assigned by means of COSY and ROESY spectra. 
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The NMR studies for tetrapeptide mimics 92 and 93 were performed in CDCl3. From 
the NMR data summarised in Table II.2 it appears that the amide protons NH4 are in an 
intramolecularly hydrogen-bonded status. In fact: (a) their resonance is shifted substantially 
downfield (8.10 and 8.18 for 92 and 93, respectively); (b) the temperature dependence of the 
NH4 chemical shift falls within the typical values for intramolecularly hydrogen bonded 
protons: 2.7 ppb/K for 93 and slightly higher (4.1 ppb/K) for 92; (c) the ∆δ (NH4) upon addition 
of CH3OH (obtained measuring the spectrum in a CDCl3/CH3OH, 4/1 mixture), is small (0.03 
in the case of 93), and the rate of exchange H4/D upon addition of CD3OD is quite slow (ca. 
960 min). In the case of proton NH1, the same parameters (i.e. values of chemical shift, 
temperature dependence, ∆δ upon addition of CH3OH and rate of exchange H1/D upon 
addition of CD3OD), are indicative of an equilibrium between an intramolecularly hydrogen-
bonded and a non-hydrogen-bonded status for both 92 and 93. A similar equilibrium is also 























NH1 7.81 -7.6 8.21 -4.6 -0.07 300 
NH2 7.03 -8.2 7.21 -5.3 0.53 160 
NH3 6.28 -9.1 6.61 -15.5 1.25 < 10 
NH4 8.10 -4.1 8.18 -2.7 0.03 960 
NH5 5.41 -1.8 6.40 -2.3 ≥ 0.7 -g 
a) Concentration 0.5 mM in CDCl3; b) Concentration 2.0 mM in CDCl3; c) at 298 K; d) determined between 238 
and 288 K; e) measured in CDCl3/CH3OH 4/1; f) measured in CDCl3/CD3OD 4/1; g) not determined due to overlap 
with other resonances. 
CHAPTER II    SYNTHESIS AND CONFORMATIONAL ANALYSIS OF PEPTIDOMIMETICS CONTAINING A NEW DKP SCAFFOLD 
 62 
NOE contacts can be highly indicative of the formation of a β-hairpin mimic when inter-
strand contacts are visible. Unfortunately, in the case of the tetrapeptide mimics 92 and 93 
we could not detect this kind of contacts, and only strong intra-strand contacts were 
observed, which are indicative of an extended conformation for the amino acid residues.  
The FT-IR spectrum of the tetrapeptide mimic 92 (2 mM solution in CHCl3), is 
characterized by two bands, at 3427 and 3395 cm-1 (free NH groups) and two prominent 
bands at 3321 and 3291 cm-1 (H-bonded NH groups), respectively.75 In the case of 93, only 
two bands can be recognized, one in the free NH region (3410 cm-1), and one at 3291 cm-1 
indicative of H-bonded NH’s.  
The NMR and IR data collected support the formation of a β-hairpin mimic involving a 
10-membered and a 18-membered H-bonded rings and a reverse turn of the growing peptide 
chain. The weak hydrogen-bonded character of NH2 might indicate that a different β-hairpin 
mimic involving a 12-membered and a 16-membered H-bonded rings (vide infra the 
molecular modelling discussion) is present as a minor conformer at the equilibrium. 
 
Computational studies designed to investigate the ability of the DKP-90 scaffold to 
induce β-hairpin conformations were performed on the tetrapeptide mimic 93. The molecule 
was subjected to an extensive, unconstrained Monte Carlo/Energy Minimization (MC/EM) 
conformational search79 by molecular mechanics methods using the AMBER* force field80 
and the implicit CHCl3 GB/SA solvent model.
81  
Only two types of conformations, both featuring a β-hairpin-like arrangement, are 
predominant among the structures found within 3 kcal/mol from the global minimum. The 
lowest energy conformer features an intramolecular hydrogen bonding pattern involving the 
formation of a 10-membered and a 18-membered H-bonded rings (Figure II.16, 93a). The 
10-membered ring of this conformer features a gauche orientation of the NH and C=O 
groups around the C2–C3 bond (β-amino acid numbering), with the β2 and β3 amino acid 
torsion angles (θ) of -87° and 81°, respectively. This cross-strand hydrogen bonding pattern 
is in agreement with the structure proposed on the basis of the NMR experiments, 
summarised in Table II.2.  
A second β-hairpin-like conformer was found at 1.09 kcal/mol from the global minimum, 
involving the formation of a 12-membered and a 16-membered H-bonded rings (Figure II.16, 
93b). The 12-membered ring requires anti C2–C3 torsion angles, with θ values of -171° and -
177° for the corresponding β2 and β3 amino acids. As also suggested by the NMR data 
reported in Table II.2, this second type of β-hairpin structure, or at least its 12-membered H-
bonded ring portion, might participate as a minor conformer to the conformational 
equilibrium.





Figure II.16.  Structures of low-energy conformers (MC/EM, AMBER*, CHCl3 GB/SA) calculated for compound 93: 
left, global minimum (93a); right, conformer with relative energy of 1.09 kcal/mol (93b). Hydrogen bonds are 
indicated with dotted lines and for clarity all non-polar hydrogen atoms and phenyl groups have been omitted. 
 
 
The solution structure of the pentapeptide mimic 94 was also studied by determining 
the temperature dependence of the NH chemical shifts at 2 mM in CDCl3 (Table II.3).  
 






δa,b ( ppm) ∆δ/∆T a,c (ppb/K) 
NH1 6.47 -2.5 
NH2 7.71 -8.3 
NH3 7.21 -14.3 
NH4 7.14 -16.0 
NH5 7.77 -6.8 
NH6 5.27 -4.8 
  a) Concentration 2.0 mM in CDCl3; b) at 298 K; c) determined between  
  258 and 298 K. 
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An equilibrium between an intramolecularly hydrogen-bonded and a 
non-hydrogen-bonded status is suggested by the various parameters for protons NH2 and 
NH5 (δ= 7.71 and 7.77; ∆δ/∆T= -8.3 and -6.8 ppb/K, respectively, Table II.3), which might be 
indicative of the presence of a β-hairpin conformation with a 10-membered and a 18-
membered H-bonded rings, in analogy to the tetrapeptide mimics 92 and 93. 
 
Finally, the conformational preferences of hexapeptide mimics 95 and 96 were studied. 
The first dramatic difference with respect to the shorter homologues was the insolubility of 
these products, in particular the hexapeptide mimic 96. In fact compound 96 was only soluble 
in DMSO and in hot methanol, while compound 95 was also sparingly soluble in CHCl3 and 
soluble in methanol. For this reason the NMR studies of these compounds were performed in 
DMSO-d6 and, in the case of 95, also in 5% CD3OH-CDCl3. All the proton resonances could 
be assigned by means of COSY and ROESY spectra. 
The analysis of the 1H-NMR spectrum of hexapeptide mimic 95 in 5% CD3OH-CDCl3 
(Table II.4) showed that protons NH2 and NH5 are notably shifted downfield with respect to 
the other NH protons (δ= 8.24 and 7.97; respectively). The temperature dependency is 
indicative of a hydrogen-bonded status for both NH2 and NH5 (∆δ/∆T= -2.5 and -1.3 ppb/K, 
respectively), and of an equilibrium between an intramolecularly hydrogen-bonded and a 
non-hydrogen-bonded status for NH7 (∆δ/∆T= -6.0 ppb/K). 
The 3J values for the NH-CαH in DMSO-d6 for both compounds 95 and 96 (Table II.4) 
are in agreement with the typical values for peptides showing a β-hairpin secondary structure 
(7.5–8.5 Hz).70 Similar values were also found for the spectrum of 95 in 5% CD3OH-CDCl3, 
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95: R = O-tBu










e,f δe,f (ppm) 3JNHCHαe,f 
NH1 6.99 -8.0 5.7 5.6 7.83 5.6 
NH2 8.24 -2.5 7.7 7.4 8.19 7.9 
NH3 7.61 -15.5 8.0 8.1 8.29 7.2 
NH4 7.68 -16.5 -g -g 8.28 -g 
NH5 7.97 -1.3 -g -g 8.25 -g 
NH6 7.42 -8.5 8.0 7.8 8.18 7.8 
NH7 5.76 -6.0 6.8 9.1 7.96 8.9 
a) Concentration 2.0 mM in 5% CD3OH-CDCl3; b) at 288 K; c) determined between 248 and 288 K; d) at 278 
K; e) Concentration 2.0 mM in DMSO-d6; f) at 298 K; g) broad signal. 
 
The 2D-NMR analysis in DMSO-d6 suggests that both compounds 95 and 96 adopt a 
β-hairpin-type conformation with a 10-membered H-bonded ring similar to that observed in 
the previous structures. In fact, the ROESY spectrum shows a set of NOE cross-peaks that 
support this conclusion (Figure II.17). In particular, in the case of 95, several interstrand NOE 
contacts were observed: a strong contact between the CαH of the Val1 and CαH of the Ala2 
residue (see also Figure II.18a); a medium contact between NH2 and the CαH of the Ala2 
residue (see also Figure II.18b) and a weak contact between NH2 and NH7 (see also Figure 
II.18c). The same contacts were also observed when the ROESY spectrum of 95 was 
collected in 5% CD3OH-CDCl3 (Figure II.19). A similar pattern is also shown by the spectrum 
of 96 in DMSO-d6 (Figure II.20), with the exception of the cross peak between NH
2 and NH7 
which is too weak to be detected in this case. 




Figure II.17.  Selected intrastrand (dashed black arrows) and interstrand (dashed red arrows) NOE contacts for 












































Figure II.18.  Sections of the ROESY spectrum of 95 (2 mM in DMSO-d6, p15=400 ms) showing: a) interstrand 





































































Figure II.19.  Sections of the ROESY spectrum of 95 (2 mM in 5% CD3OH-CDCl3, p15=400 ms) showing: a) 
interstrand NOE’s in the CαH region, b) interstrand NOE’s for CαH and NH, and c) interstrand NOE’s for the NH. 































Figure II.20.  Sections of the ROESY spectrum of 96 (2 mM in DMSO-d6, p15=400 ms) showing: a) interstrand 
NOE’s in the CαH region, b) interstrand NOE’s for CαH and NH. 
 
 
Molecular mechanics calculations were performed on the hexapeptide mimic 96, 
similarly to the tetrapeptide mimic 93, to investigate the ability of the DKP-90 scaffold to 
induce β-hairpin conformations. The molecule was subjected to an unconstrained Monte 
Carlo/Energy Minimization (MC/EM) conformational search79 in vacuo (the implicit DMSO 
solvation model is not available in the software employed) with a distance dependent 
dielectric constant of 4r, to generate a suitable starting conformation for the following 
restrained simulation in explicit DMSO solvent (see below). Two different, energetically 
equivalent, β-hairpin conformations were found within 3 kcal/mol from the global minimum 
(Figure II.21). The lowest energy conformer is characterized by the presence of hydrogen 
bonds involving the amide protons NH3, NH6 and NH1 and forming, respectively, a 12-
membered, a 16-membered and a 24-membered rings (Figure II.21, 96a). However, no 
experimental evidence is provided by the NMR data in solution (Table II.4, Figure II.17) for 
such intramolecular hydrogen bonding pattern (resembling conformer 93b of the tetrapeptide 
mimic 93, Figure II.16). The second conformer (Figure II.21, 96b) shows a β-hairpin 
conformation in agreement with the structure proposed on the basis of the spectroscopic 
data (Table II.4, Figure II.17). This conformer features a 10-membered and a 18-membered 
H-bonded rings that resemble the hydrogen bonding pattern observed in conformer 93a of 
the tetrapeptide mimic 93 (Figure II.16), and an additional 22-membered H-bonded ring 
involving the NH7 amide proton and the Ala1 carbonyl group. 
Furthermore, comparing the calculated interstrand distances in conformers 96a and 
96b between protons CαH of the Val1 and CαH of the Ala2 residues and between the proton 
CαH of the Ala2 residue and the NH
2 amide proton (Table II.5), only the 96b conformer 
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Figure II.21.  Structures of the lowest energy conformers (MC/EM, AMBER*, in vacuo) calculated for 96: left, 
global minimum (96a); right: conformer with relative energy of 0.26 kcal/mol (96b). Hydrogen bonds are indicated 
with dotted lines and for clarity all non-polar hydrogen atoms (except CαH of Val1 and Ala2 residues) and the 
phenyl residues, have been omitted. 
 
 
Table II.5.  Relevant proton distances of the low-energy conformers (MC/EM, AMBER*, in vacuo) calculated for 
compound 96. 
 
Proton distance (Å) 
Conformer 
∆E 
(kcal/mol) CαH(Val1)-CαH(Ala2) CαH(Ala2)-NH2 
96a 0.0 7.56 7.92 
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A simulated annealing protocol in explicit DMSO solvent82 using the ff03 force field83 
and the SANDER module of the AMBER7 package,84 was performed starting from conformer 
96b. According to the NOE data, two distance restraints were imposed between the protons 
CαH of the Val1 and CαH of the Ala2 residues (upper bound of 3.0 Å and force constant of 20 
kcal/mol Å) and between the proton CαH of the Ala2 residue and NH2 amide (upper bound of 
4.0 Å and force constant of 20 kcal/mol Å). The simulation converged to a unique β-hairpin 
structure (Figure II.22). Consistent with the NMR analysis, this β-hairpin arrangement 
features a 10-membered and a 18-membered H-bonded rings involving the NH5 and NH2 




Figure II.22. Simulated annealing superimposed solutions for 96b. Hydrogen bonds are indicated with dotted 
lines and all non-polar hydrogen atoms, except CαH of Val1 and Ala2 residues, have been omitted for clarity. 
  
 
Finally, the ability of peptidomimetics 92, 93, 95 and 96 to adopt an ordered secondary 
structure in solution was also evaluated by CD spectroscopy (Figure II.23). The spectra were 
measured in methanol (0.5 mM) and  showed a similar behaviour: two negative minima, one 
at 200-205 nm (201 nm for compound 96) and a second one at about 220 nm (220 nm for 
compound 96), and a negative maximum at 209-215 nm (209 nm for 96) were displayed by 
all these compounds.  
 











































Figure II.23.  CD spectra of peptidomimetics 92, 93, 95, and 96 (0.5 mM in methanol). The data are normalized for 
peptide concentration and number of residue. 
 
Unfortunately, while several CD studies have been reported for β-peptides adopting 
helical conformations (and in particular 12- and 14-helices),85-87 no conclusive data on β-
peptides assuming hairpin-type conformations have appeared in the literature. A hexapeptide 
115 (Figure II.24) consisting of β3-homo-amino, β2-homo-amino and α-amino acids with a 
central β2-β3 segment, was recently reported by Seebach and co-workers to adopt a turn-like 
conformation with a 10-membered H-bonded ring induced by the β2-β3 unit.57 Its CD 
spectrum (0.2 µM in CH3OH) displayed a similar behaviour with respect to our derivatives, 
with a minimum at 197 nm, a shoulder at 205 nm, a negative maximum at about 215 nm and 
a less pronounced minimum at ca 220 nm (Figure II.24). In addition, both minima and the 
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III.  TARGETING  INTEGRINS:  DKP  AS  RIGID  SCAFFOLDS  FOR  RGD  
SEQUENCES 
 
III.1.  INTEGRINS:  FAMILY,  FUNCTION  AND  STRUCTURE 
 
The integrin family is an extensive group of structurally related receptors for ECM 
(Extracellular Matrix) proteins and immunoglobulin superfamily molecules. Integrins are 
divalent cation dependent heterodimeric membrane glycoproteins composed of non-
covalently associated α and β subunits that promote cell attachment and migration on the 
surrounding ECM. These heterodimeric proteins are expressed by all multicellular animals, 
but their diversity varies widely among species; for example, in mammals, one of 18 possible 
α subunits heterodimerises with one of the 8 β subunits to form more than 24 distinct integrin 
proteins, whereas the Drosophila and Caenorhabditis genomes encode only five and two 
integrin α subunits respectively.88 Each integrin subunit consists of a large extracellular 
domain (approximately 80–150 kDa), a single transmembrane α-helix and a short (~30–40 




Figure II.25.  The Integrin Receptor Family. The figure depicts the mammalian subunits and their αβ associations; 
8 β can assort with 18 α subunits to form 24 distinct integrins. These can be considered in several subfamilies 
based on evolutionary relationships (coloring of α subunits), ligand specificity and, in the case of β2 and β7 
integrins, restricted expression on white blood cells. α subunits with gray hatching or stippling have inserted I/A 
domains.88 
 
CHAPTER II    SYNTHESIS AND CONFORMATIONAL ANALYSIS OF PEPTIDOMIMETICS CONTAINING A NEW DKP SCAFFOLD 
 72 
Some integrins, such as α5β1, primarily recognize a single ligand, whereas others, such 
as αvβ3, can bind several ligands. Many integrins, including αvβ3, α5β1, αIIbβ3, αvβ6 and α3β1, 
recognize the tripeptide Arg–Gly–Asp (RGD) in their ligands. Sequences flanking the RGD 
peptide are also important for integrin selectivity.89 Other integrins recognize alternative short 
peptide sequences; for example, integrin α4β1 recognizes Glu–Ile–Leu–Asp–Val (EILDV) and 
Arg–Glu–Asp–Val (REDV) in the alternatively spliced fibronectin domain known as IIICS. 
Some integrins, such as α4β1, can also bind cell surface receptors, such as vascular cell 
adhesion molecule 1 (VCAM-1), to promote cell–cell adhesion. 
 
Table II.6. Integrin extracellular ligands and recognition sequences.90 
INTEGRIN LIGAND RECOGNITION SEQUENCES 
β1 α1 Collagens, laminins GFOGER
a 
 α2 Collagens, laminins, chondroadherin GFOGER
a 
 α3 Laminins, fibronectin, thrombospondin, TIMP-2, 
uPAR, collagen, epiligrin, entactin 
RGD 
 α4 Fibronectin, VCAM IDAPS, EILDV, REDV, 
QIDS 
 α5 Fibronectin, fibrinogen, uPAR RGD 
 α6 Laminins, merosin, kalinin  
 α7 Laminins, merosin  
 α8 Fibronectin, vitronectin, tenascin-C, osteopontin,  
and nephronectin 
RGD 
 α9 Angiostatin, tenascin-C, osteopontin, and 
ADAMs, VCAM-1, tTG 
AEIDGIEL 
 α10 Collagens  
 α11 Collagens  
 αV Fibronectin, vitronectin RGD 
β2 αL ICAM-1, -2 and -3 ICAM peptides 
 αM Fibrinogen (γ-chain), ICAMs, iC3b, factor-Xa, 
denatured ovalbumin 
P1 and P2 peptide,  
ICAM peptides 
 αX Fibrinogen (α-chain), iC3b GPR 
 αD VCAM, ICAMs  
β3 αIIb Collagens, fibronectin, vitronectin, fibrinogen  
(γ-chain), vWf, thrombospondin 
RGD, 
HHLGGAKQAGDV 
 αV Fibronectin, vitronectin, fibrinogen, vWf, 
thrombospondin, FGF-2, MMP-2 and some  
RGD 
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ADAM proteins 
β4 α6 Laminins  
β5 αV Vitronectin, uPAR RGD 
β6 αV Fibronectin, tenascin RGD, DLXXL 
β7 α4 Fibronectin, VCAM, MAdCAM CS-1 peptide, LDT 
 αE E-cadherin  
 αV Collagens, laminins, fibronectin  
β8 αV Vitronectin, fibronectin  
aO as hydroxyproline. Abbreviations used in Table II.6 are: TIMP-2: tissue inhibitor of metalloproteinase; uPAR: 
urokinase-type plasminogen activator (uPA) receptor; VCAM: vascular cell adhesion molecule; ADAMs: a 
disintegrin and metalloproteinase proteins; tTG: tissue-type transglutaminase; iC3b: inactivated complement 
component 3b; ICAM: intercellular cell adhesion molecule; vWf: von Willebrand factor; FGF-2: fibroblast growth 
factor 2; MMP: matrix metallo-proteinases and MAdCAM: mucosal addressin cell adhesion molecule. 
 
 
Integrin ligation promotes integrin clustering and subsequent integrin-mediated 
intracellular signal transduction. Unlike growth factor receptors, integrins have no intrinsic 
enzymatic or kinase activities, but activate complex signalling pathways by co-clustering with 
kinases and adaptor proteins in focal adhesion complexes. A number of signalling moieties 
are activated by integrins and many of these are found within focal adhesion complexes. 
Focal adhesion complexes are composed of integrins, protein kinases, adaptor proteins, 
signalling intermediates such as Rho family GTPases, actin-binding cytoskeletal proteins 
such as talin, α-actinin, paxillin, tensin and other signalling proteins. Integrin signalling 
promotes cell migration, proliferation and survival. Loss of integrin ligation inhibits these 
events and unligated integrins can actively initiate apoptosis, even without loss of cell 
attachment. This form of cell death is stressresponse- and death-receptor-independent, but 
caspase 8-dependent, and has been called “integrin-mediated death”.91 
 
INTEGRIN  STRUCTURE 
 
The crystal structure of the extracellular domains of αvβ3 integrin published in 200192 
revealed that the αv and β3 subunits can be considered as a ‘head domain’, formed by the αv 
subunit β-propeller domain, the β3 subunit βA domain and an immunoglobulin (Ig)-like ‘hybrid’ 
domain, and two ‘legs’. The αv ‘leg’ is comprised of the Ig-like ‘thigh’ domain and two β-
sandwich ‘calf ’ domains. The β leg consists of a plexin/semaphorin/integrin (PSI) domain, 
four EGF domains and a β-tail domain (β-TD) (Figure II.26). 
CHAPTER II    SYNTHESIS AND CONFORMATIONAL ANALYSIS OF PEPTIDOMIMETICS CONTAINING A NEW DKP SCAFFOLD 
 74 
In the crystal structure, the legs are folded at the knee or ‘genu’ between the αv thigh 
and calf-1domain and between the EGF domains 1 and 2, such that the head domain is in 
proximity with the lower leg; there is evidence to suggest that this represents the resting-
state. Upon activation, the integrin is believed to move to a more extended form, 
accompanied by conformational changes within the head domain,93 including a significant 
swing in the hybrid domain that facilitates ligand binding, the so-called ‘switch-blade’ 
mechanism. However, some of the details of this mechanism still remain controversial. What 
is ceratin is that, both the ligand and unliganded structures, have a metal ion (Ca2+ or Mn2+) 
that occupies the α-genu. At the base of the propeller, blades 4-7 also contain a metal ion 




Figure II.26.  Crystal structure of the integrin αVβ3 ectodomain. (a) Ribbon diagram of the structure of the 
unliganded αVβ3. The protein is bent at a flexible region (genu, arrow) occupied by a metal ion (orange sphere). 
Four metal ions occupy the base of the propeller (indicated in orange) and an ADMIDAS ion is found in βA (purple 
sphere). (b) Ribbon diagram of the same structure in complex with the high-affinity ligand cRGD; peptide is shown 
as a ball-and-stick model, with carbons in green, amides in blue and oxygens in red. The specificity-determining 
loop (SDL) is indicated. Two extra metal ions occupy MIDAS and LIMBS (indicated in the insert).94 
 
 
III.2.  INTEGRINS:  THE  KEYS  TO  UNLOCKING  ANGIOGENESIS 
 
Angiogenesis, the development of new blood vessels, is a fundamental physiological 
process that promotes embryonic development, tissue repair and fertility, yet that also 
promotes chronic inflammation, tumour growth and tumour metastasis. New blood vessels in 
tumours can grow by sprouting from pre-existing vessels or by recruitment of rare, circulating 
bone marrow-derived endothelial progenitor cells.95 Tumour cells, macrophages and 
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fibroblasts within tumours can secrete factors, such as vascular endothelial growth factor 
(VEGF), that induce blood vessel growth in tumours.95 Basic and clinical studies indicate that 
suppression of angiogenesis can inhibit tumour progression and metastasis.96 Many lines of 
investigation implicate integrins, which are key regulators of endothelial cell migration and 
survival, as key regulators of tumour angiogenesis. As is shown in Figure II.27 tumour cells 
near pre-existing blood vessels secrete growth factors and chemokines, such as vascular 
endothelial growth factor A (VEGFA), basic fibroblast growth factor (bFGF) and tumour 
necrosis factor α (TNFα), that stimulate quiescent vascular endothelium to enter the cell 
cycle. Tumours also secrete factors such as VEGFC, VEGFA or hepatocyte growth factor 
(HGF) that stimulate the growth of new lymphatic vessels in the peritumoural space (Figure 
II.27a). These growth factors activate or upregulate expression of integrins such as α1β1, 
α2β1, α4β1, α5β1, and αvβ3 on blood vessels and α1β1, α2β1, α4β1, and α9β1 on lymphatic 
vessels (Figure II.27b). These integrins then promote endothelial cell migration and survival 
during invasion of tumour tissue, resulting in the creation of new vessel sprouts. The new 
blood vessels promote tumour growth by removing waste products and providing nutrients, 




Figure II.27.  Mechanisms regulating angiogenesis and lymphangiogenesis.97 
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Lymphangiogenesis promotes metastasis to lymph nodes and, sometimes, more 
distant tissues such as the lung, whereas angiogenesis promotes metastasis both to local 
and distant sites, such as the lung (Figure II.27d).97 
 
In vitro and in vivo data have implicated a number of endothelial cell integrins in the 
regulation of cell growth, survival and migration during angiogenesis. These integrins include 
the heterodimers α1β1, α2β1, α4β1, α5β1, α6β1, α6β4, α9β1, αvβ3 and αvβ5. Additionally, the glial 
cell integrin αvβ8 regulates blood vessel development in the brain. Although distinct 
experimental approaches, have led to conflicting theories of the roles of several integrins in 
angiogenesis (including αv integrins and α2β1 integrin), increasing molecular in vivo evidence 
points to major roles for key integrins in tumour angiogenesis.97 
 
αV INTEGRINS: As afore mentioned, the αv integrin subunit can heterodimerize with 
several different β subunits (β1, β3, β5, β6 and β8) to achieve unique ligand-binding profiles. 
The integrin αvβ3, a receptor for RGD-containing proteins such as vitronectin, fibronectin, 
fibrinogen and osteopontin, which are components of the ECM, was the first of the αv 
integrins to be characterized. It was also the first αv integrin to be shown to regulate 
angiogenesis.98 This integrin is widely expressed on blood vessels in human tumour biopsy 
samples but not on vessels in normal human tissues. Its expression on endothelial cells is 
stimulated by angiogenic growth factors such as bFGF, TNFα and IL8 and it is upregulated 
on endothelium in tumours, wounds and sites of inflammation.98 Whereas angiogenesis 
during wound healing is tightly regulated and self-limiting, angiogenesis associated with 
chronic inflammation and cancer is often persistent and abnormal.99 However, many of the 
same molecules that regulate angiogenesis in wound healing, such as integrin αvβ3, also 
regulate pathological angiogenesis. Increasing evidence points to important causative links 
between inflammation and cancer and some evidence suggests that inflammation promotes 
the angiogenic switch in tumours. 
Several experimental approaches indicate that αvβ3 has a key role in endothelial cell 
survival and migration during angiogenesis.98 Antagonists of αvβ3 inhibited angiogenesis and 
tumour growth in a variety of animal models of cancer and blocked corneal as well as 
choroidal angiogenesis in animal models of ocular disease.100 
Integrin αvβ3 antagonists induce endothelial cell apoptosis, increase the activity of the 
tumour suppressor p53, increase levels of the cell cycle inhibitor p21WAF1/CIP1 and decrease 
levels of the antiapoptotic protein BAX.101 Further studies show that αvβ3 antagonists activate 
a caspase 8-dependent cell death program.102 Thus, a sizeable body of evidence indicates 
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that integrin αvβ3 promotes angiogenesis and endothelial cell survival and that antagonism of 
this integrin suppresses angiogenesis by inducing endothelial cell apoptosis in vitro and in 
vivo. 
The related integrin αvβ5 promotes an angiogenic pathway that is distinct from that 
regulated by αvβ3. Anti-αvβ3 antibodies blocked angiogenesis induced by bFGF, whereas 
antibodies that target αvβ5 blocked the angiogenesis induced by VEGF. The VEGF-αvβ5 
pathway, but not the bFGF-αvβ3 pathway, is dependent on Src kinase and protein kinase 
C.103 In vivo angiogenesis assays showed that bFGF and TNFα depend on αvβ3 to initiate 
angiogenesis, whereas αvβ5 is required for TGFα- and VEGF-mediated angiogenesis. These 
data indicate unique roles for αvβ3 and αvβ5 integrins in angiogenesis and suggest that both 
could be important therapeutic targets. 
 
FIBRONECTIN-BINDING INTEGRINS: Fibronectin is a key ECM protein that is deposited 
by endothelial cells during normal and tumour angiogenesis. Short fibronectin peptide loops 
containing the sequence Arg–Gly–Asp (RGD) interact with integrins such as α5β1, αvβ5 and 
αvβ3.90 Fibronectin secreted by endothelial cells also contains the alternatively spliced EIIIA, 
EIIIB and IIICS domains, which bind to integrins α4β1 and α9β1. Fibronectin is essential for 
developmental angiogenesis as early embryonic lethality, which occurs when all isoforms of 
fibronectin are deleted. Deletion of only EIIIA and EIIIB alternatively spliced variants is also 
embryonically lethal, owing to severe vascular defects that suppress placentation, yolk sac 
vessel formation and heart formation.97 Thus fibronectin has a key role in angiogenesis, as 
do many of its receptors, the β1 integrins. 
 
 
III.3.  αvβ3  INTEGRIN  ANTAGONISTS 
 
Preclinical studies suggested that antagonists of several integrins might be useful to 
suppress tumour angiogenesis and growth either alone or in combination with current cancer 
therapeutics. Although antagonists of several integrins are undergoing preclinical evaluation 
and development, only a handful of integrin-based drugs have so far been tested in the clinic. 
Integrin antagonists include function-blocking antibodies, peptides and organic small 
molecules. Function-blocking anti-integrin monoclonal antibodies typically have high affinity 
and specificity, and were the first integrin antagonists to reach the clinic. Cyclic peptide or 
peptidomimetics antagonists have also been evaluated in clinical trials. Small organic 
inhibitors, particularly orally active drugs, are the most cost-effective therapeutics but the 
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development of selective and high-affinity integrin inhibitors is time-consuming. Hence, no 
organic small-molecule antagonists of integrins have yet entered clinical trials. 
Of the several integrin antagonists undergoing clinical evaluation for cancer treatment 
(Table II.7), all have proved to be non-toxic. These agents are probably non-toxic because 
the targeted integrins are only expressed or activated in remodelling tissues such as 
tumours. 
 
Table II.7 - Integrin antagonists tested in clinical trials for cancer therapy.97 
DRUG NAME TARGET DRUG TYPE TRIAL 
LAYER  






















Rena cell carcinoma 
Non-small-cell lung cancer 
Protein 
Design Labs 

















Metastatic prostate cancer 
Pancreatic cancer 
Non-small-cell lung cancer 
Glioblastoma multiforme 
Merck KGaA 
ATN-161 α5β1 Peptide I/II 
 




Concerning cyclic peptides or peptidomimetics αvβ3 antagonists a great amount of work 
was developed by Kessler and co-workers since the beginning of the 90’s. Initially, an 
extensive ligand-based drug design study, using cyclic peptide libraries with constrained 
backbone conformations, led to the discovery of the αvβ3-selective first generation cyclic 
pentapeptide 116, cyclo(-RGDfV-).104-106 This peptide shows a βII’/γ-turn arrangement with D-
Phe in the i+1 position of the βII’-turn (Figure II.28). The systematic derivatization of this 
peptide resulted in the N-alkylated cyclopeptide cyclo(-RGDf[NMe]V-)107 (117, IC50 = 0.6 nM), 
which is in clinical layer II as anticancer drug (Cilengitide, EMD121974). This is the ligand for 
which the crystal structure of the complex has been reported.93 




Figure II.28.  Cyclo(-RGDfV-) 116 and cyclo(-RGDf[NMe]V-) 117 (Cilengitide). 
 
 
Compound 117 is different from the other cyclic pentapeptides prepared by Kessler et 
al. as the hydrogen bond formation between Arg1-HN and Asp3-CO is blocked by the N-
methyl group of the valine residue. Due to steric repulsion the amide groups Asp3-D-Phe4 and 
Val5-Arg1 turn into a more perpendicular orientation with respect to the plane of the peptide 
ring. The rotation of the peptide bonds Asp3-D-Phe4 and Val5-Arg1 moreover affects the side 
chains of Arg1 and Asp3 through allylic and vinylic strain, resulting in a pronounced 
conformational difference between 116 and 117 which certainly has an effect on the αVβ3 
activity. Examination of the three-dimensional structure of 117 bound to αvβ3 integrin reveals 
a conformation characterized by an inverse γ-turn with Asp at position i+1 and by a distorted 
βII’-turn with Gly and Asp at the i+1 and i+2 positions (Figure II.28). A 8.9 Å distance 
between Asp and Arg Cβ atoms is observed in this pentapeptide-bound conformation. The 
backbone conformations of the ligand in the integrin complex and in solution (as determined 
by nuclear magnetic resonance spectroscopy in water) are very similar.108 
The same group also performed a systematic study of all retro-, inverso-, and retro-
inverso isomers of the cyclo(-RGDFV-) containing one amino acid in the D-configuration. This 
study yielded the highly active compound cyclo(-vfdGR-) (IC50 = 40 nM).
109
 Subsequently, 
novel nonpeptidic ligands have been designed by other groups.110-114 Most of them contained 
an N-terminal guanidino, benzamidino, or aminopyridine group and a carboxyl group 
separated by a well-defined distance. From this RGD-mimetic libraries115,116 derived some 
highly active compounds like the aza-Gly RGD mimics: 118a (IC50 = 150 nM) and 118b (IC50 
= 2.6 nM), possessing a β3-amino acid as the acidic C-terminal component of the molecule 
(Figure II.29), and 119 (IC50 = 6 nM) in which the C-terminal is replaced by a substituted 
glutaric acid group and the basic part of the molecule by an aminopyridine moiety (Figure 
II.29). 




Figure II.29.  Nonpeptidic inhibitors. 
 
 
In order to reduce the accessible conformational space of the cyclic RGD 
pentapeptides, Kessler’s group decided to incorporate several β-turn mimetics117 and sugar 
amino acids118 into the lead structure cyclo(-RGDfV-) 116 (Figure II.28), by replacing the D-
Phe-Val dipeptide unit, meaning the i+1 and i+2 position of the βII’-turn (Figure II.30). 
Although, it was expected that this modifications would lead to a stabilization of the βII’ turn 
simultaneously with a reduction of flexibility of the γ-turn region, it was observed that most of 
the peptidomimetic analogues contained the turn mimetic in the γ-turn region, and Gly was 
found in the i+1 position of a βII’ turn (meaning that the achiral Gly residue can act as a D-
amino acid residue). These investigations also led to several potent αvβ3 peptidomimetic 
ligands, among which the cyclo(-RGD“R-ANC”-) 120 (IC50 = 0.8 nM), containing a 3-amino 




Figure II.30.  Cyclo(-RGD“R-ANC”-). 
 
 
The combination of the recognition epitope with a secondary-structure-inducing 
element, like for example, β-amino acids,119 and cyclic or bicyclic templates was also used by 
other groups.120,121 
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Reiser et al., have synthesised a pentapeptide cyclo(-RGD-(+)-β-Acc-) (IC50 = 20 nM), 
containing a (+)-β-Acc ((+)-cis-β-aminocyclopropanecarboxylic acid) adjacent to the RGD 
sequence. Structural analysis of this cyclic pentapeptide has shown that the RGD sequence 
occupies a γ turn with glycine in the central position, and that the restrained cyclopropane 
system occupies the i+1 position of a pseudo β-turn.120 
Scolastico et al., have reported a library of cyclic RGD pentapeptide mimics, based on 
azabicycloalkane amino acid scaffolds (121, Figure II.31).121 Stereoisomeric 5,6- and 5,7-
fused bicyclic lactams showing different reverse-turn mimetic properties122 were exploited as 
dipeptide analogs for the synthesis of a library of general formula cyclo(-RGD-Lactam-) (122, 
Figure II.31). This library was found to contain specific high-affinity ligands of αVβ3 integrin, 
which are presently being evaluated as very promising antiangiogenic drugs. Among the 
peptides tested, compound ST1646 (123, Figure II.31) showed the highest affinity to αVβ3, 




Figure II.31. Cyclic RGD pentapeptide mimics based on azabicycloalkane amino acid scaffolds. 
 
 
DKPs were also used as rigid scaffolds to synthesise a small library of cyclic RGD 
peptidomimetics using solid-layer synthesis, where the RGD sequence was attached through 
the side chains of the DKP ring (cyclo-[Lys-Glu]).123 In this study Royo, Albericio and co-
workers have demonstrated that, in the case of the DKP analogues, the binding affinity to the 
αvβ3 receptor is affected by the size of the RGD-containing ring. Compound 124a (Figure 
II.32), where the loop contains just the RGD sequence, shows the highest binding affinity but 
even so with a rather modest IC50 of 4 µM. In another work reported by Robinson and co-
workers, a bicyclic template, comprising a diketopiperazine derived from L-aspartic acid and 
(2S,3R,4R)-diaminoproline, was incorporated into a cyclic four-residue loop mimetic 
containing the sequence [-Ala-Arg-Gly-Asp-template-] (125, Figure II.32). Structural analysis 
revealed that the peptide backbone of 125 is probably interconverting rapidly between two or 
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more conformational states in aqueous solution and, solid-layer binding assays reveal that 
compound 125 displays quite modest antagonist activity towards both the integrin receptor 












124a: X1 = X2 = not present
124b: X1 = not present, X2 = Gly


















Figure II.32.  Cyclic RGD peptidomimetics containing a DKP-based scaffold. 
 
 
DKPs have also been used to synthesise linear peptidomimetics of the RGD 
sequence.124 In this case, the DKP scaffold (possessing a carboxylic side chain that provides 
the acidic C-terminal component of the molecule) is linked to the basic function of the 
molecule (a guanidine, piperidone or benzamidino moiety), through a spacer of variable 
structure and length (Figure II.33). These RGD analogues were tested as inhibitors of 
platelet aggregation and of cell adhesion but only one showed a rather modest (IC50 = 27 









11 to 15 Å  
 
Figure II.33.  Linear RGD peptidomimetics containing a DKP-based scaffold. 
 
 
III. 4.  CONFORMATIONAL  STUDIES  OF  A  CYCLIC  RGD-DKP-90  PEPTIDOMIMETIC 
 
As previously discussed the examples found in literature of cyclic-RGD 
peptidomimetics containing diketopiperazine-based templates were quite discouraging. 
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However the rather modest antagonist activity shown, is probably due to the large 
conformational liberty of the molecules synthesised. In fact as discussed before in order to 
obtain potent inhibitors it is often necessary to reduce the accessible conformational space, 
like for example by incorporating a turn mimetic. Therefore, in view of the good properties of 
DKP scaffold 90 as a secondary-structure-inducing element (see discussion in Section II.4.2, 
page 60) it seemed rather logic to use this scaffold as a template for the synthesis of cyclic-























Figure II.34.  Cyclo(-RGD-DKP-90-). 
 
 
Before starting the synthetic part, computational studies aimed at investigate the 
effects of DKP scaffold 90 on the cyclopeptide conformation were performed on the cyclo(-
Asp-Gly-Arg-DKP-90-) pentapeptide mimic 126. The molecule was subjected to an 
extensive, unconstrained Monte Carlo/Energy Minimization (MC/EM) conformational search79 
by molecular mechanics methods using the AMBER* force field80 and the implicit H2O GB/SA 
solvent model.81 A simplified model of the molecule, in which the Asp and Arg side chains 
were substituted by methyl groups, was chosen in a first instance. This computational choice 
had already been applied to study RGD pentapeptide mimics containing an azabicycloalkane 
amino acid scaffold,125 due to the program limitation to treat charged systems using implicit 
solvent models. 
Only one type of conformation, featuring a β-hairpin-like arrangement, was 
predominant among the structures found within 3 kcal/mol from the global minimum. The 
lowest energy conformer features an intramolecular hydrogen bonding pattern involving the 
formation of a 12-membered and a 16-membered hydrogen-bonded rings, in which the RGD 
sequence assumes a folded conformation (Figure II.35, 126a). A second conformer was 
found at 4.20 kcal/mol from the global minimum, in which the RGD sequence assumes a 
more extended conformation showing an inverse γ-turn with Asp at the i+1 position (Figure 
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II.35, 126b). This conformation is in fact more similar to the X-ray-binding conformation of 




Figure II.35.  Structures of low-energy conformers (MC/EM, AMBER*, H2O GB/SA) calculated for compound 126: 
left, global minimum (126a); right, conformer with relative energy of 4.20 kcal/mol (126b). Hydrogen bonds are 




Figure II.36. X-ray conformation of αvβ3-bound EMD121974 (117).93 
 
 
Docking studies of compound 126 in the ligand binding site of αvβ3 integrin were 
attempted starting from the crystal structure of the αvβ3 integrin-EMD121974 complex. The 
second conformer found (Figure II.35, 126b) was docked in the ligand-bound integrin by 
superimposing the Cα atoms of the cyclopentapeptide mimic backbone and the guanidine 
and carboxy moieties of 126b to the corresponding elements of EMD121974. The resulting 
126a 126b 
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complex seemed to maintain almost the same ligand-receptor distances and interactions 
observed in the crystalline complex of EMD121974 with αvβ3 (Figure II.36). The main 
interactions observed are between the positively charged arginine of 126b and the negatively 
charged side chain of Asp218 in the α subunit and between the anionic aspartic acid and the 
metal cation in the metal ion-dependent adhesion site region of the β subunit. Further 
stabilization occurs through hydrogen bonds between the Asp side chain and the NH group 
of Asn215 and of Tyr122 in the β subunit (Figure II.37). Unfortunately the good results obtained 
in the docking studies are probably not a good representation of the reality, since the 
conformer used has a relatively high energy (4.20 kcal/mol) and therefore is not 




Figure II.37.  Top-ranking binding mode of RGD-ligand 126b into the crystal structure of the extracellular domain 
of αvβ3 integrin overlaid on the bound conformation of EMD121974 (green). Selected integrin residues involved in 
the interactions with the ligand (residues of the α subunit in blue, and those of the β subunit in brown) and crucial 





CHAPTER II    SYNTHESIS AND CONFORMATIONAL ANALYSIS OF PEPTIDOMIMETICS CONTAINING A NEW DKP SCAFFOLD 
 86 
III.5.  SYNTHESIS  OF  THE  CYCLIC-RGD-DKP-90  PEPTIDOMIMETIC 
 
The synthetic procedure designed to obtain the cyclo(-RGD-DKP-90-) 126 involves the 
cyclization of the linear precursor Asp-DKP-90-Arg-Gly. In order to minimize steric hindrance 
at the cyclization site, cyclization between the Gly and Asp residues was envisaged. These 
conditions had been already used by other groups121 and also present the advantage of 
minimizing the epimerization during the ring-closure step. In fact, since the glycine residue 
does not have a stereocentre in α, the activation of the carboxylic group and subsequent 
coupling does not present the risk of partial racemisation that eventually leads to the 
formation of the corresponding diastereomer.  
The success of the strategy designed also relies on the adequate choice of the 
protecting groups, which must be orthogonal to the conditions applied during the peptide 
chain growth. Our idea was to develop a synthetic strategy based on commercially available 
amino acids or amino acids easily obtained from the commercial derivatives. Therefore we 
decided, to use a glycine tert-butyl ester derivative in the form of hydrochloride salt and an 
arginine derivative presenting the α- and ε-amino group protected respectively as a 
carbobenzyloxy (Cbz) and a 4-methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr), and the 
carboxylic group in the form of a cyclohexylammonium salt. The acid-labile Mtr protecting 
group is normally removed with concentrate TFA in the presence of thioanisole (a 
carbocation scavenger) but it seems to be stable to the milder acidic conditions required to 
remove Boc protecting groups (TFA in dichloromethane in variable proportions).126  
The suitably protected amino acids were coupled to form the dipeptide Cbz-Arg(Mtr)-
Gly-OtBu 127, using HBTU/HOBt, EDC and DIPEA in dimethylformamide. Cleavage of the 


























Scheme II.21.  (i) HOBt, DIPEA, DMF then EDC, 0 ºC to r.t.: 87%; (ii) H2, Pd(OH)2/C, MeOH: quantitative yield. 
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Deprotected dipeptide 128 was then coupled to DKP-90 (Scheme II.22), leading to 













































Scheme II.22.  (i) H2N-Arg(Mtr)-Gly-OtBu 128, HOBt, DIPEA, DMF then EDC, 0 ºC to r.t.: 67%. 
 
At this point, in order to couple the last residue of the RGD sequence (Asp), the 
synthetic strategy designed relied in a selective removal of the Boc group while retaining the 
tert-butyl ester of the glycine residue. Some selective procedures based on the higher kinetic 
lability of N-Boc groups in respect to tert-butyl esters were reported in the literature.127,128 An 
alternative strategy involved the deprotection of both groups followed by re-esterification in 
situ of the carboxylic group under acid-catalyzed conditions in the presence of a t-Butyl 
cation source.129 In this last case, the authors claim that it is likely that the removal of a Boc 
group is an irreversible process due to protonation of the amine product and loss of CO2, 
while the deprotection of a tert-butyl ester should be reversible under acidic conditions 
(Scheme II.23). Indeed, tert-butyl esters are generally prepared under acid-catalyzed 






In our case, all attempts to selective remove the N-Boc group of derivative 129 in the 
presence of the tert-butyl ester using the described conditions were unsuccessful. The use of 
different protic acids in organic solvents (like EtOAc and CH2Cl2) led to a 1:1 mixture of the 
desired amino ester and the completely deprotected amino acid as a result of tert-butyl ester 
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removal. On the other hand when CH3SO3H was used in the presence of tBuOAc and CH2Cl2 
as a co-solvent, a 2:1 mixture of the desired amino ester and the completely deprotected 
amino acid was obtained. 
This failure obliged us to re-consider the original strategy and, as an alternative, we 
decided to start from glycine methyl ester which could be later transesterified to its benzyl 
counterpart. Using the Arg derivative described before and the commercially available Cbz-
Asp(OtBu)-OH, it would be possible to obtain the linear precursor Cbz-Asp(OtBu)-DKP-90-
Arg(Mtr)-Gly-OCH2Ph, containing both extremities protected with groups susceptible to 
catalytic hydrogenolysis (Cbz and Bn) while the Arg and Asp side chains would be 
orthogonally protected with acid-labile groups (Mtr and tBu groups, respectively). 
As is exemplified in Scheme II.24 the alternative synthetic strategy started with the 
synthesis of dipeptide Cbz-Arg(Mtr)-Gly-OMe 130. Cleavage of the Cbz group through 
catalytic hydrogenolysis afforded the deprotected dipeptide 131. Deproteced dipeptide 131 
was then coupled to the C-terminus of DKP-90, affording the desired Boc-DKP-90-Arg(Mtr)-
Gly-OMe 132. Removal of the Boc group using TFA in dichloromethane at 0 ºC allowed the 
coupling of Cbz-Asp(OtBu)-OH to the N-terminus of DKP-90, leading to the desired Cbz-
amino ester 133. 
The transformation of the methyl ester 133 to the corresponding benzyl derivative 134 
was performed under smooth conditions using a large excess of benzyl alcohol, titanium 
isopropoxide [Ti(OiPr)4] and molecular sieves to trap the methanol formed.
130 Using this 
methodology the corresponding benzyl ester 134 was obtained with an excellent yield (97%). 
Simultaneous deprotection of the benzyl ester and Cbz group, through catalytic 
hydrogenolysis, leaded to the desired linear precursor 135 in quantitative yield. 
Finally the macrocyclization step was performed in dimethylformamide using 
HATU/HOAt as coupling agent and collidine as a base, under nitrogen atmosphere, affording 
cyclo(-RGD-DKP-90-) 136 in satisfactory yield (61%). Moderately high dilution conditions (20 
mM) were used in order to favour the intramolecular condensation. 
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Scheme II.24.  (i) KHSO4 (1 M) and (ii) HBTU, HOBt, DIPEA, DMF: 78% over two steps; (iii) H2, Pd(OH)2/C, 
MeOH: quantitative yield; (iv) NH2-Arg(Mtr)-Gly-OMe, DKP-90, HBTU, HOBt, DIPEA, DMF: 72%; (v) TFA/CH2Cl2 
(1:1, v/v) and (vi) Cbz-Asp(OtBu)-OH, HATU, HOAt, DIPEA, DMF: 89% over two steps; (vii) BnOH, Ti(OiPr)4, 
THF, MS 4 Å: 97%, (viii) H2, Pd/C, MeOH: quantitative yield; (ix) HATU, HOAt, collidine, DMF: 61%. 
 
Side-chain deprotection was achieved by treating 136 with TFA, in the presence of ion 
scavengers: triethylsilane (2.5%), ethanedithiol (5%), phenol (5%), thioanisole (5%), water 
(2.5%) (Scheme II.25).  




Scheme II.25.  “Cleavage cocktail”: TFA (80%), triethylsilane (2.5%), ethanedithiol (5%), phenol (5%), thioanisole 
(5%), H2O (2.5%). 
 
After TFA removal, under reduced pressure, the cyclic RGD peptide mimic 126 was 
precipitated with diisopropyl ether, centrifuged and the resulting pellet was washed, several 
times, with diisopropyl ether. Finally, the crude compound was purified by HPLC (Water's 




III.6.  BIOLOGICAL  EVALUATION  OF  THE  CYCLIC  RGD-DKP-90  PEPTIDOMIMETIC 
 
RECEPTOR BINDING ASSAY: the cyclic RGD peptide mimic 126 was examined in vitro for 
its ability to compete with biotinylated vitronectin for binding to the purified αvβ3 receptor 
(Table II.8). Screening assays were performed by measuring the effects of the RGD 
cyclopeptide on the interaction between immobilized integrin receptors and biotinylated 
soluble ligands. The ability of the new compound 126 to inhibit the binding of vitronectin to 
the isolated αvβ3 receptor was compared with that of the standard compound 
cyclo(RGDf[NMe]V) and are reported in Table II.8. 
  
Table II.8. Inhibition of biotinylated vitronectin binding to αvβ3 receptor. 
COMPOUND IC50 (nM) ± SD a 
cyclo(RGDf[NMe]V) 18.9 ± 3.1 (measured with 125I-Echistatin) 
126 3898 ± 418 
a Values are the means ± standard deviation of triplicate determinations. 
 
The high IC50 value of compound 126 is to be acribed to the folded conformation which 
has been found as a global minimum energy in the molecular mechanics calculations that we 
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discussed above. In fact the conformation that the highly active cyclo(RGDf[NMe]V) assumes 
both in the solid state and in water solution features an extended conformation of the RGD 
moiety which is thus able to interact with the active site of the receptors. Our efforts are now 
devoted to the synthesis and biological evaluation of other cyclic RGD-diketopiperazine 
peptidomimetics possessing a different configuration of the DKP-side arms (e.g. R and S).  
 
 
IV.  CONCLUSIONS  AND  PERSPECTIVES 
 
There is no doubt that without the ability of nature to form very stable aggregates of 
small molecules, or to form well-defined secondary, tertiary and even quaternary structures 
of macromolecules, life as we know it could not exist. The folding of polypeptide chains into 
secondary and eventually a bewildering array of tertiary structures results in protein 
molecules that are responsible for most of the biological interactions and functions found in 
nature. A logical next step is evidently to mimic nature and to create nonbiologically derived 
molecules that fold into well-defined structures. Since the early 1990’s, a great deal of 
literature has been devoted to these types of biomimetic structures, involving intramolecular 
folding of unnatural molecules that are capable of mimicking or antagonizing the biological 
action(s) of a natural parent peptide, the so called: PEPTIDOMIMETICS. 
The development of these chemical model systems provides valuable insights into 
biomolecular structure and interactions by allowing researchers to simplify, isolate, and 
manipulate aspects of the complex molecular machinery of living systems. 
 
Herein, we reported the synthesis of a new bifunctional diketopiperazine scaffold 90, 
derived from L-aspartic acid and (S)-2,3-diaminopropionic acid. DKP-90 bears an amino and 




Figure II.38.  β-Hairpins bearing DKP-90 (a constrained β-dipeptide). 
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 As a consequence, DKP scaffold 90 can be seen as a conformationally constrained 
mimic of a dipeptide formed by two β-amino acids (namely a β2- and a β3-amino acids, Figure 
II.38). When inserted into a peptidic sequence, involving α-amino acids, DKP-90 is 
accommodated into the turn position of a β-hairpin (Figure II.38). IR, NMR and CD 
experiments provide strong support to this conclusion, strengthened by molecular modelling 
and molecular dynamics calculations. 
 
 Potential applications of the αv integrin antagonists range from angiogenesis and 
vascular disorders to osteoporosis. A large amount of research has been especially devoted 
to ascertain the value of the αv integrin antagonists in the cancer therapy. 
The expression of integrin adhesion molecules αvβ3 on sprouting capillary cells and their 
interaction with specific matrix ligands play a key role in angiogenesis, the formation of new 
blood vessels from pre-existing vasculature, that is essential for tumour growth, and 
formation of metastasis. 
Herein we describe the synthesis, conformational analysis, and biological evaluation of 
a cyclic RGD-DKP-90 peptidomimetic (126, Figure II.39). Its biological activity was examined 
in vitro for its ability to compete with biotinylated vitronectin in binding to the purified αvβ3 
receptor. The biological results are in agreement with the conformational studies and show a 




Figure II.39.  Cyclic RGD-DKP-90 peptidomimetic. 
 
Our efforts are now devoted to the synthesis and biological evaluation of other cyclic 
RGD-diketopiperazine peptidomimetics possessing a different configuration of the DKP-side 
arms (e.g. R and S) as well as different functionalities in the DKP ring. 
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I.  HUMAN  IMMUNODEFICIENCY  VIRUS  (HIV) 
 
Human immunodeficiency virus (HIV) is a lentivirus (a member of the retrovirus family) 
that can lead to acquired immunodeficiency syndrome (AIDS), a condition in humans in 
which the immune system begins to fail, leading to life-threatening opportunistic infections.  
Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, 
or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus 
within infected immune cells. The four major routes of transmission are unprotected sexual 
intercourse, contaminated needles, breast milk, and transmission from an infected mother to 
her baby at birth. Screening of blood products for HIV has largely eliminated transmission 
through blood transfusions or infected blood products in the developed world. 
HIV infection in humans is now a pandemic and is considered one of the most 
destructive ones in recorded history. Every day, approximately 6800 persons acquire the 
infection and 5700 die from AIDS. The estimated number of people living with HIV in 2007 
was 33.2 million, of which 2.1 million are children. The number of new infections in 2007 was 
2.5 million and the number of deaths was estimated to 2.1 million. 
 
I.1.  HIV-1  REPLICATION  CYCLE 
 
HIV-1 infects cells of the human immune system that express its main entry receptor, 
CD4, on their surface (Figure III.1). The primary targets of HIV-1 are T-lymphocytes and 
macrophages, but the virus can infect many other cells, such as monocytes, dendritic cells, 
and microglial cells in the brain. Depletion of CD4+ T-lymphocytes due to HIV-1 infection 
leads to loss of cellular immunity and is the main cause of AIDS. 
HIV life cycle is characterized by the following stages: 
 
BINDING AND ENTRY: HIV can only replicate (make new copies of itself) inside human 
cells. The process typically begins when a virus particle bumps into a cell that carries on its 
surface a special protein called CD4. The spikes on the surface of the virus particle stick to 
the CD4 and allow the viral envelope to fuse with the cell membrane. The contents of the HIV 
particle are then released into the cell, leaving the envelope behind.  
REVERSE TRANSCRIPTION AND INTEGRATION: once inside the cell, the HIV enzyme 
reverse transcriptase converts the viral RNA into DNA, which is compatible with human 
genetic material. This DNA is transported to the cell's nucleus, where it is spliced into the 
human DNA by the HIV enzyme integrase. Once integrated, the HIV DNA is known as 
provirus.  
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TRANSCRIPTION AND TRANSLATION : HIV provirus may lie dormant within a cell for a long 
time, but when the cell becomes activated, it treats HIV genes in much the same way as 
human genes. First it converts them into messenger RNA (using human enzymes). Then the 
messenger RNA is transported outside the nucleus, and is used as a blueprint for producing 
new HIV proteins and enzymes. 
ASSEMBLY , BUDDING AND MATURATION : among the strands of messenger RNA 
produced by the cell are complete copies of HIV genetic material. These gather together with 
newly made HIV proteins and enzymes to form new viral particles, which are then released 
from the cell. The enzyme protease plays a vital role at this stage of the HIV life cycle by 
chopping up long strands of protein into smaller pieces, which are used to construct mature 
viral cores. The newly matured HIV particles are ready to infect another cell and begin the 
replication process all over again. In this way the virus quickly spreads through the human 




Figure III.1.  HIV-1 life cycle.1 
 
 
I.2.  THERAPIES 
 
HIV life cycle shows several susceptible points that might be blocked by 
pharmaceutical agents. Two important characteristics of anti-HIV drugs are that they must be 
Maturation 
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specific for HIV-1, and interfere minimally with normal cellular processes. Current AIDS 
treatment involves an approach known as Highly Active Antiretroviral Therapy (HAART), in 
which antiretroviral drugs, typically three or four, are taken in combination. HAART 
combination therapy appears to overcome the ability of the virus to rapidly produce mutants 
that are drug resistant. 
There are currently 30 antiretroviral drugs approved by the FDA, which are broadly 
classified by the layer of the retrovirus life-cycle that the drug inhibits, namely: i) Nucleoside 
and nucleotide reverse transcriptase inhibitors (NRTIs and NtRTIs, respectively), ii) Non-
nucleoside reverse transcriptase inhibitors (nNRTIs), iii)  Protease inhibitors (PIs), iv)  
Integrase inhibitors, and v) Entry inhibitors (or fusion inhibitors). 
 
 
I.3.  HIV-1  PROTEASE  AND  PROTEASE  INHIBITORS 
 
I.3.1.  HIV-1  PROTEASE  STRUCTURE 
 
The HIV-1 protease (PR) was structurally characterized by X-ray crystallography for the 
first time in 19892-5 and a large number of different crystal structures are presently available. 
HIV-1 protease (Figure III.2) consists of two identical 99-residue monomers 
assembled into a C2-symmetric structure, giving rise to a dimer with a molecular weight of 
22 kDa. The enzyme is active only in its dimeric form.6 Each monomer folds into a compact 






Dimer interface  
 
Figure III.2.  HIV-1 protease structure. Major mutations that confer resistance to active-site directed drugs are 
shown in the left monomer (blue spheres). 
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ACTIVE SITE: Formation of the active protease dimer is a reversible process and high 
concentrations of monomer are needed for this to occur, this is the case in the newly budded 
virions. The monomer concentration inside the host cell is too low, preventing the active 
protease from forming and degradation of cellular proteins is avoided. The C2-symmetric 
active site is located at the dimer interface and each subunit contributes with one catalytic 
aspartic acid residue present in a tripeptide sequence, Asp-Thr-Gly.7 
FLAP REGION : The active site is flanked by the two flaps, which have to open in order to 
let the substrate in. The flaps then close for catalysis to take place, after which they open 
again to release the products. Inhibitors or substrates bind between the two subunits in the 
dimer through hydrogen bonds and van der Waals interactions with the active site. The flaps 
fold down over the substrate or inhibitor and act during catalysis both to bind substrate and 
exclude water molecules from the active site.7,8 
DIMER INTERFACE: It is structured in a 4-stranded antiparallel β-sheet formed by the 
interdigitation of N-terminal (residues 1−4) and C-terminal (residues 96−99) β-strands of each 
monomer. 
 
HIV PR SUBSTRATE SPECIFICITY  
Although the native protein is a symmetric dimer, inhibitors bind in an asymmetric 
manner. The active site contains a number of well-defined subsites where protruding 
substrate or inhibitor side chains can be accommodated upon binding.7 According to the 
Schechter and Berger nomenclature, the amino acid residues of the substrate are termed 
P1, P2…Pn and P1’, P2’…Pn’ counted from the bond which is cleaved during hydrolysis, 
called the ‘scissile’ bond (Figure III.3). The enzyme subsites occupied by these amino acid 
residues have the same numbering beginning with the letter: S, S1, S2…Sn and S1’, 
S2’…Sn’. Hydrophobic amino acid residues account for most of the PR subsites, and the 
S1/S1’ pockets are adjacent to S3/S3’. As a consequence of the symmetric nature of the 




Figure III.3.  Standard nomenclature used to denote the substrate amino acid residues and enzyme subsites. 
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I.3.2.  PROTEASE  INHIBITORS (PIS) 
 
As it was mentioned before, HIV PR is an aspartic protease that is essential for the life 
cycle of HIV.9 HIV PR cleaves newly synthesised polyproteins (gap and gap-pol) at the 
appropriate places to create the mature protein components of an infectious HIV virion. 
Without effective HIV PR, HIV virions remain uninfectious.10,11 Thus, mutation of HIV PR’s 
active site or inhibition of its activity disrupts HIV’s ability to replicate and infect additional 
cells,12 making HIV PR inhibition the subject of much pharmaceutical research.13,14 
The protease inhibitors mimic the structure of its regular substrate and compete with its 





















































































































































Figure III.4.  Structures of currently FDA-approved HIV PR inhibitors. The peptidomimetic core structure found 
within all PIs (except in Tipranavir) is shown in red. 
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All of the currently available HIV PR inhibitors (Figure III.4), except for Tipranavir 145, 
which is based on the coumarin lactone scaffold, can be considered as peptidomimetics. 
They are built upon a nonhydrolyzable hydroxyethylene or hydroxyethylamine moiety 
(instead of the normal peptidic bond), which mimics the peptide linkage (Figure III.3) in the 
polyprotein precursor gag–pol. Basically, the core (the nonhydrolyzable hydroxyethylene or 
hydroxyethylamine moiety) is a good isostere replacement at the scissile bond that is 
believed to mimic the tetrahedral transition state of the proteolytic reaction.15 
Compared with the substrate analogue, those clinical drugs are smaller and make few 
interactions with PR. All of these drugs bind to the active site of PR by hydrogen bonds and 
van der Waals interactions, depending on the nature of the groups at each position. 
 
MULTI-THERAPY  AND  PIS  LIMITATIONS 
 
Shortly after the introduction of the first antiretroviral drug, the limited effects of 
monotherapy on HIV became clear. However, when the first PIs were launched in the mid 
1990s, a new treatment strategy including combination therapy with drugs from different 
classes of anti-HIV agents was evaluated. Several reports indicated efficient suppression of 
viral loads and reduced mortality among HIV patients receiving the combination regimen.16-19 
Initially, two NRTIs and one PI were used in this highly active antiretroviral therapy (HAART) 
and today several different drug associations are available, combining: NRTIs, NtRTIs, PIs 
and nNRTIs.20 
Nevertheless, viral resistance to protease inhibitors administrated alone or in 
combination with reverse transcriptase inhibitors have been described in vivo.21 The 
mechanism for the development of resistance to PIs is quite complicated, since the locations 
of PI-resistant mutations vary from substrate/inhibitor binding site, dimer interface, and flap 
region to surface of protease (Figure III.2). 
Besides drug resistance, the adverse metabolic side effects are another major issue 
involving the PI treatment. The adverse effects that have been reported include peripheral 
lipodystrophy, visceral adiposity, hyperlipidemia, diabetes mellitus, cardiovascular disease, 
hypertension and insulin resistance.22,23 As more and more evidence accumulates, it has 
been confirmed that PIs do not specifically target HIV PR as designed and they disturb the 
function of a number of unrelated molecules. 
The drug resistance as well as the adverse side-effects suggests that there is a need 
for structurally diverse antiproteases. Since all protease inhibitors used in HIV-1 therapy 
interact with the active site it is probably necessary to target other binding locus for HIV-1 PR 
inhibitors. 
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II.  INHIBITORS  OF  HIV-1  PROTEASE  DIMERIZATION 
 
As mentioned before, the HIV PR is composed of 2 monomers, of 99 amino acids each 
(Figure III.5) that are self assembling into a homodimeric structure (see also, Figure III.2). 
The association of these two monomers allows the formation of the active site, meaning that 




Figure III.5.  Primary structure of the HIV-1 PR monomer. 
 
The HIV protease is characterized among others, by three important areas: i) the active 
site, were Asp25 and Asp25’ (in red, Figure III.5) provide important interactions with the 
substrate or the inhibitor; ii)  the flap region, where the residues Ile50 and Ile50’ (in purple, 
Figure III.5) also provide important interactions with the substrate or the; and iii) the 
dimerization interface, structured in  a 4-stranded β-sheet formed by the residues N-terminal 
P-Q-I-T ([1-4 and 1’-4’], in green, Figure III.5) and C- terminal T-L-N-F ([96-99 and 96’-99’], in 
blue, Figure III.5) of each monomer. 
In the crystal structures of HIV-1 PR, the polypeptide termini are held at a distance of 
approximately 10 Å. This four-stranded β-sheet provides a network of hydrogen bonds, by 
forming an array of 10 and 14 member rings of hydrogen bonds (Figure III.6). It is estimated 
that this structure contributes close to 75% of the total Gibbs free energy of dimerization.24  
An important feature of this region of dimerization is that it is found less mutated, even 
among viruses resistant to antiretroviral treatment,25 making it an interesting alternative target 
compared to the classic target, which is the active site. Blocking the assembly of the HIV-1 
PR homodimer or disturbing the dimeric interface would be a novel means of inhibiting 
protease activity. 
The development of the PR dimerization inhibitors is based on a thorough knowledge 
of its structure. In the next sections, the design and synthesis of new dimerization inhibitors 
of HIV-1 PR will be discussed. 
Pro Gln Ile Thr  Leu Trp Gln Arg Pro Leu Val Thr Ile       13 
Lys Ile Gly Gly Gln Leu Lys Glu Ala Leu Leu Asp Thr     26 
Gly  Ala Asp Asp Ser Ile Val  Ala Gly Ile  Glu Leu Pro      39 
Gly Arg Trp Lys Pro Lys Met Val Gly Gly Ile Gly Gly        52 
Phe Ile Lys Val Arg Gln Tyr Asp Gln Ile Leu Ile Glu         65 
Ile  Cys Gly His Lys Ala  Ile Gly Thr  Val Leu Val Gly       78 
Pro Thr Pro Ile Asn  Ile   Ile Gly Arg Asn Leu Leu Thr      91 
Gln Ile Gly Cys Thr Leu Asn Phe                                     99 




Figure III.6.  Antiparallel β-sheet formed by the interdigitation of N-terminal (residues 1-4) and C-terminal 
(residues 96-99) β-strands of each monomer of the PR. H-bonds represented by dotted lines.  
 
 
II.1.  INHIBITORS  IN  LITERATURE  
 
The recently approved PIs Tipranavir and Darunavir, which target the HIV-1 PR active 
site, also disrupt dimer interface.26,27 Koh et al have also reported others non peptidyl small 
molecules as dimerization inhibitors.27 The next section describes some short peptides, 
cross-linked interfacial peptides and non-peptide based inhibitors of PR dimerization. 
 
II.1.1.  SHORT  PEPTIDES 
 
Short synthetic peptides corresponding to the amino acid sequences of the N- and C-
terminal of HIV-1 PR 147−157 have been shown to inhibit proteolytic activity by binding to 
the inactive PR subunits and preventing their association into active dimer.28-31 However, the 
concentration of these peptides required to effectively inhibit the PR monomer-dimer 
equilibrium by 50% (IC50) is relatively high (30-100 µM, Table 3.1).32 Schramm et al. 
demonstrated that it was possible to significantly improve their inhibitory properties 
(approximately 50-200 fold) through modification of their amino-acid composition and the 
addition of a hydrophobic moiety, such aminocaproyl or palmitoyl, to the N-terminus of the 
peptide.32,33 The development of these more potent peptide inhibitors firmly established that 
PR dimerization was a rational target for the development of AIDS therapeutics, and that 
small-size peptide mimetics could be derived for HIV-1 therapy. In this regard, N-terminally 
palmitoyl-blocked peptides 155−157 consisting of only three residues, one of which is a non-
natural amino acid, have been developed and shown to exhibit good inhibitory potency of 
nanomolar range against PR dimerization.34-37 
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Table III.1.   Peptide and small molecule inhibitors of HIV-1 PR dimerization. Kinetic analyses were carried out 
according to the method described by Zhang et al.28 
 
STRUCTURE K id  (nM) 
PEPTIDES DERIVED FROM THE N- TERMINUS OF HIV-1 PR 
147:  H-Leu-Gln-Ile-Thr-Trp-OH32 




PEPTIDES DERIVED FROM THE C- TERMINUS OF HIV-1 PR 
149:  Ac-Thr-Leu-Asn-Phe-OH28 
150:  H-Ile-Ser-Tyr-Glu-Leu-OH32 
151:  H-Ser-Tyr-Glu-Trp-OH32 
152:  H-Ser-Tyr-Glu-Leu-OH32 
153:  H-Tyr-Glu-Leu-OH32 








MODIFIED PEPTIDES DERIVED FROM THE C-TERMINUS OF HIV-1 PR 
155:  Palmitoyl-Tyr-Glu-Leu-OH34 
156:  Palmitoyl-Thr-Val-Ser-Tyr-Glu-Leu-OH34 







II.1.2.  CROSS-LINKED  INTERFACIAL  PEPTIDES  
 
Cross-linking of the N- and C-terminal peptides to form a mimic of the HIV-1 PR 
dimerization interface has provided an alternative strategy for the development of more 




Figure III.7.  Schematic representation of the strategy used to inhibit PR dimerization by cross-linked interfacial 
peptides. The PR N-terminus is indicated (N). The 4-stranded β-sheet formed by amino acid residues at the N- 
and C-termini of PR is a major binding determinant in the formation of dimeric PR. Cross-linked interfacial 
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peptides containing a tether region of approximately 10 Å inhibit PR dimerization by permitting the formation of a 
pseudo antiparallel β-sheet with one of the PR subunits. 
 
 
II.1.2.1.  PEPTIDES  WITH  FLEXIBLE  SPACERS 
 
This approach was initially adopted by Babe et al.,30,38 who cross-linked peptide 
sequences containing the N- and C-terminal regions of HIV PR with a 3.5 Å tether composed 
of three glycine residues 158, (IC50 = 40 µM, Figure III.8). However, the resulting compounds 
were not potent inhibitors of PR dimerization. In the crystal structures of HIV-1 PR, the 
polypeptide termini are held at a distance of approximately 10 Å (Figure III.7) and this can 
explain why the N- and C-terminal PR-derived peptides with a 3.5 Å tether are not good 
inhibitors of PR dimerization.  
Accordingly, more potent cross-linked interfacial peptide compounds have been 
developed using tethers that bridge this gap. For example, Zutshi et al. synthesised 
interfacial peptides cross-linked with alkyl chains in order to reproduce the β-sheet structure 
with one HIV-1 PR monomer.39 Their best inhibitor 159 (IC50 = 2 µM) was constructed with 
HN-PQITLW-OH and HN-STLNF-OH polypeptide chains tethered with a C14 alkyl chain 
(Figure III.8). The major drawback of these cross-linked inhibitors is related to their high 
conformational freedom which induces an unfavourable entropy term in the interaction 
energy of the inhibitor-HIV-1 PR monomer complex. 
In an effort to simplify the synthesis of HIV-1 PR inhibitor libraries, a new tether, 12-
aminododecanoic acid (12-Ado), was developed (Figure III.8). This tether, was crosslink to 
interfacial peptide, in which the directionality of the southern peptide was changed from N→C 
to C→N. Furthermore, the terminal amine of the southern peptide can be used to incorporate 




































Figure III.8.  Peptides with flexible spacers. 
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Designed agents based on cross-linked interfacial peptides of protease showed good 
potency against HIV-1 protease dimerization and activity, but high molecular complexity.39 
Efforts to identify the minimal structure necessary for activity led to an agent that functioned 
as a dimerization inhibitor, but with reduced potency.41 On the basis of a model of the 
complex of inhibitor 161 (Ki = 3000 nM) and the HIV-1 protease monomer, Chmielewski et al. 
designed a focused library (Figure III.9) of agents, in an effort to regain high potency, by 
replacing successively the amino acids in positions 1, 2, 3, 4, 5 with unnatural amino acids, 
bearing side chains like: Thx (thyroxine), Chg (cyclohexylglycine), NaI (naphthylalanine), Cha 
(cyclohexylalanine), Paf (4-aminophenylalanine) and Hfe (homophenylalanine) (Figure III.9). 
Concerning the single position modifications, the best result was obtained when the Phe 
residue at position 1 was replaced with the biphenyl ether moiety of Thx (Ki = 71 nM).
42 An 
even more powerful inhibitory potency against PR dimerization was obtained when two 
amino acids of the starting structure 161. The best results were obtained maintaining the 
previous modification (Phe1→Thx) and introducing a Paf residue at position 4 or a NaI 
residue at position 5 (Ki = 29 nM, in both cases).
43 
Irreversible inhibition of PR dimerization has also been achieved by designing a cross-
linked interfacial peptide molecule (162: Kinac = 3.7 µM) that can form a disulfide bond with 




























































































Figure III.9.  Peptides with flexible spacers. 
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II.1.2.2.  PEPTIDES  WITH  UNCHARGED  AND  CHARGED  RIGID  SPACERS 
 
Molecular tongs 
Sicsic et al. introduced in 199945 a more rigid scaffold in the tether (to increase 
conformational constrain), such as resorcinol, 2,6-pyridinediol (163a and 163b, respectively) 
and 2,7-naphthalenediol 164a (Figure III.10), leading to compounds (named, “molecular 
tongs”) active in the micro and submicromalor range. In 200446 were introduced new 
molecular tongs based on quinoline and naphthalene scaffolds (164a and 164b, respectively) 
linked to two peptidic strands of different sequences. In order to increase the resistance to 
proteolysis of these molecular tongs, in 200647 were inserted peptidomimetic motifs into one 
peptidic strand of the molecular tongs (for more details see Section II.2, page 112).  
 
Guanidinium-based inhibitors 
Dimerization inhibitors of HIV-1 PR based on a chiral lipophilic bicyclic guanidinium 
subunit 165 (Figure III.10) as the central tether between a short peptide mimicking the C-
terminal native strand, to interact with both C and N termini of the monomer, and an 
additional hydrophobic bulky group (TBDPS, Cholesteryl) targeting the dimer interface have 
also been described.48 Some of the compounds described inhibited the dimerization of HIV 




Figure III.10.  Peptides with uncharged and charged rigid spacers. 
 
Dibenzofuran-based inhibitors 
Song et al. have used dibenzofuran-based amino acid 27 (Kelly’s “β-sheet nucleator” 
discussed in Chapter I, page 21) to connect the interfacial N- and C-terminal peptide 
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fragments from the protease sequence, to obtain inhibitor 166 (Kid = 5.4 µM).49 They have 
also synthesised compound 166 (Kid = 9.1 µM) containing an “unnatural β-strand mimetic” (5-
amino-2-methoxybenzoic hydrazide derivative; Nowick’s template also discussed in Chapter 
I, page 27) which interferes with the β-sheet interaction between the two PR monomers and 
inhibits the enzymatic activity (Figure III.10).49  
 
II.1.2.3.  NON-PEPTIDE  BASED  INHIBITORS  OF  PR  DIMERIZATION 
 
To date, two structurally unrelated classes of small-organic molecules which inhibit PR 
dimerization, have been identified.50,51 The first class of molecules, which exhibit a polycyclic 
triterpene structure, were identified following a search of the Cambridge Structural Database 
(www.ccdc.cam.ac.uk) for pharmacophores that could bridge the 10 Å gap between the 
termini of a PR subunit.50 Extensive kinetic analysis of one of these triterpenes, ursolic acid 
168 (Figure III.11), demonstrated that these compounds inhibited PR dimerization with 
relatively high potency (Ki = 3.4 µM). The second class of molecules that inhibited PR 
dimerization include penta ester derivatives of  didemnaketal A 169 (Ki = 2.1 µM, Figure 
III.11).51 The identification of these classes of small molecules is significant, as in general 
many empirical searches for low molecular mass pharmacological inhibitors (<400) of 




Figure III.11.  Non-peptide based inhibitors of PR dimerization. 
 
 
II.2.  PREVIOUS  WORK  IN  OUR  LABORATORY  
 
Our contribution to the antidimer strategy was the synthesis of the first “molecular 
tongs” based on a conformationally constrained scaffold attached to two peptidic strands 
through two carboxypropyl linkers. The advantage of this strategy is that the two peptidic 
strands could be suitably oriented by the scaffold allowing the putative formation of an 
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antiparallel β-sheet with the C-terminal and N-terminal of one HIV-1 PR monomer, thus 
leading to an entropy benefit (Figures 3.12 and 3.13). 
 
 
Figure III.12.  Strategy of molecular tongs based on conformationally constrained scaffolds. 
 
 
The amino acids of the molecular tongs that inhibited PR are believed to be involved in 
hydrogen bond interactions with the N- and C-terminal of one PR monomer, favoring the 
formation of a β-sheet structure and mimicking the 4-stranded β-sheet structure of the PR 
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Figure III.13.  Illustration of possible interactions (network of 10- and 14-membered H-bond rings) of two peptidic 
arms of our molecular tong with the N- and C-terminal residues of HIV-1 PR. 
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For the design of new rigid scaffolds by molecular modeling, crystallographic protease 
structure 8HVP, downloaded from the Protein Data Bank, was used.45 One monomer and the 
TLNF and QITL strands of the other monomer were retained and different rigid scaffolds 
were bound to the TLNF and QITL strands. The tongs were built on the TLNF and QITL 
fragments in such a way that the minimization procedure of the obtained complexes 
converged easily (termination gradient of 0.5 kcal/mol Å). Four constrained scaffolds were 
designed based on resorcinol, 2,6-pyridinediol, 2,7- naphthalenediol and 2,7- quinolinediol on 
which carboxypropyl links were bound (Figure III.14).45 The carboxypropyl links also allowed 
some flexibility which may be necessary during the complexation process with one monomer 
of HIV-1 PR.45 
  
 




II.2.1.  PEPTIDIC  MOLECULAR  TONGS 
 
Two peptidic strands (dipeptide, tripeptide or tetrapeptide) were attached to the scaffold 
(Figure III.14b).45 First symmetrical molecular tongs were evaluated,45 secondly 
unsymmetrical molecular tongs bearing two different peptidic arms were synthesised and 
biologically evaluated.46  
Table III.2 indicates the best results of inhibition of HIV-1 PR by the synthesised 
molecules within their limit of solubility in test medium (no inhibition was observed for all the 
resorcinol based tongs). 
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Table III.2.  Biological result of molecular tongs (binding analysis used the Zhang28 procedure, E* for tert-butyl 
ester of the glutamate). 
 
MOLECULE  SCAFFOLD  PEPTIDE 1 PEPTIDE 2 K id  (ΜM) 
170 pyridinediol T-I-V-OMe T-I-V-OMe 1.4 
171 pyridinediol T-L-N-F-OMe T-L-N-F-OMe 10.0 
172 pyridinediol V-L-V-OMe V-L-V-OMe 3.0 
173 pyridinediol Q-I-T-L-OMe Q-I-T-L-OMe ni 
174 naphthalenediol Q-I-T-L-OMe Q-I-T-L-OMe ni 
175 naphthalenediol T-L-N-F-OMe T-L-N-F-OMe 1.0 
176 naphthalenediol V-L-V-OMe V-L-V-OMe 0.56 
177 quinolinediol V-L-V-OMe V-L-V-OMe 0.13 
178 naphthalenediol V-L-V-OMe T-L-OMe 1.4 
179 quinolinediol V-L-V-OMe T-L-OMe 1.5 
180 naphthalenediol V-L-V-OMe I-T-NH2 1.5 
181 quinolinediol V-L-V-OMe I-T-NH2 0.25 
182 naphthalenediol V-L-V-OMe E*-L-NH2 0.42 
183 quinolinediol V-L-V-OMe E*-L-NH2 0.53 
184 naphthalenediol V-L-V-OMe E-L-NH2 0.9 
185 quinolinediol V-L-V-OMe E-L-NH2 20% at 5.7 µM 
186 quinolinediol V-L-V-OMe I-T-L- OMe 0.40 
187 quinolinediol V-L-V-OMe T-L-N-OMe 0.08 
188 naphthalenediol V-L-V-OMe Y-E*-L-NH2 0.23 
189 quinolinediol V-L-V-OMe Y-E*-L-NH2 0.41 
 
 
These results may be discussed as follows: 
a) for molecular tongs 170-176 45 : the naphthalenediol- and pyridinediol-based 
scaffolds appear efficient to induce peptidic interface inhibition on PR, while the resorcinol-
based scaffold appears inefficient. From a steric point of view, the necessary distance of 10 
Å between the two peptidic strands of the tongs could be more easily reached by the 
naphthalenediol-based tongs than by the two other types of tongs. On the other hand, from 
an electronic point of view, only the pyridinediol-based tongs could form a favourable ionic 
interaction between the positively charged pyridine in the medium test and the negatively 
charged Phe-O- 99 of the C-end of HIV-1 PR monomer. This argument is supported by the 
fact that scaffold pyridinediol•HCl had a pKa = 6.15 as measured potentiometrically. The 
assumption that steric effect and/or electronic effect are favourable for the tongs to induce 
inhibitory activity could explain why the resorcinol-based tongs were devoid of activity.  
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The peptidic sequence TLNF-OMe reproducing the internal C-terminal strands of the 
antiparallel β-sheet of HIV-1 PR led to the active tongs 171 and 175, while the peptidic 
sequence QITL-OMe reproducing the external N-terminus β-sheet strand led to the inactive 
tongs 173 and 174. These results are consistent with those described in the literature where 
the best inhibitions were observed with interfacial peptides reproducing the C-terminal 
strand.28,32  
Surprisingly, the short peptidic sequence VLV-OMe appeared as the best sequence for 
inducing inhibitory potency (compounds 172 and 176), although it did not reproduce the 
sequences involved in the natural antiparallel β-sheet of HIV-1 PR.45 
b) for molecular tongs 177-189 46 : to improve the potency of this family of HIV-1 PR 
dimerization inhibitors, the structure of the scaffold was modified and also nonsymmetric 
tongs were introduced, consisting of two different peptidic strands attached to each scaffold. 
Firstly, a quinoline-based scaffold was introduced, as quinoline contains structural 
requirements of both naphthalene and pyridine (Figure III.14). 
Secondly, in order to easily establish a structure-activity relationship, it was decided to 
keep unchanged one of the two peptidic strands of these nonsymmetric tongs. According to 
the first results (molecular tongs 170-17645), the peptidic strand P1 was fixed as VLV-OMe for 
all compounds. The other peptidic strand P2 varied in size (di- or tripeptide) and sequence. In 
one case P2 was a part of the C-terminal TLNF strand of monomers of HIV-1 PR (187); in 
other cases it was a part of the N-terminal PQITL strand (180, 181 and 186) of monomers. 
For compounds 178 and 179, P2 was fixed to TL-OMe which is a part of both C-terminal 
TLNF and N-terminal QITL strands of each monomer. The peptides EL and YEL and their O-
protected glutamate analogues were introduced in compounds 182-185, 188 and 189 are 
parts of the powerful dimerization inhibitor lipopeptide Pam-Y-E-L designed by Schramm.34 
Symmetric compounds 177 (P1 = P2 = VLV-OMe) based on the quinoline scaffold were also 
synthesised for comparison with symmetric tongs 176 based on the naphthalene scaffold. 
 
FIRST  CONCLUSIONS 
• quinoline and naphthalene derivatives are valuable scaffolds and are superior to 
pyridine and resorcinol derivatives (Figure III.15); 
• the attached tripeptidic strands induce generally better inhibitions than the dipeptidic 
and tetrapeptidic ones;  
• the best peptidic sequence is Val-Leu-Val-OMe; 
• hydrophobicity of the attached peptidic strands is a favourable property to induce 
inhibition (molecular tongs peptides EL, 184 and 185, are less active than their O-
protected glutamate analogues, 188 and 189, respectively). 




Figure III.15. Comparison of the rigid scaffolds. 
 
 
II.2.2.  MOLECULAR  TONGS  WITH  ONE  PEPTIDOMIMETIC  ARM 
 
Unsymmetrical molecular tongs containing amino acid mimetic fragments in one strand 
with the other peptidic strand being VLV-OMe (Figure III.16) were synthesised.47 These new 
molecular tongs 190a–195a,b were designed to have less peptidic character and 
consequently to be less susceptible to proteases in vivo. The peptidic character of a 
molecule can be decreased by replacing one or more amino acids with groups that mimic 
their hydrogen-bonding properties. The amino acids of the molecular tongs that inhibited PR 
are believed to be involved in hydrogen bond interactions with the N- and C-termini of one 
PR monomer, favouring the formation of a β-sheet structure and mimicking the 4-stranded β-
sheet structure of  the PR  dimer (see Figure III.17). Consequently, the groups replacing 
amino acids should ideally provide the same array of H-bonding groups as one edge of a 
peptide β-strand. In literature, Nowick and Sanderson have introduced a 5-amino-2-
methoxybenzoic hydrazide derivative52-57  and a 3-amino-6-methylpyridin-2(1H)-one group,58 
respectively, to potentially form hydrogen bonds like those of amino acids. Consequently, our 
group has designed new molecular tongs with one peptidomimetic strand bearing a 5-amino-
2-methoxybenzoic hydrazide derivative (192a and 193a,b), a 5-nitro-2-methoxybenzoic 
hydrazide derivative (194a,b), a Sanderson motif (190a and 191a) or a simplified version of 
this motif, where the methyl group was omitted (195a,b).47  
Two cases were examined: first, the mimic unit was attached directly to the 
carboxypropyl link (molecules 190a, 191a, and 192a, Figure III.16); second, it was linked 
through a Val residue (compounds 193a,b, 194a,b and 195a,b, Figure III.16). The results of 
building several possible complexes using the Sybyl 7.0 molecular modelling tools indicated 
that forming the postulated β-sheet structure between the N- and C-terminal of one PR 
monomer and molecule 193a,b, 194a,b or molecule 195a,b (Figure III.17) is energetically 
possible, since the correct array of alternating 10- and 14-membered H-bonded rings is still 
present after minimization. Conversely, no stable β-sheet structure was formed with 
molecules 190a, 191a and 192a.47  




a : X = C

























































































































































































































Figure III.17.  Putative complexes between HIV-1 PR monomer and molecular tongs 193a and 195a based on 
molecular modeling.47  
 
The inhibitory activities of compounds 190a–195a,b were assayed against recombinant 
wild-type PR at pH 4.7 and 30 °C using a fluorometr ic assay. Compound 195a was also 
assayed against six recombinant mutated proteases (Table III.3). The results are in 
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agreement with molecular modelling and no dimerization inhibition was observed for 
molecular tongs 190a, 191a and 192a.47  
 
Table III.3.  Inhibition of wild-type and mutated HIV-1 PR by molecular tongs with one peptidomimetic arm 
(amutations in the active site showed in bold, bcompetitive active-site inhibition, cdimerization inhibition, 
dunpublished results). 
 
COMPOUND WILD-TYPE (WT) OR MUTATED PROTEASESa K ic  (µM)
b K id  (µM)
C 
190a47  9.7  
191a47  8.4  
192a47  28 % inhibition at 5 µM 
193a47 WT  0.2 
193bd WT  0.2 
194ad WT 30 % inhibition at 1 µM 
194bd WT  0.4 
195a47 WT  0.4 
195a47 D30N  0.5 
195a47 I50V  0.1 
195a47 V82A  0.24 
195a47 G48V/L90M  0.5 
195a47 MDR-HN  4.8 
195a47 ANAM-11  0.2 
195bd WT 30 % inhibition at 2.8 µM 
 
For the molecular tongs 193a,b, 194a,b and 195a,b the results indicate that replacing 
the tripeptide VLV (compound 176) with a peptidomimetic strand composed of a valine 
residue linked to the Nowick motif (compounds 193a,b and 194b) or to the demethylated 
Sanderson motif (compound 195a) results in antidimer inhibitors that are still fully active 
against wild-type PR (Kid = 0.2 µM for 193a,b; Kid = 0.4 µM for 194b;  Kid = 0.4 µM for 195a, 
compared to Kid = 0.56 µM for 176). Thus, the Nowick and demethylated Sanderson 
peptidomimetic units can be used to replace amino acids in the structures of the previously 
described molecular tongs. The results are in agreement with molecular modelling, indicating 
that the antidimer property depends on the position of the mimic unit in the peptidomimetic 
strand. It was also suggested that the flexibility of valine is required for the formation of the 
H-bonds in a 4-stranded antiparallel β-sheet, implicating the N- and C-terminal of the PR 
monomer.47  
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One of these dimerization inhibitors 195a was also evaluated against proteases with 1, 
2, 6, and 11 point mutations; and it was as active (and in some cases more active) on 
mutated proteases as on wild-type PR. For example, the affinity of ANAM-11 protease for 
compound 195a was 2-fold greater (Kid = 200 nM) than that of wild-type PR (Kid = 400 nM). In 
contrast, the affinities of this mutated protease for indinavir, nelfinavir, saquinavir, and 
ritonavir were about 2030, 2840, 4200, and 78 000 times lower than that of wild-type PR.59 
This demonstrates that the peptidomimetic molecular tong 195a still acts as an efficient 
inhibitor of the dimerization of mutated proteases.47 This result confirmed the hypothesis 
suggesting that inhibitors of dimerization are poorly sensitive to mutations. 
Finally, the stability of the peptide (176) and peptidomimetic (193a and 195a) molecular 
tongs in RPMI culture medium containing 20% fetal calf serum was studied. The half-life of 
compound 176 was about 28 h and that of 195a about 41 h; no significant degradation of 
compound 193a was observed after 33 h of incubation. The results suggest that the 
metabolic stability has been improved by inserting peptidomimetics into one arm of the 
molecular tongs.47 
 
II.2.3.  MOLECULAR  TONGS  WITH  TWO  PEPTIDOMIMETIC  ARMS 
 
Molecular tongs discussed in this section were synthesised by Anamaria Vidu.i In order 
to establish the superiority or inferiority of the unsymmetrical molecular tongs (193a and 
195a) over inhibitors with two identical peptidomimetic strands, we decided to synthesise the 
symmetric molecular tongs 196 and 197, containing a valine residue linked to the 5-amino-2-
methoxybenzoic hydrazide derivative and the demethylated Sanderson group, respectively 
(Figure III.18). Evaluation of these molecular tongs against HIV-1 PR showed that they 
behaved as mixed inhibitors (Kic = 0.2 µM and Kid = 0.029 µM for 196; and Kic = 0.4 µM and 




Figure III.18.  Molecular tongs with two peptidomimetic arms. 
                                                 
i Unpublished results. 
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II.2.3.1.  INTRODUCTION  OF  A  POLAR  AMINO  ACID: LYSINE 
 
In order to increase the solubility of our molecular tongs, specially solubility in mediums 
compatible with biological evaluation, it was decided to replace the valine residue in the 












Figure III.19.  Chemical structure of lysine. 
 
Lysine was chosen because it has a positively charged ε-amino group in physiological 
conditions which promotes solubility. However, since the side chain has three methylene 
groups, even though the terminal amino group will be charged under physiological 
conditions, the side chain does have significant hydrophobic character.  
Lysine has already been used in β-sheet peptidomimetics, in order to increase the 
solubility without destabilizing the secondary structure.60 
Two new peptidomimetic arms were then synthesised containing the lysine residue 
linked to the 5-amino-2-methoxybenzoic hydrazide derivative (198) and the 3-amino pyridin-
2-one derivative (201). After deprotection of the NHα of both peptidomimetic fragments, the 
new arms were then attached to naphthalene scaffold affording molecular tongs 199 and 
202, respectively. Finally, deprotection of the NHε gave rise to the deprotected molecular 
tongs 200 and 203, respectively (Figure III.20). 
Evaluation of molecular tongs 199 and 202 against HIV-1 PR showed that they are also 
mixed inhibitors (Kic = 0.15 µM and Kid = 0.053 µM for 199; and Kic = 0.2 µM and Kid = 0.12 
µM for 202). Comparison of the mixed inhibitors 196 vs 197 and 199 vs 202, show that the 
ones containing the 5-amino-2-methoxybenzoic hydrazide derivative (196 and 199) are 
better than the ones containing the 3-amino pyridin-2-one derivative (197 and 202). 
On the other hand, the deprotected molecular tongs 200 and 203 show much less 
activity (30% inhibition at 14 µM and 28% inhibition at 12 µM, respectively) than the 



















Figure III.20.  Symmetrical molecular tongs bearing a lysine residue (I). 
 
 
II.2.3.2  LOSING  TOTALLY  THE  PEPTIDIC  CHARACTER  
 
As was shown before the peptidomimetic fragments are linked to the scaffold through 
the lysine unit. The presence of the two amino groups of lysine (α-amino group and ε-amino 
group), gives us the possibility of designing other molecular tongs (Figure III.21). 
In fact the peptidic character of the molecular tongs may be totally lost if the linkage to 
the scaffold is done through the ε-amino group of the lysine residue of peptidomimetic 
fragment 198 and 201 (Figure III.21), giving rise to molecular tongs 204 and 206, 
respectively. Consequently, it is possible to study the influence of the introduction of a totally 
non-peptidic arm as well as the influence of supplementary flexibility. Finally, deprotection of 
the NHα gave rise to the deprotected molecular tongs 205 and 207, respectively (Figure 
III.21). 
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Figure III.21.  Symmetrical molecular tongs bearing a lysine residue (II). 
 
 
Evaluation of the totally peptidomimetic molecular tongs against HIV-1 PR showed that 
tong 204 is a pure antidimer inhibitor (Kid = 0.28 µM), while tong 206, bearing the 3-amino 
pyridin-2-one derivative, is only a poor inhibitor of the active site (Kic = 15.5 µM). We could 
once again note the superiority of the 5-amino-2-methoxybenzoic hydrazide derivative over 
the demethylated Sanderson motif. The deprotected molecular tongs 205 and 207 show 
much less activity (30% inhibition at 28 µM, in both cases) than the respective protected 
analogues 204 and 206. 
The good result obtained with molecular tong 204 demonstrated that is possible to 
completely suppress the peptidic character without compromising the activity. On the other 
hand, increasing the polarity of the molecular tong arms has proven to be a much harder 
task, as by deprotecting the lysine amino group we lose activity without sufficiently improving 
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II.3.  CONCEPTION  OF  OUR  MOLECULES  
 
The contribution of our laboratory to the antidimer strategy has been the synthesis of 
molecular tongs based on a conformationally constrained scaffold, in which peptidic45,46 or 
peptidomimetic arms,47 were attached through a carboxypropyl link.  
Despite the good activity demonstrated in vitro, all attempts to test the molecular tongs 
in cell failed due to the lack of solubility in the biological medium.  
Consequently, we are now concerned in decreasing the peptidic character of the 
molecular tongs and increasing their hydrosolubility. For that we have conceived two different 
strategies: i) the introduction of hydrophilic groups in the scaffold and ii) the synthesis of new 
peptidomimetic arms with increased hydrophilicity. 
The final aim will be the evaluation of the antiviral efficacy of the new compounds in cell 
culture assays, as well as, their bioavailability. 
 
CONCERNING THE RIGID SPACER 
Previous work in our laboratory showed that both the naphthalenediol and the 
quinolinediol were suitable rigid spacers, meaning that they were able to impose the distance 
of 10 Å between the two peptidic or peptidomimetic arms of the molecular tongs. 
Since comparable Kid values were obtained for both naphthalene- and quinoline-based 
molecular tongs (Table III.2, page 115 and Table III.3, page 119), we have decided to 
continue working with the naphthalene scaffold because the synthesis of the corresponding 
molecular tongs is shorter and easier. 
Moreover the naphthalene scaffold is also a suitable candidate for the introduction of 
hydrophilic groups, affording spacers with increased polarity. 
 
PEPTIDIC ARM 
Previous studies have also demonstrated that the peptidic sequence Val-Leu-Val-OMe 
led to the best dimerization inhibitor, and for that reason we have decided to keep this 
sequence as the peptidic arm in the synthesis of unsymmetrical molecular tongs. 
 
PEPTIDOMIMETIC ARM 
Concerning the peptidomimetic arms, our group demonstrated in previous studies, that 
it was possible to keep the valine residue and to replace the other two amino acids of the 
arm by the 5-amino-2-methoxybenzoic hydrazide derivative, which mimics a dipeptide. Later 
on, it was demonstrated that the valine residue could also be replaced by a amino acid (e.g. 
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lysine), affording a new peptidomimetic arm without peptidic character. We have decided to 




Figure III.22. Peptidomimetic arms bearing the 5-amino-2-methoxybenzoic hydrazide derivative. 
 
 
II.3.1.  INTRODUCTION  OF  A  POLAR  FRAGMENT  TO  THE SCAFFOLD  
 
The first strategy designed to increase the solubility of our molecular tongs is based on 
the synthesis of new hydrophilic scaffolds. The simplest way to accomplish this purpose 
relies on the introduction of hydrophilic groups in the naphthalene scaffold. Meaning that it is 
possible to maintain the steric benefit of this scaffold and to individually study the influence of 
a hydrophilic group on it. 
The hydrophilic group can be introduced through an amination reaction, either using: 
1) "Ullmann-type" Reaction: involving a copper-catalyzed nucleophilic aromatic 







HNu = NHRR', HOAr, HSR,...
 
 
or 2) Buchwald-Hartwig Cross Coupling Reaction: meaning, palladium-catalyzed 
synthesis of aryl amines. Starting materials are normally aryl halides and primary or 
secondary amines. 











Using one of the two strategies, different polar groups (like: amino propanediol, amino 
acids, primary amines) will be introduced in the naphthalene scaffold, to afford polar 
scaffolds of general formula 208. 
In order to establish the superiority or inferiority of the symmetrical molecular tongs 
containing the naphthalene scaffold (196 and 204) over inhibitors with a modified 
naphthalene scaffold, the new scaffolds will be attached to peptidomimetic arms bearing the 
5-amino-2-methoxybenzoic hydrazide derivative (Figure III.22), affording molecular tongs of 











R = polar amine
 
 
Figure III.23.  Molecular tongs with modified naphthalene scaffold. 
 
 
II.3.2.  INTRODUCTION  OF  A  NEW  HYDROPHILIC  PEPTIDOMIMETIC  ARM 
 
The second strategy designed to increase the solubility of our molecular tongs is based 
on the introduction of new peptidomimetic motifs with increased hydrophilicity.  
It was then necessary to search peptidomimetics compatible with our concept of 
antiparallel β-sheets. Ideally, suitable candidates should have low molecular weight, and 
should be able to provide the same array of hydrogen-bonding groups, as one edge of a 
peptidic β-strand. 
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As was largely discussed in Chapter I (Section III.3, page 17 and Section III.4, page 
20) several groups have developed peptidomimetics that were successfully applied in 
chemical models of β-strands, β-hairpins and β-sheets. These systems, able to mimic the 
alternating array of hydrogen-bond donors and acceptors of a peptide in a β-strand 
conformation, inspired Li and co-workers, to design and synthesise a new class of highly 
stable hydrazide-based heterodimers61-63 ADDA-DAAD (A = hydrogen-bond acceptor, D = 
hydrogen-bond donor), that were successful used in the self-assembly of hydrogen bond-
mediated supramolecular systems with well-established structures (Figure III.24). 
The new type of quadruply hydrogen-bonded heterodimers 210 involved the 
combination of two different series of hydrazide derivatives (I and II, Figure III.24). The 
hydrogen-bonding components, meaning the C-O and NH units in both series, were 




































































Figure III.25.  Hydrazide-based motif to incorporate in new peptidomimetic arms. 
 
With the help of molecular modelling (Figure III.27) we have designed a new 
peptidomimetic arm 211, containing the dihydrazide motif of the ADDA monomer (Figure 
III.25) and a valine residue. This new peptidomimetic arm was then incorporated in the 
unsymmetrical molecular tong 212 (Figure III.26) and the symmetrical molecular tong 213 
(Figure III.26). 
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This new hydrazide-based motif should increase the hydrophilicity of the molecular 
tongs, decrease their molecular weight and hopefully stabilize the β-sheet formed between 
the molecular tong and the homodimer of the HIV-1 PR. 
Later on, in order to completely suppress the peptidic character of the new hydrazide-




































































Figure III.26.  Unsymmetrical and symmetrical hydrazide-based molecular tongs. 




Figure III.27.  Overview of interactions between hydrazine-based molecular tong with R = L-Val-NH2 (showed in 
green) and the C- and N-terminal of HIV-1 protease monomer (showed in grey). O and N atoms are shown in red 
and blue, respectively. Hydrogen bonds are indicated with dotted lines.  
CHAPTER III                        MOLECULAR TONGS CONTAINING PEPTIDOMIMETIC FRAGMENTS: NEW DIMERIZATION INHIBITORS OF HIV-1 PR 
 129 
II.4.  SYNTHESIS  OF  THE  TARGET  MOLECULES  
 
II.4.1.  SYNTHESIS  OF  THE  POLAR  SCAFFOLDS  
  
The synthetic procedure designed to obtain the modified naphthalene scaffolds relies 
on the initial introduction of a halogen (in this case, Br) in position 3 of the 2,7-
dihydroxynaphthalene, that could later be substituted by an amine.  
Bromination of 2,7-dihydroxynaphthalene gave rise to a mixture of two dibromo 
derivatives (1,3- and 1,6-isomers), which was initially reduced with β-naphthol and 
hydrobromic acid in acetic acid.64 However this procedure led to rather complex crude 
mixtures and therefore it was complicated, if not impossible, to purify the desired product. 
Alternatively, 2,7-dihydroxynaphthalene was brominated as described before giving 
rise to the mixture of 1,3- and 1,6-dibromo derivatives which, by in situ hydrogenolysis of the 
Br−C(1) bond using Sn powder,65 afforded the desired 3-bromonaphthalene-2,7-diol 214, in 
excellent yield (94%). Compound 214 was then alkylated with benzyl 4-bromobutyrate, to 




Scheme III.1.  i) Br2, CH3COOH followed by ii) Sn powder, H2O: 93%; iii) Br(CH2)3COOBn, K2CO3, DMF: 89%. 
 
Initially, we have decided to couple aryl halide 215 to a primary amine bearing an 2,2-
dimethyl-1,3-dioxolane methyl group, which would be the precursor of the polar fragment 
(respectively, an amino propanediol group). 
Nucleophilic aromatic substitution of aryl halide 215 was initially tried using a copper 
catalyst in presence of base, Ullmann condensation reaction,66 without (Table III.4, entry 1) 
or with the presence of a ligand (Table III.4, entries 2-6). 
As it is summarised in Table III.4, no substitution is observed without the presence of a 
ligand (entry 1), however the introduction of L-proline67,68 as a promoter (entries 2 and 3) was 
not successful, resulting in complex crude mixtures. Finally, we have decided to use a 
bidentate ligand69,70 (entries 4-6), that afforded the desired substituted product but in low 
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yields. The conditions that afforded the best result are indicated in entry 5: DMEDA (10 
equiv), K2CO3 (2 equiv) in dioxane at 110 ºC for 24 h, afforded product 216 in 25% yield. 
   
 
Table III.4. Ullmann-type conditions tried in the amination reaction of 215. 
 
ENTRY Cu 
SOURCE LIGAND (MOL %) BASE (EQUIV) SOLVENT TEMP. RX TIME RESULT 
1 CuI — K2CO3 (3) DMSO 135 °C 48 h SM
 
2 CuI Proline (40) K2CO3 (3) DMSO 135 °C 48 h DP
 
3 CuI Proline (20) K2CO3 (2) DMSO 110 °C 24 h DP
 
4 CuI DMEDA (10) K2CO3 (2) Dioxane 75 °C 24 h SM 
5 CuI DMEDA (10) K2CO3 (2) Dioxane 110 °C 24 h 25%
a (+SM) 
6 CuI DMEDA (20) K2CO3 (2) Dioxane 125 °C 24 h 8%
a 
(SM + DP) 
a Yield of pure isolated compound. Abbreviations used in the table: SM = Starting Material, DP = Degradation products. 
 
As an alternative to the copper-catalyzed reaction, we decided to try the Buchwald-
Hartwig reaction,71,72 in which C(sp2)-N bond formation is palladium-catalyzed, in presence of 
a ligand and a base. 
Table III.2 summarizes the different conditions tried, always using the bidentate ligand: 
9,9-dimethyl-4,5-bis(diphenylphosphino)-xanthene (Xantphos, Figure III.28).73,74 The best 
result (entry 4) was obtained using Pd (II) acetate as catalyst and potassium carbonate as 
base, in dry dioxane. It was observed that the reaction is only complete when a large excess 
of base is used (20 equiv), the same observation had been already reported by others.75,76 
On the other hand, the use of strong bases (e.g., sodium tert-butoxide71 – entry 6) led mainly 




Figure III.28.  Xantphos structure. 
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Table III.5. Buchwald-Hartwig conditions tried in the amination reaction of 215. 
 
ENTRY Pd SOURCE LIGAND BASE (EQUIV) SOLVENT TEMP. RX TIME RESULTa 
1 Pd(OAc)2 Xantphos K2CO3 (5) Dioxane 110 °C  15 h 27% 
2 Pd(OAc)2 Xantphos K2CO3 (10) Dioxane 110 °C  15 h 66% 
3 Pd(OAc)2 Xantphos K2CO3 (15) Dioxane 110 °C  15 h 67% 
4 Pd(OAc)2 Xantphos K2CO3 (20) Dioxane 110 °C 15 h 70% 
5 Pd(OAc)2 Xantphos Cs2CO3 (20) Dioxane 110 °C  15 h 51% 
6 Pd(OAc)2 Xantphos NaOt-Bu (2) Dioxane 110 °C  15 h 4%
b 
7 Pd2(dba)3 Xantphos K2CO3 (20) Dioxane 110 °C  15 h 50% 
a Yield of pure isolated compound, b the reaction led mainly to degradation products. 
 
Using entry 4 conditions, other amines were coupled to aryl halide 215. For example, 
coupling of HCl•H-Gly-OEt afforded compound 217, bearing an amino ester functionality, 
precursor of an amino acid group (Scheme III.2). 
Arylamine 219 was obtained by initial coupling of benzophenone imine to scaffold 215, 
affording intermediate 218 that was subsequently reduced with hydroxylamine in methanol, 
in presence of sodium acetate,77 to afford primary amine 219. Terminal amine in the new 
scaffold 219 can then be used to incorporate different functional groups (e.g. water-soluble 
groups).78 All attempts to obtain the N-alkylated product 220, using an excess of bromoacetic 
acid tert-butyl ester in presence of DIPEA,78 met with no success (Scheme III.2). 
 
 




Scheme III.2.  i) Pd(OAc)2, Xantphos, K2CO3, dioxane: 76%; ii) Pd(OAc)2, Xantphos, K2CO3, dioxane, and iii) 
HCl•NH2OH, NaOAc•3H2O, MeOH: 62% over two steps; iv) BrCH2COOt-Bu, NaI, DIPEA, AcCN. 
 
 
II.4.2.  SYNTHESIS  OF  THE  MOLECULAR  TONGS  ARMS 
 
II.4.2.1.  SYNTHESIS  OF  THE  PEPTIDIC  ARM  VLV-OME 
 
The peptidic arm VLVOMe was synthesised by solution layer synthesis (Boc strategy) 
starting from the C-terminus (Scheme III.3). 
 Boc-L-Leu-OH was condensed with HCl•H-L-Val-OMe using isobutyl chloroformate as 
condensing agent in CH2Cl2, in presence of NMM, to afford the dipeptide 221. The N-
terminus of the dipeptide 221 was deprotected using a solution of HCl in methanol (6 N), and 
the corresponding hydrochloride salt was then coupled with Cbz-L-Val-OH, using 
HBTU/HOBt in DMF, in presence of DIPEA, giving rise to the protected tripeptide 222. 
Finally, catalytic hydrogenolysis of the tripeptide 222 in methanol, in presence of HCl (6 
N), afforded VLV-OMe 223 as a stable salt. All the yields of coupling and deprotecting 
reactions were satisfactory (Scheme III.3). 






































Scheme III.3.  Synthesis of peptidic arm VLVOMe: i) (CH3)2CHCH2OCOCl, NMM, CH2Cl2: 68%; ii) methanolic HCl 




II.4.2.2.  SYNTHESIS  OF  5-AMINO-2-METHOXYBENZOIC  HYDRAZIDE  DERIVATIVES 
 
The peptidomimetics strands, bearing the 5-amino-2-methoxybenzoic hydrazide 
derivative, were obtained starting from commercially available 2-methoxybenzoic acid, 
following procedures described in our laboratory.47 The 2-methoxybenzoic acid was initially 
nitrated to give compound 224, and successively coupled with tert-butyl carbazate affording 
225. The nitro group of 225 was then reduced, through catalytic hydrogenation, to afford the 
Boc-protected 5-amino-2-methoxybenzoic hydrazide 226, described in the literature by 
Nowick.55  
Compound 226 was then acetylated to afford 227. After Boc deprotection with TFA in 
CH2Cl2 of hydrazide 227, coupling of either Boc-L-Val-OH or Nα-Boc-Nε-Cbz-L-Lys-OH, 
afforded protected peptidomimetic arms 228 and 198, respectively (Scheme III.4).  
A final Boc deprotection of 228 afforded the peptidomimetic arm 229 in the form of TFA 
salt, ready to be coupled to the desired scaffold. On the other hand, cleavage of the Cbz 
group through catalytic hydrogenolysis, afforded the Nε-deprotected peptidomimetic arm 
230, ready to be coupled to the desired scaffold. 














































































Scheme III.4.  Synthesis of peptidomimetic arm containing the 5-amino-2-methoxybenzoic hydrazide derivative: i) 
NH4NO3, H2SO4: 80%; ii) BocNHNH2, HOBt, EDC•HCl, CH2Cl2: 85%; iii) H2, Pd/C, MeOH: 95%; iv) Ac2O, THF: 
quantitative yield; v) TFA/CH2Cl2 (1:1, v/v) and vi) Boc-L-Val-OH, HBTU, HOBt, DIPEA, DMF: 68% over two steps; 
vii) TFA/CH2Cl2 (1:1, v/v): 83%; viii) TFA/CH2Cl2 (1:1, v/v) and ix) Nα-Boc-Nε-Cbz-L-Lys-OH, HBTU, HOBt, 
DIPEA, DMF: 73% over two steps; x) H2, Pd/C, MeOH: 96%. 
 
 
II.4.2.3.  SYNTHESIS  OF  HYDRAZIDE-BASED  PEPTIDOMIMETIC  ARMS 
 
The synthetic procedure designed to obtain the new peptidomimetic arm involves the 
synthesis of a dihydrazide motif that will be common to all hydrazide-based arms (Scheme 
III.5). Thus, compound 231 was first prepared from the reaction of commercially available 
compounds tert-butyl carbazate and phenyl chloroformate in dichloromethane, in presence of 
pyridine.79 Treatment of 231 with hydrazine hydrate afforded intermediate 232 in 72% yield.63 
Compound 232 was then treated with phenyl chloroformate in THF, in presence of pyridine, 
to afford the common dihydrazide motif 233, in good yield (91%). 
Initial tries to couple the dihydrazide motif with HCl•H-L-Val-OMe met with no success. 
Instead of desired linear compound 234, the major product isolated from the reaction was the 
cyclic compound 235 (6-membered ring formation). 























































Scheme III.5. i) ClCO2Ph, pyridine, CH2Cl2: 97%; ii) H2NNH2•H2O, MeOH: 72%; iii) ClCO2Ph, pyridine, THF: 91%; 
iv) HCl•H-L-Val-OMe, Et3N, AcCN: 55%. 
 
 
In order to avoid intramolecular aminolysis we decided to use a valine residue 
presenting the carboxylic group protected as an amide (instead of ester). Compound 233 
was then coupled with HCl•H-L-Val-NH2 giving rise to the Boc-protected peptidomimetic arm 
236 in good yield (93%). A final Boc deprotection of 236 afforded the new peptidomimetic 
arm 237 in the form of TFA salt, ready to be coupled to the naphthalene scaffold (Scheme 
III.6.). 
In order to completely suppress the peptidic character of the new polar arms, the valine 
residue was after substituted by methyl amine and β-alanine methyl ester, to afford Boc-
protected peptidomimetic arms 238 and 240, respectively. In both cases, a final Boc 
deprotection afforded the new peptidomimetic arms 239 and 241, respectively, in the form of 
TFA salt, ready to be coupled to the naphthalene scaffold (Scheme III.6.). 
 

































































































Scheme III.6. i) HCl•H-L-Val-NH2, Et3N, AcCN: 93%; ii) TFA/CH2Cl2 (1:1, v/v): quantitative yield; iii) HCl•NH2CH3, 
Et3N, AcCN: 70%; iv) TFA/CH2Cl2 (1:1, v/v): quantitative yield; v) HCl•H-β-Ala-OMe, Et3N, AcCN: 67%; vi) 
TFA/CH2Cl2 (1:1, v/v): quantitative yield. 
 
 
II.4.3.  SYNTHESIS  OF  MOLECULAR  TONGS  WITH  THE  NEW  HYDRAZIDE-BASED  ARM 
 
II.4.3.1.  SYNTHESIS  OF  UNSYMMETRICAL  MOLECULAR  TONGS 
 
Unsymmetrical naphthalene-based molecular tongs were synthesised after differential 
protection of the two OH groups of 2,7-dihydroxynaphthalene, according to a reported 
procedure of our laboratory.46 The mono alkylated compound 242 was obtained by 
etherification of one hydroxyl group of the commercial available 2,7-dihydroxynaphthalene, 
using 0.9 equiv of the commercial available ethyl 4-bromobutyrate in presence of K2CO3, as 
base, in DMF. Monoester 242 was obtained in 36% yield, along with the diester product and 
unchanged starting material. Subsequent benzylation of the other OH group gave compound 
243, giving rise to distinguishable OH functions. Compound 243 was then hydrolyzed under 
basic conditions to afford the desired acid 244, with 92% yield (Scheme III.7). 
Compound 245 was synthesised by coupling the peptidic strand HCl•H-Val-Leu-Val-
OMe 223 (synthesis reported in Scheme III.3) to the C-terminus of scaffold 244, using 
HBTU/HOBt in DMF, in presence of a tertiary amine (in this case, Et3N). After a 
debenzylation step, alcohol 246 was O-alkylated with benzyl 4-bromobutyrate, affording the 
corresponding ester 247 in good yield (81%). 
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The benzyl protected compound was used in order to selectively generate compound 
248 in the subsequent step of deprotection without modifying the terminal ester of the 
tripeptide strand. 
Finally, condensation of 248 with the hydrazide-based peptidomimetic arm 237 
(Scheme III.6), using HBTU/HOBt in DMF, in presence of DIPEA, afforded the final 


















































































































Scheme III.7.  Synthesis of the unsymmetrical molecular tong 249: i) Br(CH2)3COOEt, K2CO3, DMF: 36%; ii) BrBn, 
K2CO3, CH3CN: 60%; iii) methanolic KOH 10%: 92%; iv) HCl•H-VLV-OMe, Et3N, HBTU, HOBt, DMF: 90%; v) H2, 
Pd/C, MeOH/DMF: quantitative yield; vi) Br(CH2)3COOBn, K2CO3, DMF: 81%; vii) H2, Pd/C, MeOH/DMF: 
quantitative yield; viii) peptidomimetic 237, DIPEA, HBTU, HOBt, DMF: 49%. 
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II.4.3.2.  SYNTHESIS  OF  SYMMETRICAL  MOLECULAR  TONGS 
 
Compound 250 was synthesised as previously reported by our laboratory,45 by 
alkylation of the two hydroxyl groups of commercially available 2,7-naphthalenediol with ethyl 
4-bromobutyrate. Total hydrolysis of 250 with methanolic KOH afforded the diacid 251, in 
excellent yield. Finally, symmetrical molecular tongs 252, 253, and 254 were obtained by 
condensation of 251 with peptidomimetic arms 237, 239, and 241 (synthesis reported in 
Scheme III.6), respectively, using HBTU/HOBt in DMF, in presence of DIPEA. The three 
hydrazide-based symmetrical molecular tongs were obtained in satisfactory yields (56%, 


























































































































Scheme III.8.  Synthesis of hydrazide-based symmetrical molecular tongs: i) Br(CH2)3COOEt, K2CO3, DMF: 87%; 
ii) methanolic KOH 10%: 97%; iii) peptidomimetic 237, HBTU, HOBt, DIPEA, DMF: 56%; iv) peptidomimetic 239, 
HBTU, HOBt, DIPEA, DMF: 55%; v) peptidomimetic 241, HBTU, HOBt, DIPEA, DMF: 73%. 
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II.4.4.  SYNTHESIS  OF  SYMMETRICAL MOLECULAR  TONGS  WITH  A  POLAR  SCAFFOLD  
 
Scaffold 216 was deprotected by catalytic hydrogenolysis, to afford compound 255 that 
was then coupled with peptidomimetic arm 229 and 230 (synthesis reported in Scheme III.4) 
using HBTU/HOBt in DMF, in presence of DIPEA, to afford molecular tongs 256 and 258 
(Scheme III.9), respectively, in satisfactory yields (50% and 59%, respectively). 
The 2,2-dimethyl-1,3-dioxolane methyl group of compound 256 was finally deprotected 
with HCl in EtOH/THF,80 affording molecular tong 257, in satisfactory yield (60%). In the case 
of compound 258, the final deprotection step was performed with p-toluene sulfonic acid in 
methanol81 due to the presence of acid-labile groups (Nα-Boc), but even so molecular tong 
259 was obtained in low yield (30%). Compound 259 was obtained in a very small amount 
and therefore was only characterized by mass spectroscopy. 
 
 
Scheme III.9.  Synthesis of symmetrical molecular tongs with polar scaffold 216: i) H2, Pd/C, MeOH/EtOAc: 
quantitative yield; ii) peptidomimetic 229, HBTU, HOBt, DIPEA, DMF: 50%; iii) 1 M HCl, EtOH/THF: 60% ; iv) 
peptidomimetic 230, HBTU, HOBt, DIPEA, DMF: 59%; v) p-TsOH, MeOH: 30%. 
 
 
Scaffold 219 was deprotected by catalytic hydrogenolysis, to afford compound 260 that 
was then coupled with peptidomimetic arm 229 using HBTU/HOBt in DMF, in presence of 
DIPEA, to afford molecular tong 261 (Scheme III.10), in satisfactory yields (68%). 




Scheme III.10.  Synthesis of symmetrical molecular tongs with polar scaffold 219: i) H2, Pd/C, MeOH/EtOAc: 
quantitative yield; ii) peptidomimetic 229, HBTU, HOBt, DIPEA, DMF: 68%. 
 
 
III.  BIOLOGICAL  RESULTS  AND  DISCUSSION 
 
In this section we will first present a description of the technique used for biological 
tests, and the operating conditions of these tests. This is followed by a reminder of the theory 
of enzyme kinetics. Finally we will present the obtained biological results with a discussion of 
these results. 
 
III.1.  TECHNICAL   
 
III.1.1.  USED MATERIAL  
 
PR: was produced in the laboratory of Prof. Reboud-Ravaux (Laboratoire 
d’Enzymologie Moléculaire, FRE2852, CNRS – Université Paris 6). It is characterized by a 
molecular weight of 22 kDa and a molar extinction coefficient of 12300 M-1 at 280 nm. Two 
solutions (17 or 34 µM) are stored at -80 ° C in buffer MES 50 nM, pH = 6, EDTA 1mM, DTT 
1mM, NaCl 0.5 M, 5% glycerol (v/v). 
PRODUCTS: to help the solubilisation of molecules in aqueous solutions, DMSO 
(spectral quality Merck) was used as co-solvent. 
 The fluorogenic substrate DABCYL-γ-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS 
(Bachem) is used for measuring the activity of the PR. To do this, it is solubilised in DMSO at 
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a concentration of 3 mM and stored at -20 °C. The p roduct EDANS, 5-[(2-
aminoethyl)amino]naphthalene-1 sulfonic acid (Sigma) is used as fluorescence standard.  
BUFFER: the buffer used is a solution of sodium acetate 100 mM, EDTA 1 mM, 1 M 
NaCl, pH = 4.7.  
 
III.1.2.  KINETIC  AND  BIOCHEMICAL  METHODS  OF  ANALYSIS  
 
STABILITY , SOLUBILITY AND SPECTRAL PROPERTIES OF COMPOUNDS  
 
Firstly, the solubility of molecular tongs in the co-solvent (DMSO) and buffer was 
systematically evaluated. The stability and solubility of the inhibitors in buffers used for 
kinetic analysis, were monitored over a period of 1 h at 30 °C, using spectrofluorometry. 
Time intervals of 5 minutes were chosen between two consecutive spectra. The lack of 
change or modification of the absorption spectrum (250 - 450 nm) shows a good solubility 
and stability under measurement conditions.  
 
DETERMINATION OF ENZYME ACTIVITY 
 
a) Fluorometric activity assay:  the fluorometric activity assay of PR, whose protocol 
was described by Matayoshi et al.,82 has the advantage of using very small amounts of PR 
and substrate concentrations well below the Michaelis constant Km (Km = 103 mM). It is 
based on the principle of Fluorescence Resonance Energy Transfer (FRET).  
The internally quenched fluorogenic substrate DABCYL-γ-Abu-Ser-Gln-Asn-Tyr-Pro-
Ile-Val-Gln-EDANS consists of a fluorescent or donor group EDANS connected by a short 




Figure III.29.  The principle of fluorometric activity assay of PR, using the fluorogenic substrate DABCYL-γ-Abu-
Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS. 
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The group EDANS absorbs light at 340 nm and fluoresce at 490 nm, while the group 
DABCYL, absorbs at 490 nm and it is not fluorescent. The peptide chain mimics the 
cleavage site MA/CA (p17/p24) of the protein gag-pol. When the substrate is not hydrolyzed, 
the intrinsic fluorescence of EDANS group is insignificant because of the transfer by 
resonance of its emission energy to the DABCYL group. However, when there is hydrolysis, 
the separation of these two groups (donor and acceptor) over 100 Å, caused by breaking of 
the enzymatic cleavage site of PR (at the Tyr-Pro bond) prevents the transfer of energy. The 
fluorescence emitted by the fragment Pro-Ile-Val-Gln-EDANS at 490 nm is proportional to the 
amount of hydrolyzed substrate. Proteolysis activity may be followed by recording the 
increase of fluorescence intensity in function of time. 
 
b) Proteolysis activity: the PR is first diluted in the kinetic buffer containing 1 mg/mL 
bovine serum albumin to stabilize its enzyme activity throughout a day of experience.  
The experimental conditions for kinetic action are: the single substrate or, substrate 
and inhibitor, prior dissolved in DMSO (final concentration 3% v/v) incubated for 5 min at 30 
°C. The PR (7.5 nM) is then added to generate the r eaction. Liberation of substrate 
hydrolysis product (Pro-Ile-Val-Gln-EDANS) leads to the emergence of fluorescence which is 
followed for 3 min at 490 nm (λexc = 340 nm). The initial speeds are evaluated during the first 
moments of the reaction, when the fluorescence intensity varies linearly with time.  
There is a standard line involving the intensity of fluorescent concentration ([EDANS] = 0-450 
nM). It can express hydrolysis speed in function of the number of moles of substrate 
hydrolyzed per unit of time. This can correct any fluctuations in the fluorescence intensity due 
to spectrofluorometer.  
 Zhang analysis is performed on at least six concentrations of PR (3.5 nM – 31.7 nM).  
The inhibition of PR is measured at different concentrations of inhibitor (0.56 µM – 17 µM). 
[E]0 is varying while [S] is fixed. 
 
KINETIC ANALYSIS OF INHIBITION 
 
a) Determination of IC 50 values:  the IC50 value corresponds, for a given concentration 
of substrate, to the concentration of inhibitor leading to a reduction of enzyme activity by 
50%. To determine the IC50 value of a product, were the inhibitory effect varies from 10 to 
80%, we calculate the percentages of inhibition of PR (Eq. 1, where vi(I) and vi(0) are, 
respectively, the inhibition rate in presence and absence of inhibitor and [I]0 is the initial 
concentration of inhibitor), which are determined in relation to the enzyme activity in the 
absence of inhibitor (control). This calculation is made for seven to twelve concentrations of 
the product in question. 
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% inhibition = 100 (vi(I)/ vi(0)) = 100 x [I]0/(IC50 + [I]0) Eq. 1 
 
For a competitive inhibitor type, the value of the inhibition constant Kic can be estimated 
from the IC50 value using the equation of Cheng & Prusoff (Eq. 2, where [S]0 is the initial 
concentration of the substrate and Km, the constant of Michaelis). 
 
IC50 = Kic (1 + [S]0/Km) Eq. 2 
 
b) Determining the mechanism of action of inhibitor s and kinetics of inhibition:  
when a molecule shows a potent inhibitor character, the mechanism of inhibition is obtained 
by kinetic analysis. For that, different techniques are used to evaluate the inhibition constant 
characteristics.  
First, we begin by determining the reversible and irreversible inhibition.  
Recall that the reversible inhibition is characterized by the formation of weak links between 
the enzyme and inhibitor. The activity of the enzyme, in this case is found after removal of 
inhibitor. However, it is not possible to recover the activity of the enzyme after the action of 
an irreversible inhibitor because the inhibitor remains bound to the enzyme by a covalent 
bond. The various states of equilibrium achieved by monomer (M), dimeric enzyme (D), 
substrate (S), and inhibitor (I) are represented in Figure III.30. 
In the case of dimerization inhibition, the only method used to determine the kinetic 




Figure III.30.  Equilibrium states between monomer (M), dimer (D), substrate (S), and inhibitor (I). 
 
Competitive inhibition:  the inhibitor competes with the substrate for the occupation of 
the catalytic site and forms a complex enzyme-inhibitor.  
Uncompetitive inhibition:  the inhibitor cannot bind to the free enzyme. It has an 
affinity for the complex enzyme-substrate and form a ternary inactive complex.  
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Noncompetitive inhibition:  the inhibitor binds either to the free enzyme or to the 
complex enzyme-substrate.  
Inhibition of dimerization:  the conventional Dixon’s method is no longer adequate 
because it does not distinguish an inhibitor of the active site from an inhibitor of dimerization. 
In both cases, the kinetic analysis using this method may lead only to a competitive 
inhibition. The only method that allows identifying an inhibitor of dimerization and gives 
access to the inhibition constant Kid (inhibition constant of dimerization) was described by 
Zhang.28  
 
The mechanism of inhibition of PR by other compounds was the assessed using 
Zhang-Poorman kinetic analysis in which plots of [E]0/√νi vs √νi, with √νi = Kexp[S]0, are 
constructed28 in order to discriminate between inhibition of dimerization alone (parallel lines), 
competitive inhibition (altered slopes and unaltered y-axis intercept), and mixed inhibition 
(altered slopes and altered y-axis intercepts). The respective curves are represented in 
Figure III.31 and 3.32. The values of constants Kic and Kid are calculated respectively from 
the ordinate values at the origin (Eq. 3 and 4, respectively), where ai and a0 represent the 
slopes of straight lines obtained respectively in the presence and absence of inhibitor and bi 
and b0 represent intercept lines obtained respectively in the presence or in the absence of 
inhibitor. 
 
Kic = a0 x [I]/(ai – a0)  Eq. 3 
 
Kid = b0 x [I]/(ai – a0)  Eq. 4 
 
In practice, two concentrations of inhibitors (situated in both sides of the IC50 value) are 
chosen and tested in the presence of six to ten concentrations of enzyme for a fixed 


























































Figure III.31.  Zhang plots for: a) dimerization inhibition and b) competitive inhibition. 






























Figure III.32.  Zhang plot for mixed inhibition. 
 
 
III.2.  RESULTS  AND  DISCUSSION  
 
The inhibitory activities of the unsymmetrical and symmetrical hydrazide-based 
molecular tongs (249 and 252-254, respectively) and symmetrical molecular tongs bearing a 
modified naphthalene scaffold 256-258 and 261 (Table III.6) were assayed against 
recombinant wild-type PR at pH 4.7 and 30 °C using a fluorometric assay.45,47 Until now we 
have not been able to obtain molecular tongs 253 and 257 in a satisfactory degree of purity 
for biological evaluation. 
The mechanism of inhibition of PR by all compounds was assessed using Zhang-
Poorman kinetic analysis in which plots of [E]0/√νi vs √νi, with √νi = Kexp[S]0, are constructed28 
in order to discriminate between inhibition of dimerization alone (parallel lines), competitive 
inhibition (altered slopes and unaltered y-axis intercept), and mixed inhibition (altered slopes 
and altered y-axis intercepts). In pure dimerization inhibition, the inhibitor binds to the 
interface region, whereas a competitive inhibitor binds to the active site and a mixed inhibitor 
may bind to the active site as well as to the interfacial region. The results are summarised in 
Table III.6. 
Parallel lines (Figure III.33) were obtained for all molecular tongs tested (249, 252, 256, 
258 and 261), except for molecular tong 254, which is consistent with pure dimerization 
inhibition. On the other hand, molecular tong 254, did not show inhibition activity. 
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Figure III.33.  Plots of [E]0/√νi vs √νi for the hydrolysis of the fluorogenic substrate DABCYL-γ-Abu-Ser-Gln-Asn-
Tyr-Pro-Ile-Val-Gln-EDANS by HIV-1 PR WT at pH 4.7 and 30 °C, in the absence ( ■), and presence of 11 µM(▲) 
and 4.25 µM (▼) for compound 256. 
                 
Table III.6. In vitro inhibition of wild-type HIV-1 PR by the new molecular tongs (30 °C and pH 4.7, K id = 
dimerization inhibition constant). 
 
COMPOUNDS K id  (µM) 
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These results may be discussed as follows: 
• All active molecular tongs (249, 252, 256, 258 and 261) are pure dimerization inhibitors. 
• The best results were obtained with the unsymmetrical and symmetrical hydrazide-based 
molecular tongs bearing a valine residue (249 and 252, respectively). Both molecular 
tongs are good dimerization inhibitors, however unsymmetrical molecular tong bearing the 
peptidic arm VLV-OMe (249) shows a better activity (Kid = 0.15 µM compared with Kid = 
0.7 µM for 252). 
• On the other hand the totally peptidomimetic hydrazide-based molecular tong (254), which 
is partially water soluble, did not show inhibition activity. Contrary to our expectation, 
increasing the hydrophilicity of the arms led to a complete loss of activity. 
• Considering symmetrical molecular tongs with a modified scaffold (256-258 and 261), two 
different aspects can be analysed.  
Firstly, we can compare the influence of different peptidomimetic arms when attached to 
the same scaffold. In this case, molecular tong 256, with the peptidomimetic arm bearing a 
valine residue is approximately two times better than molecular tong 258, with the tottaly 
peptidomimetic arm bearing a lysine (Kid = 2.7 µM vs Kid = 5.9 µM). 
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Secondly, using the best peptidomimetic arm (meaning, the one with the valine residue) 
we can compare the influence of the introduction of different groups in the naphthalene 
scaffold. In this case, molecular tong 261, bearing the scaffold with the terminal amine is 
much better than molecular tong 256, bearing the scaffold with the 2,2-dimethyl-1,3-
dioxolane methyl group (Kid = 0.4 µM vs Kid = 2.7 µM). This may be caused by the larger size 




IV.  CONCLUSIONS  AND  PERSPECTIVES 
 
HIV-1 protease (PR) is an important target for anti-AIDS drugs because its inhibition 
results in the production of uninfectious virus. Nevertheless, viral resistances to protease 
inhibitors (inhibitors that interact with the active site preventing the binding of enzyme natural 
substrates) administered alone or in combination with reverse transcriptase inhibitors have 
been described in vivo suggesting that there is a need for structurally diverse antiproteases. 
One possibility is to design inhibitors that prevent the dimerization of PR or favour the 
dissociation of the dimer, since the protease is only active in its dimeric form. Protein-protein 
interactions in the dimer include the antiparallel β-sheet formed by interdigitation of the N- 
(residues 1-4) and C- (residues 96-99) terminal strands of each monomer, which contributes 
close to 75% of the total Gibbs free energy of dimerization. This antiparallel β-sheet is an 
attractive target for overcoming resistance to clinical drugs because its amino acid residues 
are highly conserved in most HIV-1 and HIV-2 isolates. Blocking the formation of the 
homodimer or disrupting it is an effective way of inhibiting protease activity. 
 
In the present thesis we described the design, synthesis and enzyme inhibitory activity 
against wild-type HIV-1 PR new unsymmetrical and symmetrical peptidomimetic molecular 
tongs as inhibitors of HIV-1 PR dimerization. 
The main goal of this thesis was to increase hydrosolubility of our molecular tongs. In 
order to achieve this goal we took two possibilities into consideration: i) design of new 
peptidomimetics motifs with decreased lipophilicity (hydrazide-based motifs); ii)  design of 
new hydrophilic scaffolds, by introducing a hydrophilic group on the naphthalene scaffold. 
The main conclusions are presented below: 
1. 3 new hydrazide-based arms were synthesised (237, 239 and 241), two of them 
completely peptidomimetic (239 and 241). 
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2. 3 new scaffolds with increased hydrophilicity were synthesised: scaffold 216, 217 and 
219. 
3. In total, 9 new molecular tongs were synthesised using the new hydrazide-based arms 
and the new scaffolds. 
a) 4 hydrazide-based molecular tongs were synthesised: two bearing peptidomimetic arm 
237 (one unsymmetrical (249), with one peptidic arm, and one symmetrical (252), with 
two peptidomimetic arms) and two symmetrical bearing peptidomimetic arms 239 and 
241 (253 and 254, respectively). 
b) 5 symmetrical molecular tongs with modifed scaffolds 216 and 219 were synthesised: 
three of them bearing in the both strands the amino acid valine and the peptidomimetic 5-
amino-2-methoxybenzoic hydrazide derivative (256, 257 and 261) and, the other two, 
bearing in the both strands the amino acid lysine and the peptidomimetic 5-amino-2-
methoxybenzoic hydrazide derivative (258 and 259). 
4. The inhibitory activities of the new molecular tongs were assayed against recombinant 
wild-type PR and the results show that: 
a) all hydrazide-based molecular tongs, except 254 that does not present inhibitory 
activity, are pure dimerization inhibitors under micromolar range. The best result was 
obtained with unsymmetrical molecular tong 249. 
b) all molecular tongs bearing a modified scaffold are also pure dimerization inhibitors, 
although the introduction of an 2,2-dimethyl-1,3-dioxolane methyl group in the 
naphthalene scaffold led to a decrease on the inhibitory activity. 
 
In perspective new peptidomimetic arms bearing the dihydrazide motif can be 
designed, although special attention should be given to the motif that will replace the valine 
residue. We must wait for the biological evaluation of the deprotected molecular tong 257 to 
assess if the propanediol group is able to increase hydrosolubility without compromising the 
PR dimerization inhibition activity. 
On the other hand, scaffold 217 can be used to synthesise new molecular tongs and 
new hydrophilic groups may be introduced on the naphthalene scaffold in order to obtain 
more hydrophilic scaffolds that will eventually lead to more water-soluble molecular tongs. 
When this purpose is accomplished, we will be able to evaluate their antiviral efficacy in cell 
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I.  CHAPTER II  EXPERIMENTAL  PART 
 
MATERIALS AND METHODS : All manipulations requiring anhydrous conditions were carried out 
in flame-dried glassware, with magnetic stirring and under a nitrogen atmosphere. All 
commercially available reagents were used as received. Anhydrous solvents were purchased 
from commercial sources and withdrawn from the container by syringe, under a slight 
positive pressure of nitrogen. (2S)-aspartic acid β-allyl ester hydrochloride,1 N-(tert-
butoxycarbonyl)-(2S)-aspartic acid β-allyl ester,1 (S)-serine methyl ester hydrochloride,2 (S)-
N-benzylserine methyl ester3 and Boc-(S)-Ala-NH-CH2-Ph
4 were prepared according to 
literature procedures and their analytical data were in agreement with those already 
published. Reactions were monitored by analytical thin layer chromatography using 0.25 mm 
pre-coated silica gel glass plates (DURASIL-25 UV254) and compounds visualized using UV 
fluorescence, aqueous potassium permanganate or ninhydrin. Flash column chromatography 
was performed according to the method of Still and co-workers5 using Chromagel 60 ACC 
(40-63 µm) silica gel. 
Melting points were obtained in an open capillary apparatus and are uncorrected. Proton 
NMR spectra were recorded on a spectrometer operating at 400.16 MHz. Proton chemical 
shifts are reported in ppm (δ) with the solvent reference relative to tetramethylsilane (TMS) 
employed as the internal standard. The following abbreviations are used to describe spin 
multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad signal, dd 
= doublet of doublet. Carbon NMR spectra were recorded on a spectrometer operating at 
100.63 MHz, with complete proton decoupling. Carbon chemical shifts are reported in ppm 
(δ) relative to TMS with the respective solvent resonance as the internal standard. Infrared 
spectra were recorded on a standard FT-IR and peaks are reported in cm-1. Optical rotation 
values were measured on an automatic polarimeter with a 1 dm cell at the sodium D line and 
are given in units of 10-1 deg.cm2.g-1. Elemental analyses were performed using a Perkin 
Elmer 2400 Series II CHNS/O Analyzer. High resolution mass spectra (HRMS) were 
performed on a hybrid quadrupole time of flight mass spectrometer equipped with an ESI ion 
source. A Reserpine solution 100 pg/µl (about 100 count/s), 0.1% HCOOH/CH3CN 1:1 was 
used as reference compound (Lock Mass). FAB mass spectra were recorded using a 
glycerol matrix. 
 
COMPUTATIONAL METHODS : Monte Carlo/Energy Minimization (MC/EM) conformational 
searches on the compounds 93 and 96, were performed within the framework of 
Macromodel6 version 8.5, using the MacroModel implementation of the Amber all-atom Force 
field.7 Duplicate conformations and those with an energy greater than 6.00 kcal/mol above 
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the global minimum were discarded. For each search, at least 1000 starting structures for 
each variable torsion angle were generated and minimized until the gradient was less than 
0.05 kJ/Å mol using the truncated Newton-Raphson method8 implemented in MacroModel. 
For compound 96, simulated annealing protocol in explicit DMSO solvent9 was performed 
using the ff03 force field10 and the SANDER module of the AMBER7 package.11 According to 
the NOE data, two distance NOE restraints were imposed between the protons CαH of the 
Val1 and CαH of the Ala2 residues (upper bound of 3.0 Å and force constant of 20 kcal/mol 
Å) and between the proton CαH of the Ala2 residue and NH2 amide (upper bound of 4.0 Å 
and force constant of 20 kcal/mol Å). A 9 Å cutoff and the Ewald sums were used for non-
bonded interactions. The SHAKE algorithm12 was used to keep the hydrogen atoms fixed 
together with a 1 fs time step. The 96b conformation was solvated in a cubic box by 643 
DMSO molecules and gradually heated at 900 K. The density of the system was first 
equilibrated at 300 K for 140 ps, then was kept constant for the next of the simulated 
annealing steps. After 1 ns of equilibration at 900 K, the system was cooled up to 0 K during 
1 ns. Structures for analysis were saved every 10 ps. 
 
SOLID-LAYER RECEPTOR-BINDING ASSAY : Purified αvβ3 and αvβ5 receptors (Chemicon 
International, Inc., Temecula, CA) were diluted to 0.5  µg/mL in coating buffer containing 20 
mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L MnCl2, 2 mmol/L CaCl2 and 1 mmol/L 
MgCl2. An aliquot of diluted receptors (100 µL/well) was added to 96-well microtiter plates 
(NUNC MW 96F MEDISORP STRAIGHT) and incubated overnight at 4 °C. The plates were 
then incubated with blocking solution (coating buffer plus 1% bovine serum albumin) for 
additional 2 hours at room temperature to block nonspecific binding followed by 3-hour 
incubation at room temperature with various concentrations (10-10−10-5 M) of test compounds 
in the presence of 1 µg/mL vitronectine biotinylated using EZ-Link Sulfo-NHS-Biotynilation kit 
(Pierce, Rockford, IL). After washing, the plates were incubated for 1 hour at room 
temperature with streptavidin-biotinylated peroxidase complex (Amersham Biosciences, 
Uppsala, Sweden) followed by 30-minutes incubation with 100 µL Substrate Reagent 
Solution (R&D Systems, Minneapolis, MN) before stopping the reaction by addition of 50 µL 
of 1 N H2SO4. Absorbance at 415 nm was read in a Synergy™ HT Multi-Detection Microplate 
Reader (BioTek Instruments, Inc.). Each data point is the result of the average of triplicate 
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SOLUTION  LAYER SYNTHESIS  OF  PEPTIDOMIMETICS : GENERAL  PROCEDURES  
 
GENERAL PROCEDURE A FOR DEPROTECTION REACTIONS: To a solution of the N-Boc-protected 
amino acid or peptide in CH2Cl2 (0.13 M) was added an equal volume of TFA and the 
reaction was stirred at r.t. for 3 h. The solvent was evaporated, methanol (3×) was added 
followed by evaporation, and then ether was added and evaporated to afford the 
corresponding TFA salt. 
 
GENERAL PROCEDURE B FOR COUPLING REACTIONS : The TFA salt of the amino acid or peptide 
derivative was dissolved in DMF (0.1 M), and the N-protected amino or peptide acid (1.05 
equiv) was added followed by HOBt (1.1 equiv) and DIPEA (2 equiv). The solution was 
cooled in an ice bath and treated with EDC (1.1 equiv). The reaction was stirred at 0 ºC for 1 
h and at r.t. overnight. The mixture was diluted with EtOAc and consecutively extracted with 
1 M KHSO4 (2×), aqueous NaHCO3 (2×) and brine (2×), dried over Na2SO4 and the solvent 
evaporated under reduced pressure to afford the crude product. 
 
GENERAL PROCEDURE C FOR COUPLING REACTIONS : To a solution of the N-protected amino 
acid in CH2Cl2, under nitrogen atmosphere and at 0 ºC, was added HATU (1.1 equiv) and 
DIPEA (2 equiv). After 30 min, a solution of the TFA salt of the peptide in CH2Cl2 and DIPEA 
(1 equiv), was added and the reaction mixture was stirred at 0 ºC for 1 h and at r.t. overnight. 
The mixture was diluted with EtOAc and consecutively extracted with 1 M KHSO4 (2×), 
aqueous NaHCO3 (2×) and brine (2×), dried over Na2SO4 and the solvent evaporated under 
reduced pressure to afford the crude product. 
 
GENERAL PROCEDURE D FOR COUPLING REACTIONS : To a solution of the N-protected amino 
acid (or N-protected DKP) in DMF, under nitrogen atmosphere and at 0 ºC, was added HBTU 
(1.2 equiv), HOBt (1.2 equiv) and DIPEA (3 equiv). After 30 min, a solution of the TFA salt of 
the peptide in DMF and DIPEA (1 equiv), was added and the reaction mixture was stirred at 
0 ºC for 1 h and at r.t. overnight. The mixture was diluted with EtOAc and consecutively 
extracted with 1 M KHSO4 (2×), aqueous NaHCO3 (2×) and brine (2×), dried over Na2SO4 
and the solvent evaporated under reduced pressure to afford the crude product. 
 
GENERAL PROCEDURE E FOR COUPLING REACTIONS : To a solution of the N-protected amino 
acid in DMF, under nitrogen atmosphere and at 0 ºC, was added HATU (1.5 equiv), HOAt 
(1.5 equiv) and DIPEA (3 equiv). After 30 min, a solution of the TFA salt of the peptide in 
DMF and DIPEA (1 equiv), was added and the reaction mixture was stirred at 0 ºC for 1 h 
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and at r.t. overnight. The mixture was diluted with EtOAc and consecutively extracted with 1 
M KHSO4 (2×), aqueous NaHCO3 (2×) and brine (2×), dried over Na2SO4 and the solvent 
evaporated under reduced pressure to afford the crude product. 
 
 




Acetyl chloride (10.4 mL, 0.15 mol, 4 equiv) was added dropwise to ice-cold allylic alcohol 
(45 mL). The resulting solution was stirred at 0 ºC for 15 min and then at r.t. for 1 h. (S)-
aspartic acid (5.00 g, 38 mmol) was added in a single portion and the suspension was stirred 
at r.t. for 18 h and then poured into ice-cold Et2O. After stirring at 0 ºC for 1 h the precipitate 
was collected by filtration and washed on the pad with Et2O, to afford hydrochloride 98 as a 
white solid (7.09 g, 90%). 
Mp: 181-183 °C (Lit. 185-186 °C) 13 
[α]20D = +22.7 (c 1.0, CH3OH) 
1H NMR (400 MHz, D2O) δ:  5.86-5.96 (m, 1H), 5.23-5.33 (m, 2H), 4.64 (d, 2H, J=5.7 Hz), 
4.34-4.37 (m, 1H), 3.11 (dd, 2H, J1=18.4 Hz, J2=4.8 Hz). 
13C NMR (100 MHz, D2O) δ: 171.5, 171.2, 131.8, 119.3, 67.1, 49.7, 34.4. 
IR (KBr) νmax: 3437, 2913, 1742, 1726, 1505, 1227, 1206. 
 
 




Triethylamine (11.8 mL, 84 mmol, 3 equiv) was added dropwise to a stirred solution of Boc2O 
(7.37 g, 34 mmol, 1.2 equiv) and compound 98 (5.90 g, 28 mmol) in H2O/dioxane (50 mL, 1:1 
v/v). After 18 h the solution was extracted with petroleum ether (2 × 50 mL) and the aqueous 
layer was cooled on ice and carefully acidified to pH 3 by slow addition of 1 M KHSO4 
solution. The urethane was then extracted into EtOAc (3 × 50 mL) and the combined organic 
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layers were washed with brine (2 × 25 mL), dried over Na2SO4, filtered and concentrated 
under reduced pressure to give product 99 as a viscous transparent oil (7.38 g, 96%). 
[α]20D = +33.3 (c 1.0, CHCl3) 
1H NMR (400 MHz, CDCl3) δ:  9,90 (br s, 1H), 5.86-5.94 (m, 1H), 5.57 (d, 1H, J=8.4 Hz), 5.19-
5.32 (m, 2H), 4.52-4.60 (m, 3H), 3.07 (dd, 1H, J1=17.2 Hz, J2=4.2 Hz), 2.89 (dd, 1H, J1=17.1 
Hz, J2=4.8 Hz), 1.46 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ: 176.2, 171.2, 156.0, 132.0, 119.1, 80.9, 66.2, 50.2, 36.9, 28.7. 
IR (Nujol) νmax: 3331, 2980, 1732, 1504, 1385, 1163. 
 
 




Acetyl chloride (16.2 mL, 0.23 mol, 4 equiv) was added dropwise to ice-cold methanol (45 
mL). The resulting solution was stirred at 0 ºC for 15 min and (S)-serine (6.00 g, 57 mmol) 
was added in a single portion and the reaction mixture was brought to reflux. After refluxing 
for 2.5 h, the mixture was cooled to r.t. and then poured into ice-cold Et2O (200 mL). The 
resulting precipitate was collected by filtration and washed on the pad with Et2O, to afford 
hydrochloride 100 as a white powder (7.27 g, 82%). 
Mp:  162-164 °C (Lit. 160-165 °C) 
[α]20D = +3.98 (c 1.0, CH3OH) 
1H NMR (400 MHz, D2O) δ: 4.25 (t, 1H, J=3.8 Hz), 4.08 (dd, 1H, J1=12.6 Hz, J2=4.3 Hz), 3.98 
(dd, 1H, J1=12.6 Hz, J2=3.4 Hz), 3.83 (s, 3H). 
13C NMR (100 MHz, D2O) δ: 169.3, 59.6, 55.1, 54.1. 
IR (KBr) νmax: 3358, 2928, 1750, 1595, 1510, 1260, 1095, 1040. 
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Compound 100 (1.20 g, 7.7 mmol) was dissolved in methanol (18 mL) and cooled to 0 ºC. 
Triethylamine (1.5 mL, 11 mmol, 1.4 equiv) was added, the reaction was then stirred for 10 
min, and freshly distilled benzaldehyde (0.79 mL, 7.7 mmol, 1 equiv) was successively 
added. The reaction mixture was stirred for 2 h, at which time NaBH4 (584 mg, 15.4 mmol, 2 
equiv) was added portionwise to the reaction mixture over a period of 30 min. The solution 
was partitioned between 4 M HCl (12 mL) and Et2O (30 mL). The organic layer was extracted 
with 4 M HCl (2 × 7 mL) and the combined aqueous layers were washed with Et2O (2 × 15 
mL). All organic layers were discarded. The aqueous layers were carefully neutralized with 
sat. aqueous NaHCO3, until a pH 8 was reached. The aqueous layer was then extracted with 
Et2O (4 × 15 mL) and the combined organic layers dried over Na2SO4. Evaporation of 
volatiles under reduced pressure afforded product 101 as a transparent oil (1.39 g, 86 %). 
[α]20D = -39.4 (c 1.0, CHCl3) 
1H NMR (400 MHz, CDCl3) δ:  7.26-7.38 (m, 5H), 3.91 (d, 1H, J=13.0 Hz), 3.82 (dd, 1H, 
J1=10.9 Hz, J2=4.4 Hz), 3.75-3.79 (m, 4H), 3.66 (dd, 1H, J1=10.8 Hz, J2=6.2 Hz), 3.46 (dd, 
1H, J1=6.1 Hz, J2=4.5 Hz), 2.78 (s, 1H). 
13C NMR (100 MHz, CDCl3) δ:  173.6, 139.3, 129.0, 128.8, 127.8, 62.8, 62.2, 52.6, 52.4. 








To a solution of 99 (329 mg, 1.2 mmol) in CH2Cl2 (8 mL), under a nitrogen atmosphere and at 
0 ºC, was added HATU (510 mg, 1.3 mmol, 1.1 equiv) and DIPEA (417 µL, 2.4 mmol, 2 
equiv). After 30 min, a solution of 101 (251 mg, 1.2 mmol, 1 equiv) in CH2Cl2 (1.6 mL) was 
added and the reaction was stirred at 0 ºC for 1 h and at r.t. for 24 h. The mixture was then 
diluted with EtOAc (100 mL) and the organic layer was washed in order with: 1 M KHSO4 (2 × 
20 mL), aqueous NaHCO3 (2 × 20 mL) and brine (2 × 20 mL), dried over Na2SO4 and 
volatiles were removed under reduced pressure. The residue was purified by flash 
chromatography on silica gel (petroleum ether/EtOAc, 75/25) to afford product 97 as a yellow 
oil (401 mg, 72%).  
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[α]21D = -2.65 (c 1.0, CHCl3) 
1H NMR (400 MHz, CDCl3) δ: 7.24-7.34 (m, 5H), 5.83-5.93 (m, 1H), 5.48 (d, 1H, J=8.2 Hz), 
5.30 (d, 1H, J=17.2 Hz), 5.23 (d, 1H, J=10.4 Hz), 4.51-4.61 (m, 3H), 4.32-4.48 (m, 2H), 3.88 
(d, 1H, J=13.1 Hz), 3.75 (s, 3H), 3.73 (d, 1H, J=13.1 Hz), 3.55 (t, 1H, J=4.7 Hz), 2.99 (dd, 
1H, J1=17.0 Hz, J2=4.3 Hz), 2.85 (dd, 1H, J1=17.0 Hz, J2=4.7 Hz), 2.21 (br s, 1H), 1.45 (s, 
9H).  
Two set of signals were observed in the 13C spectrum due to the presence of two rotational 
isomers A:B (20:1 ratio): 13C NMR (100 MHz, CDCl3) δ: 172.8 (A), 172.1 (B), 171.0 (A), 170.3 
(B), 155.7 (A), 155.0 (B), 139.6 (A), 138.9 (B), 132.1 (A), 131.4 (B), 128.9 (A), 128.7 (A), 
128.1 (B), 127.9 (B), 127.6 (A), 126.9 (B), 119.1 (A), 118.4 (B), 80.6 (A), 79.9 (B), 66.2 (A), 
66.1 (A), 65.5 (B), 65.4 (B), 59.5 (A), 58.8 (B), 52.7 (A), 52.2 (A), 51.9 (B), 51.4 (B), 50.3 (A), 
49.6 (B), 37.1 (A), 36.4 (B), 28.7 (A), 27.9 (B). 
IR (CHCl3) νmax: 3438, 3338, 3026, 2983, 2953, 2857, 1739, 1500, 1453, 1378, 1341, 1279, 
1247, 1176.  
HRMS (ESI) m/z calcd for [C 23H33N2O8]
+: 465.22314 [M+H]+; found: 465.22326.  
Anal. Calcd for C 23H32N2O8: C 59.47, H 6.94, N 6.03; found C 59.07, H 7.01, N 5.91. 
 
 





Dipeptide 97 (1.95 g, 4.2 mmol) was deprotected according to general procedure A. The 
corresponding trifluoroacetate salt was dissolved in a mixture of saturated aqueous 
NaHCO3/EtOAc (0.1 M, 1:1 v/v) and stirred at r.t. for 24-48 h. Subsequently, the layers were 
separated and the aqueous layer was extracted with EtOAc (4×). The combined organic 
layers were washed with brine, dried over Na2SO4 and volatiles were removed under 
reduced pressure. The residue was purified by flash chromatography on silica gel 
(CH2Cl2/CH3OH, 97/3) to afford product 102 as a white solid (1.13 g, 81%). 
Mp:  119-120 ºC 
[α]25D = -72.1 (c 1.0, CHCl3) 
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1H NMR (400 MHz, CDCl3) δ: 7.25-7.37 (m, 5H), 7.05 (br s, 1H), 5.84-5.94 (m, 1H), 5.25-5.34 
(m, 3H), 4.55-4.66 (m, 2H), 4.49-4.51 (m, 1H), 4.07 (d, 1H, J=15.0 Hz), 3.98 (d, 1H, J=11.1 
Hz), 3.85-3.89 (m, 2H), 3.21 (dd, 1H, J1=17.5 Hz, J2=2.8 Hz), 3.16 (br s, 1H); 3.13 (dd, 1H, 
J1=17.5 Hz, J2=10.4 Hz). 
13C NMR (100 MHz, CDCl3) δ: 171.9, 167.0, 166.3, 135.6, 131.9, 129.5, 128.6, 119.5, 66.4, 
61.3, 60.5, 52.8, 47.6, 40.7. 
IR (CHCl3) νmax: 3388, 3275, 3031, 3017, 2945, 1728, 1680, 1452, 1379, 1336, 1276, 1183, 
1124.  
MS (FAB+) m/z 333 ([M+1]+,  80%), 275 (11%), 154 (57%), 136 (48%), 91 (100%). 
Anal. Calcd for C 17H20N2O5: C 61.44, H 6.07, N 8.43; found C 61.23, H 5.97, N 8.24. 
X-ray crystallographic data of  102. Crystal data: C17H20N2O5; MW = 332.35 g mol
-1; T = 
293 K; λ(Mo, Kα) = 0.71073 Å, monoclinic, space group P21, a = 7.394(4) Å, b = 10.764(19) 
Å, c = 10.800(5) Å, β = 99.71(4)°, V = 847(2) Å 3, ρcalc = 1.303 g cm-3, Z = 2; µ(Mo, Kα) = 1.0 








To a solution of 102 (565 mg, 1.7 mmol) in CH2Cl2/toluene (6.6 mL/12.2 mL), under nitrogen 
atmosphere and at -20 ºC, was added PPh3 (530 mg, 2.0 mmol, 1.2 equiv) and the mixture 
was stirred until a solution was obtained. Hydrazoic acid (0.45 M in toluene,14 7.6 mL, 3.4 
mmol, 2 equiv) was added followed by a dropwise addition of DIAD (0.41 mL, 2.0 mmol, 1.2 
equiv) and the reaction was stirred at -20 ºC for 3.5 h. After evaporation of the solvent under 
reduced pressure, a quick chromatographic purification (petroleum ether/EtOAc, 6/4) was 
performed to remove the hydrazo-derivative and the resulting crude residue was then 
purified by flash chromatography on silica gel (CH2Cl2/CH3OH, 99/1) to afford product 105 as 
a colorless oil (291 mg, 48%). 
[α]23D = -72.7 (c 1.9, CHCl3) 
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1H NMR (400 MHz, CDCl3) δ: 7.26-7.39 (m, 5H), 6.91 (br s, 1H), 5.89-5.99 (m, 1H), 5.36 (d, 
1H, J=17.2 Hz), 5.30 (d, 1H, J=10.4 Hz), 5.18 (d, 1H, J=15.0 Hz), 4.62-4.71 (m, 2H), 4.51-
4.54 (m, 1H), 4.20 (d, 1H, J=15.0 Hz), 3.95 (br s, 1H), 3.89 (dd, 1H, J1=12.7 Hz, J2=1.7 Hz), 
3.68 (dd, 1H, J1=12.7 Hz, J2=3.4 Hz), 3.31 (dd, 1H, J1=17.7 Hz, J2=2.2 Hz), 3.08 (dd, 1H, 
J1=17.7 Hz, J2=11.2 Hz). 
13C NMR (100 MHz, CDCl3) δ: 171.6, 165.7, 165.1, 135.3, 131.8, 129.6, 128.8, 128.6, 119.6, 
66.5, 58.8, 52.6, 51.1, 48.0, 40.7. 
IR (thin film) νmax: 2984, 2929, 2853, 2119, 1734, 1686, 1667, 1451, 1336, 1274, 1181. 
MS (FAB+) m/z 358 ([M+1]+,  12%), 330 (2%), 149 (16%), 109 (27%), 91 (100%).  
Anal. Calcd for C 17H19N5O4: C 57.14, H 5.36, N 19.60; found C 57.39, H 5.28, N 19.25. 
 
 
[(2S,5S)-4-Benzyl-5-( tert-butoxycarbonylamino-methyl)-3,6-dioxo-piperazin-2- yl]-acetic 




To a solution of azide 105 (268 mg, 0.75 mmol) in THF (2.5 mL), under nitrogen atmosphere 
and at -20 ºC, was added Me3P (830 µL of 1 M solution in THF, 0.83 mmol, 1.1 equiv) and 2-
(t-butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON, 206 mg, 0.83 mmol, 1.1 equiv). 
After stirring for 5 h at r.t., CH2Cl2 (60 mL) was added and the solution was washed with H2O 
(3 × 30 mL) and brine. The organic layer was dried over Na2SO4 and volatiles were removed 
under reduced pressure. The residue was purified by flash chromatography on silica gel 
(CH2Cl2/CH3OH, 99/1) to afford product 108 as a white solid (253 mg, 78%). 
Mp:  57-58 ºC 
[α]28D = -123.7 (c 1.0, CHCl3) 
1H NMR (400 MHz, CDCl3) δ: 7.28-7.36 (m, 5H), 7.06 (br s, 1H), 5.86-5.96 (m, 1H), 5.56 (d, 
1H, J=15.1 Hz), 5.25-5.36 (m, 3H), 4.60-4.69 (m, 2H), 4.48-4.51 (m, 1H), 4.09 (d, 1H, J=15.1 
Hz), 3.80-3.86 (m, 2H), 3.45-3.49 (m, 1H), 3.27 (dd, 1H, J1=17.6 Hz, J2=1.7 Hz), 2.85 (dd, 
1H, J1=17.6 Hz, J2=11.1 Hz), 1.46 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ: 171.5, 166.7, 164.9, 156.2, 135.6, 131.8, 129.4, 128.9, 128.5, 
119.3, 80.8, 66.4, 59.2, 52.4, 47.2, 40.8, 40.6, 28.7. 
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IR (Nujol) νmax:  3323, 3308, 1716, 1684, 1658, 1339, 1272, 1167, 1127. 
MS (FAB+) m/z 432 ([M+1]+,  12%), 376 (49%), 332 (41%), 302 (16%), 91 (100%). 
Anal. Calcd for C 22H29N3O6: C 61.24, H 6.77, N 9.74; found C 61.47, H 6.93, N 9.56. 
 
 
[(2S,5S)-4-Benzyl-5-( tert-butoxycarbonylamino-methyl)-3,6-dioxo-piperazin-2- yl]-acetic 




To a solution of 108 (242 mg, 0.56 mmol) in CH2Cl2 (3.0 mL), under nitrogen atmosphere and 
at 0 ºC, was added pyrrolidine (56 µL, 0.67 mmol, 1.2 equiv), PPh3 (26 mg, 0.10 mmol, 0.18 
equiv) and then [Pd(PPh3)4] (24 mg, 0.02 mmol, 0.04 equiv). After stirring for 1 h at 0 ºC, 
EtOAc (25 mL) was added and the solution was extracted with aqueous NaHCO3 (4 × 10 
mL). The combined aqueous layers were acidified to pH 2 with a 1 M KHSO4 solution and 
then extracted with CH2Cl2. The resulting organic layer was dried over Na2SO4 and the 
solvent evaporated to afford product 90 as a fluffy white solid (209 mg, 95%). 
Mp:  85-86 ºC 
[α]26D = -69.9 (c 1.0, CHCl3) 
1H NMR (400 MHz, CDCl3, 50ºC) δ: 10.02 (br s, 1H), 8.05 (br s, 1H), 7.25-7.37 (m, 5H), 5.59 
(d, 1H, J=14.2 Hz), 5.36 (br s, 1H), 4.52 (d, 1H, J=11.4 Hz), 4.03 (br s, 1H), 3.88 (s, 1H), 
3.79-3.85 (m, 1H), 3.49-3.54 (m, 1H), 3.28 (dd, 1H, J1=17.7 Hz, J2=2.3 Hz), 2.74 (dd, 1H, 
J1=17.7 Hz, J2=11.4 Hz), 1.50 (s, 9H). 
13C NMR (100 MHz, CDCl3, 50ºC) δ: 175.1, 168.1, 164.9, 157.0, 135.4, 129.4, 128.8, 128.6, 
81.4, 59.5, 52.4, 47.3, 40.9, 40.6, 28.7. 
IR (Nujol) νmax:  3382, 3325, 3227, 1715, 1659, 1647, 1272, 1162, 1125. 
HRMS (ESI) m/z calcd for [C 19H25N3NaO6]
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According to general procedure B (without DIPEA, because no TFA salt of the amino acid 
was present), coupling of benzylamine (26 mL, 0.24 mmol) with DKP-90 (98 mg, 0.25 mmol, 
1.05 equiv), afforded product 109 (103 mg, 90%) as a white solid after purification by flash 
chromatography on silica gel (CH2Cl2/CH3OH, 95/5). 
Mp:  88-90 ºC 
[α]23D = -100.7 (c 0.29, CHCl3) 
1H NMR (400 MHz, DMSO-d6, 50 ºC) δ: 8.33 (br s, 1H), 7.93 (br s, 1H), 7.26-7.36 (m, 10H), 
6.85 (br s, 1H), 5.17 (d, 1H, J=15.3 Hz), 4.31-4.41 (m, 3H), 4.13 (d, 1H, J=15.3 Hz), 3.78 (t, 
1H, J=4.2 Hz), 3.55 (dt, 1H, J1=14.1 Hz, J2=5.6 Hz), 3.44 (dt, 1H, J1=14.1 Hz, J2=4.2 Hz), 
2.83 (dd, 1H, J1=15.3 Hz, J2=3.8 Hz), 2.74 (dd, 1H, J1=15.3 Hz, J2=7.9 Hz), 1.38 (s, 9H). 
13C NMR (100 MHz, DMSO-d6) δ: 170.2, 166.6, 165.9, 156.5, 139.9, 137.5, 129.4, 129.2, 
128.6, 128.3, 128.2, 127.7, 78.9, 59.5, 52.9, 47.6, 43.1, 41.9, 41.3, 29.0. 
IR (Nujol) νmax:  3301, 3198, 3168, 1711, 1658, 1643, 1276, 1167, 1126. 
MS (FAB+) m/z 481 ([M+1]+, 14%), 425 (21%), 381 (32%), 245 (15%), 154 (33%), 136 
(30%), 91 (100%). 
Anal. Calcd for C 26H32N4O5: C 64.98, H 6.71, N 11.66; found C 64.63, H 6.83, N 11.48. 
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Compound 109 (48 mg, 0.10 mmol) was deprotected according to general procedure A. To a 
solution of the corresponding trifluoroacetate salt in CH2Cl2 (2.0 mL) and DIPEA (52 µL, 0.30 
mmol, 3 equiv), was added the acetic anhydride (28 µL, 0.30 mmol, 3 equiv) and the solution 
was stirred at r.t. during 18 h. The mixture was concentrated in vacuo and the residue was 
recrystallized from methanol to afford 91 as a white solid (35 mg, 80%). 
Mp:  136-138 ºC 
[α]27D = -84.9 (c 1.0, CHCl3) 
1H NMR (400 MHz, CDCl3) δ: 8.29 (br s, 1H), 7.63 (br s, 1H), 7.39 (br s, 1H), 7.18-7.35 (m, 
10H), 5.35 (d, 1H, J=15.2 Hz), 4.25-4.41 (m, 3H), 4.18 (d, 1H, J=15.2 Hz), 3.88 (m, 1H), 3.72 
(m, 2H), 3.05 (dd, 1H, J1=15.7 Hz, J2=3.1 Hz), 2.96 (dd, 1H, J1=15.7 Hz, J2=8.8 Hz), 1.80 (s, 
3H). 
13C NMR (100 MHz, CDCl3) δ: 171.9, 170.4, 166.3, 166.2, 138.0, 135.7, 129.4, 129.0, 128.6, 
128.5, 127.9, 58.3, 52.9, 47.4, 43.9, 40.2, 39.5, 23.0. 
IR (Nujol) νmax: 3264, 3224, 3199, 1645, 1551, 1302. 
HRMS (ESI) m/z calcd for [C 23H26N4NaO4]
+: 445.18463 [M+Na]+; found: 445.18364. 
 
 




Boc-(S)-Ala-NH-CH2-Ph (67 mg, 0.24 mmol) was deprotected according to general 
procedure A. Coupling of the corresponding trifluoroacetate salt with DKP-90 (98 mg, 0.25 
mmol, 1.05 equiv), according to general procedure B, afforded 111 (122 mg, 92%) as a white 
solid after purification by flash chromatography on silica gel (CH2Cl2/CH3OH, 95/5). 
Mp: 112-113 ºC 
[α]28D = -98.4 (c 0.50, CHCl3) 
1H NMR (400 MHz, CDCl3, 40 ºC) δ: 7.48 (br s, 1H), 7.18-7.34 (m, 12H), 5.83 (br s, 1H), 5.41 
(d, 1H, J=15.0 Hz), 4.51-4.59 (m, 1H), 4.35-4.44 (m, 3H), 3.99 (d, 1H, J=15.0 Hz), 3.78 (br s, 
1H), 3.61-3.72 (m, 1H), 3.49-3.59 (m, 1H), 3.05 (dd, 1H, J1=15.1 Hz, J2=3.9 Hz), 2.74 (dd, 
1H, J1=15.1 Hz, J2=8.8 Hz), 1.42 (s, 9H), 1.36 (d, 3H, J=6.9 Hz). 
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13C NMR (100 MHz, CDCl3, 40 ºC) δ: 172.5, 170.4, 166.4, 166.1, 156.4, 138.6, 135.6, 129.3, 
128.9, 128.8, 128.5, 128.0, 127.7, 80.6, 59.2, 53.2, 49.6, 47.5, 43.9, 41.7, 41.4, 28.8, 18.5. 
IR (Nujol) νmax: 3354, 3320, 3240, 1717, 1658, 1639, 1552, 1532, 1249, 1173, 1076. 
MS (FAB+) m/z 552 ([M+1]+,  4%), 452 (18%), 369 (6%), 147 (31%), 109 (54%), 91 (100%). 
Anal. Calcd for C 29H37N5O6: C 63.14, H 6.76, N 12.70; found C 62.84, H 6.75, N 12.53. 
 
 




Compound 111 (61 mg, 0.11 mmol) was deprotected according to general procedure A. 
Coupling of the corresponding trifluoroacetate salt with Boc-(S)-Ala-OH (21 mg, 0.11 mmol, 1 
equiv), according to general procedure C, afforded 92 (54 mg, 82%) as a white solid, after 
purification by flash chromatography on silica gel (CH2Cl2/CH3OH, 95/5). 
Mp:  127-128 ºC 
[α]25D = -42.5 (c 0.41, CH3OH) 
1H NMR (400 MHz, CDCl3) δ: 8.20 (br s, 1H), 8.06 (br s, 1H), 7.75 (d, 1H, J=6.9 Hz), 7.55 (br 
s, 1H), 7.26-7.35 (m, 7H), 7.15-7.21 (m, 3H), 5.52 (d, 1H, J=7.5 Hz), 5.39 (d, 1H, J=15.0 Hz), 
4.67 (t, 1H, J=6.0 Hz), 4.47 (t, 1H, J=6.7 Hz), 4.41 (br s, 2H), 4.08 (br s, 1H), 3.99 (br s, 1H), 
3.96 (d, 1H, J=15.0 Hz), 3.75-3.82 (m, 2H), 3.16 (d, 1H, J=15.2 Hz), 2.80 (d, 1H, J=15.2 Hz), 
1.42 (d, 3H, J=6.0 Hz), 1.29 (br s, 12H). 
13C NMR (100 MHz, CDCl3) δ: 173.9, 173.7, 170.3, 166.1, 165.7, 155.9, 138.4, 135.5, 129.4, 
129.0, 128.7, 128.5, 127.6, 127.2, 80.1, 57.1, 52.4, 49.8, 46.9, 43.6, 39.5, 38.3, 28.7, 20.8, 
19.4. 
IR (CHCl3) νmax:  3429, 3395, 3330, 3295, 2930, 1689, 1657, 1556, 1506, 1449, 1368, 1332, 
1255, 1166. 
HRMS (ESI) m/z calcd for [C 32H42N6NaO7]
+: 645.30072 [M+Na]+; found: 645.29916. 
Anal.  Calcd for C 32H42N6O7: C 61.72, H 6.80, N 13.50; found C 61.42, H 6.78, N 13.35. 
 
 
CHAPTER IV              EXPERIMENTAL PART 
 168 




Compound 111 (72 mg, 0.13 mmol) was deprotected according to general procedure A. 
Coupling of the corresponding trifluoroacetate salt with Ac-(S)-Ala-OH (17 mg, 0.13 mmol, 1 
equiv), according to general procedure C, afforded 93 (54 mg, 76%) as a white solid after 
purification by flash chromatography on silica gel (CH2Cl2/CH3OH, 94/6). 
Mp:  178-179 ºC 
[α]27D = -22.8 (c 0.20, CH3OH) 
1H NMR (400 MHz, CDCl3) δ: 8.31 (br s, 1H), 8.27 (br s, 1H), 7.53 (br s, 1H), 7.22-7.37 (m, 
11H), 6.55 (br s, 1H), 5.36 (d, 1H, J=14.9 Hz), 4.71-4.78 (m, 2H), 4.51 (dd, 1H, J1=15.1 Hz, 
J2=6.0 Hz), 4.28 (dd, 1H, J1=15.1 Hz, J2=4.3 Hz), 4.18 (br, 1H), 4.07 (d, 1H, J=14.9 Hz), 4.05 
(br, 1H), 3.86-3.93 (m, 1H), 3.66-3.75 (m, 1H), 3.28-3.35 (m, 1H), 2.78-2.88 (m, 1H), 1.71 (s, 
3H), 1.43 (d, 3H, J=6.8 Hz), 1.28 (d, 3H, J=7.0 Hz). 
13C NMR (100 MHz, CDCl3) δ: 173.4, 170.4, 169.8, 166.1, 165.4, 138.2, 135.6, 129.4, 129.1, 
128.6, 128.5, 127.8, 57.3, 52.3, 49.6, 48.8, 47.1, 43.9, 39.6, 38.2, 23.4, 20.3, 19.7. 
IR (CHCl3) νmax:  3413, 3290, 2931, 1687, 1652, 1556, 1518, 1448, 1372, 1330, 1281. 
HRMS (ESI) m/z calcd for [C 29H36N6NaO6]
+: 587.25885 [M+Na]+; found: 587.25770. 
 
 




According to general procedure B (without DIPEA, because no TFA salt of the amino acid 
was present), coupling of butylamine (200 µL, 2.0 mmol) with Boc-(S)-Ala-OH (405 mg, 2.1 
mmol, 1.05 equiv), afforded 112 (467 mg, 95%) as a white solid. 
Mp:  75-76 ºC 
[α]27D = -33.9 (c 1.0, CHCl3) 
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1H NMR (400 MHz, CDCl3) δ: 6.36 (br s, 1H), 5.14 (br s, 1H), 4.14 (br, 1H), 3.22-3.27 (m, 
2H), 1.44-1.50 (m, 2H), 1.44 (s, 9H), 1.34 (d, 3H, J=7.0 Hz), 1.28-1.39 (m, 2H), 0.91 (t, 3H, 
J=7.3 Hz). 
13C NMR (100 MHz, CDCl3) δ: 173.2, 155.9, 80.1, 50.4, 39.4, 31.9, 28.7, 20.3, 19.1, 14.1. 
IR (Nujol) νmax:  3328, 3280, 1683, 1652, 1554, 1529, 1322, 1248, 1170, 1071, 1023. 
MS (FAB+) m/z 245 ([M+1]+, 28%), 189 (100%), 145 (95%). 
Anal. Calcd for C 12H24N2O3: C 58.99, H 9.90, N 11.47; found C 59.35, H 10.25, N 11.22. 
 
 




Compound 112 (244 mg, 1.0 mmol) was deprotected according to general procedure A. 
Coupling of the corresponding trifluoroacetate salt with Boc-(S)-Val-OH (228 mg, 1.05 mmol, 
1.05 equiv), according to general procedure B, afforded 113 (338 mg, 96%) as a white solid. 
Mp:  147-149 ºC 
[α]26D = -45.5 (c 0.53, CHCl3) 
1H NMR (400 MHz, CDCl3) δ: 6.67 (d, 1H, J=6.2 Hz), 6.45 (br s, 1H), 5.07 (d, 1H, J=7.3 Hz), 
4.44-4.52 (m, 1H), 3.95 (br, 1H), 3.17-3.32 (m, 2H), 2.12-2.20 (m, 1H), 1.44-1.53 (m, 2H), 
1.46 (s, 9H), 1.39 (d, 3H, J=7.0 Hz), 1.30-1.39 (m, 2H), 0.98 (d, 3H, J=6.8 Hz), 0.90-0.94 (m, 
6H). 
13C NMR (100 MHz, CDCl3) δ: 172.3, 172.0, 156.4, 80.4, 60.3, 49.3, 39.6, 31.9, 31.4, 28.7, 
20.4, 19.6, 18.7, 18.1, 14.1 
IR (Nujol) νmax:  3333, 3290, 1689, 1647, 1554, 1529, 1304, 1248, 1173, 1047, 1021. 
MS (FAB+) m/z 344 ([M+1]+, 36%), 288 (75%), 244 (15%), 145 (100%), 116 (41%). 
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Compound 113 (113 mg, 0.33 mmol) was deprotected according to general procedure A. 
Coupling of the corresponding trifluoroacetate salt with DKP-90 (137 mg, 0.35 mmol, 1.05 
equiv), according to general procedure B, afforded 114 (161 mg, 80%) as a white solid after 
purification by flash chromatography on silica gel (CH2Cl2/CH3OH, 94/6). 
Mp:  117-119 ºC 
[α]20D = -102.8 (c 0.50, CHCl3) 
1H NMR (400 MHz, CDCl3, 45 ºC) δ: 7.25-7.37 (m, 6H), 7.14 (br s, 1H), 6.98 (br s, 1H), 6.52 
(br s, 1H), 5.49 (d, 1H, J=15.0 Hz), 5.42 (br s, 1H), 4.47-4.56 (m, 2H), 4.33 (t, 1H, J=7.3 Hz), 
4.08 (d, 1H, J=15.0 Hz), 3.84-3.86 (m, 1H), 3.72-3.78 (m, 1H), 3.57-3.62 (m, 1H), 3.17-3.31 
(m, 3H), 2.75 (dd, 1H, J1=15.4 Hz, J2=8.9 Hz), 2.11-2.21 (m, 1H), 1.45-1.52 (m, 11H), 1.38 
(d, 3H, J=7.0 Hz), 1.30-1.36 (m, 2H), 0.99 (d, 3H, J=4.0 Hz), 0.97 (d, 3H, J=4.0 Hz), 0.91 (t, 
3H, J=7.2 Hz). 
13C NMR (100 MHz, CDCl3) δ: 172.5, 171.2, 171.1, 166.1, 156.5, 135.3, 129.5, 128.8, 80.4, 
59.1, 58.9, 53.2, 49.2, 47.4, 41.0, 39.6, 31.9, 31.7, 28.8, 20.4, 19.6, 18.8, 14.1. 
IR (CHCl3) νmax:  3439, 3363, 3344, 3309, 2972, 2935, 2875, 1682, 1653, 1526, 1509, 1453, 
1393, 1369, 1335, 1165. 
MS (FAB+) m/z 617 ([M+1]+, 23%), 517 (100%), 487 (11%), 318 (18%), 245 (16%), 154 
(40%), 136 (32%), 91 (79%). 
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Compound 114 (148 mg, 0.24 mmol) was deprotected according to general procedure A. 
Coupling of the corresponding trifluoroacetate salt with Boc-(S)-Ala-OH (46 mg, 0.24 mmol, 1 
equiv), according to general procedure C, afforded 94 (142 mg, 85%) as a white solid after 
purification by flash chromatography on silica gel (CH2Cl2/CH3OH, 95/5). 
Mp:  129-131 ºC 
[α]22D = -31.0 (c 0.23, CH3OH) 
1H NMR (400 MHz, CDCl3, 45 ºC) δ: 7.68 (br s, 1H), 7.54 (d, 1H, J=6.1 Hz), 7.47 (br s, 1H), 
7.27-7.36 (m, 5H), 7.21 (br s, 1H), 6.48 (br s, 1H), 5.43 (d, 1H, J=15.0 Hz), 5.35 (br s, 1H), 
4.41-4.48 (m, 3H), 4.37 (t, 1H, J=7.3 Hz), 4.05 (d, 1H, J=15.0 Hz), 3.99 (br s, 1H), 3.86-3.92 
(m, 1H), 3.73-3.79 (m, 1H), 3.15-3.30 (m, 2H), 3.10 (dd, 1H, J1=15.5 Hz, J2=4.7 Hz), 2.98 
(dd, 1H, J1=15.5 Hz, J2=5.6 Hz), 2.12-2.20 (m, 1H), 1.44-1.51 (m, 11H), 1.37 (d, 6H, J=7.0 
Hz), 1.29-1.36 (m, 2H), 1.02 (d, 3H, J=4.6 Hz), 1.00 (d, 3H, J=4.6 Hz), 0.92 (t, 3H, J=7.3 Hz). 
13C NMR (100 MHz, CDCl3) δ: 174.3, 172.9, 171.9, 170.9, 166.3, 166.1, 156.1, 135.4, 129.4, 
128.8, 128.6, 80.5, 59.8, 57.4, 52.8, 50.2, 47.1, 39.7, 31.9, 31.3, 28.8, 20.4, 20.3, 19.4, 18.7, 
17.9, 14.1. 
IR (Nujol) νmax:  3504, 3389, 3314, 3288, 3198, 1680, 1660, 1629, 1540, 1528, 1248, 1166. 
HRMS (ESI) m/z calcd for [C 34H53N7NaO8]
+: 710.38478 [M+Na]+; found: 710.38410. 
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Compound 94 (76 mg, 0.11 mmol) was deprotected according to general procedure A. The 
corresponding trifluoroacetate salt was then coupled to Boc-(S)-Val-OH (21 mg, 0.11 mmol, 
1 equiv), a slightly modified general procedure C (no aqueous quenching and immediate 
purification of the reaction mixture by flash chromatography on silica gel, CH2Cl2/CH3OH, 
96/4), which afforded 95 (61 mg, 70%) as a white solid. 
Mp:  235-236 ºC 
[α]22D = -26.0 (c 0.39, CH3OH) 
1H NMR (400 MHz, DMSO-d6) δ: 8.31 (br s, 1H), 8.27 (d, 1H, J=8.1 Hz), 8.26 (s, 1H), 8.12 
(d, 1H, J=7.4 Hz), 8.02 (d, 1H, J=7.8 Hz), 7.72 (t, 1H, J=5.6 Hz), 7.23-7.33 (m, 5H), 6.87 (d, 
1H, J=9.1 Hz), 4.86 (d, 1H, J=14.8 Hz), 4.53 (t, 1H, J=7.4 Hz), 4.25-4.38 (m, 4H), 3.85-3.94 
(m, 2H), 3.48-3.62 (m, 2H), 3.01-3.10 (m, 2H), 2.77-2.90 (m, 2H), 1.91-2.02 (m 2H), 1.37 (s, 
9H), 1.34-1.41 (m, 2H), 1.23-1.30 (m, 2H), 1.20 (d, 3H, J=7.1 Hz), 1.12 (d, 3H, J=6.9 Hz), 
0.78-0.91 (m, 15H). 
13C NMR (100 MHz, DMSO-d6) δ: 173.1, 172.5, 171.9, 170.9, 170.6, 167.3, 165.6, 156.3, 
137.7, 129.3, 128.5, 128.1, 78.9, 60.3, 59.3, 58.8, 52.4, 49.1, 48.6, 48.0, 40.9, 39.5, 38.9, 
32.0, 31.9, 31.5, 29.0, 20.2, 20.1, 19.9, 19.6, 19.1, 19.1, 18.8, 14.5. 
IR (Nujol) νmax:  3310, 3278, 3273, 3247, 3231, 3174, 1685, 1668, 1633, 1532, 1172. 
HRMS (ESI) m/z calcd for [C 39H62N8NaO9]
+: 809.45320 [M+Na]+; found: 809.45219. 
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Compound 94 (83 mg, 0.12 mmol) was deprotected according to general procedure A. The 
corresponding trifluoroacetate salt was then coupled to Ac-(S)-Val-OH (19 mg, 0.12 mmol, 1 
equiv), according to a slightly modified general procedure C (no aqueous quenching and 
immediate purification of the reaction mixture by flash chromatography on silica gel, 
CH2Cl2/CH3OH, 90/10), which afforded 96 (50 mg, 60%) as a white solid. 
Mp:  257-258 ºC 
[α]22D = +15.7 (c 0.23, CH3OH) 
1H NMR (400 MHz, DMSO-d6) δ: 8.29 (d, 1H, J=7.2 Hz), 8.28 (br s, 1H), 8.25 (t, 1H, J=5.3 
Hz), 8.19 (d, 1H, J=7.8 Hz), 8.18 (d, 1H, J=7.9 Hz), 7.96 (d, 1H, J=8.9 Hz), 7.83 (t, 1H, J=5.6 
Hz), 7.24-7.32 (m, 5H), 4.92 (d, 1H, J=15.6 Hz), 4.51 (t, 1H, J=7.3 Hz), 4.38 (t, 1H, J=7.3 
Hz), 4.32 (t, 1H, J=7.5 Hz), 4.22-4.29 (m, 3H), 3.89-3.91 (m, 1H), 3.49-3.62 (m, 2H), 3.05 (q, 
2H, J=6.5 Hz), 2.78-2.89 (m, 2H), 1.89 (s, 3H), 1.86-1.99 (m, 2H), 1.34-1.41 (m, 2H), 1.23-
1.30 (m, 2H), 1.20 (d, 3H, J=7.0 Hz), 1.13 (d, 3H, J=7.0 Hz), 0.89 (d, 3H, J=3.9 Hz), 0.87 (d, 
3H, J=3.9 Hz), 0.80-0.85 (m, 9H). 
13C NMR (100 MHz, DMSO-d6) δ: 173.2, 172.7, 171.8, 170.9, 170.6, 170.1, 167.2, 165.6, 
137.6, 129.3, 128.6, 128.1, 59.1, 58.8, 58.3, 52.4, 48.9, 48.6, 47.9, 39.6, 38.9, 31.9, 31.9, 
31.7 , 23.3, 20.2, 20.1, 19.9, 19.4, 19.3, 19.1, 19.0, 14.5. 
IR (Nujol) νmax:  3521, 3418, 3276, 3243, 1685, 1649, 1629, 1539, 1224, 1156, 1075. 
HRMS (ESI) m/z calcd for [C 36H56N8NaO8]
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Cbz-Arg(Mtr)-OH•CHA (1.76 g, 3.4 mmol, 1.05 eq) was dissolved in EtOAc (200 mL) and 
washed with 1 M KHSO4 (2 × 50 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated under reduced pressure. Coupling of the corresponding free acid Cbz-Arg(Mtr)-
OH with HCl•H-Gly-OMe (404 mg, 3.22 mmol, 1 equiv), according to general procedure D, 
afforded 130 (1.56 g, 78%) as a white solid after purification by flash chromatography on 
silica gel (EtOAc/CH3OH, 97/3). 
Mp: 69-70 °C 
[α]26D = +16.9 (c 1.0, CHCl3) 
1H NMR (400 MHz, CDCl3) δ: 7.61 (t, 1H, J=5.2 Hz), 7.29-7.34 (m, 5H), 6.53 (s, 1H), 6.33 (s, 
2H), 6.12 (br s, 1H), 6.01 (d, 1H, J=7.9 Hz), 5.07 (s, 2H), 4.35-4.39 (m, 1H), 4.02 (dd, 1H, 
J1=17.8 Hz, J2=5.5 Hz), 3.89 (dd, 1H, J1=17.8 Hz, J2=5.5 Hz), 3.83 (s, 3H), 3.67 (s, 3H), 3.36-
3.13 (m, 2H), 2.67 (s, 3H), 2.61 (s, 3H), 2.13 (s, 3H), 1.86-1.92 (m, 1H), 1.70-1.62 (m, 3H). 
13C NMR (100 MHz, CDCl3) δ: 173.3, 171.1, 159.0, 157.0, 156.9, 138.9, 137.0, 136.6, 133.7, 
128.9, 128.5, 128.3, 125.3, 112.2, 67.4, 55.8, 54.5, 52.7, 41.5, 40.6, 30.4, 25.6, 24.5, 18.7, 
12.4. 
IR (KBr) νmax:  3343, 2944, 1719, 1671, 1622, 1551, 1250, 1175. 
HRMS (ESI) m/z calcd for [C 27H37N5O8SNa]
+: 614.22550 [M+Na]+;  found: 614.22460. 
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Compound 130 (450 mg, 0.76 mmol) was dissolved in methanol (20 mL) and Pd(OH)2/C (45 
mg, 10% weight) was added. The reaction flask was purged three times with hydrogen, and 
stirring was maintained under hydrogen atmosphere at r.t. overnight. The mixture was filtered 
trough Celite, and the cake was washed thoroughly with methanol. The filtrate was 
concentrated and dried, under vacuum, to give product 131 (345 mg, 99 %) as a white foam, 
that was used without further purification. 
1H NMR (400 MHz, CDCl3) δ: 7.95 (t, 1H, J=5.6 Hz), 6.53 (s, 1H), 6.41 (br, 3H), 4.00 (d, 2H, 
J=5.7 Hz), 3.83 (s, 3H), 3.72 (s, 3H), 3.44-3.52 (m, 1H), 3.18-3.26 (m, 2H), 2.67 (d, 3H, J=7.3 
Hz), 2.60 (d, 3H, J=7.4 Hz), 2.13 (d, 3H, J=3.8 Hz), 2.05 (br s, 2H), 1. 77-1.92 (m, 1H), 1. 56-
1.72 (m, 3H). 
13C NMR (100 MHz, CDCl3) δ: 175.8, 171.0, 158.9, 157.0, 138.8, 136.9, 133.8, 125.2, 112.2, 
55.8, 54.6, 52.7, 41.3, 41.0, 32.1, 25.6, 24.5, 18.7, 12.4. 
IR (KBr) νmax:  3436, 3343, 2942, 1751, 1690, 1624, 1555, 1119. 
 
 




According to general procedure D, coupling of 131 (119 mg, 0.26 mmol) with DKP-90 (100 
mg, 0.26 mmol, 1 equiv), afforded 132 (156 mg, 72%) as a white solid after purification by 
flash chromatography on silica gel (CH2Cl2/CH3OH, 93/7). 
Mp: 121-122 °C 
[α]24D = -48.9 (c 0.94, CHCl3) 
1H NMR (400 MHz, CDCl3) δ: 7.96 (s, 1H), 7.50-7.77 (m, 2H), 7.25-7.30 (m, 5H), 6.52 (s, 
1H), 6.41 (br s, 3H), 6.09 (br s, 1H), 5.44 (d, 1H, J = 14.5 Hz), 4.57 (br s, 1H), 3.99-4.10 (m, 
3H), 3.77-3.83 (m, 4H), 3.63-3.76 (m, 5H), 3.38-3.55 (m, 1H), 3.10-3.33 (m, 3H), 2.78-2.96 
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(m, 1H), 2.66 (s, 3H), 2.59 (s, 3H), 2.12 (s, 3H), 1.83-1.98 (m, 1H), 1.54-1.80 (m, 2H), 1.41 
(s, 9H). 
13C NMR (100 MHz, CDCl3) δ: 173.0, 171.1, 166.9, 166.3, 158.9, 156.9, 156.6, 138.9, 136.9, 
135.7, 133.8, 129.4, 128.8, 128.5, 125.3, 112.2, 80.4, 59.1, 55.8, 53.4, 53.0, 52.8, 47.6, 41.5, 
41.0, 30.1, 28.8, 25.5, 24.5, 18.7, 12.4. 
IR (KBr) νmax:  3337, 1655, 1551, 1453, 1254, 1167, 1119. 
HRMS (ESI) m/z calcd for [C 38H54N8O11SNa]
+: 853.35250 [M+Na]+; found: 853.35043. 
 
 




Compound 132 (290 mg, 0.34 mmol) was deprotected according to general procedure A. 
The corresponding trifluoroacetate salt was then coupled to Cbz-L-Asp(OtBu)-OH (167 mg, 
0.52 mmol, 1.5 equiv), according to general procedure E, afforded 133 (298 mg, 84%) as a 
white solid after purification by flash chromatography on silica gel (CH2Cl2/CH3OH, 93/7). 
Mp:  122-123 °C 
[α]24D = -30.6 (c 1.0, CHCl3) 
1H NMR (400 MHz, CDCl3) δ: 7.97 (m, 3H), 7.0 (br s, 1H), 7.29 (m, 10H), 6.52 (s, 1H), 6.31 
(s, 3H), 6.11 (br s, 1H), 5.39 (d, 1H, J=13.9 Hz), 5.09 (d, 1H, J=12.0 Hz), 5.00 (d, 1H, J=12.0 
Hz), 4.67-4.71 (m, 2H), 4.41 (br s, 1H), 3.88-4.01 (m, 4H), 3.82 (s, 3H), 3.68-3.72 (m, 2H), 
3.64 (s, 3H), 2.95-3.21 (m, 4H), 2.60-2.68 (m, 8H), 2.12 (s, 3H), 1.81-1.96 (m, 1H), 1.65-1.75 
(s, 3H), 1.39 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ: 173.4, 171.7, 171.0, 170.9, 170.7, 166.4, 166.0, 158.9, 156.8, 
156.6, 139.0, 137.1, 136.5, 135.5, 129.4, 128.9, 128.7, 128.6, 128.5, 128.2, 125.3, 112.2, 
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82.2, 67.2, 57.5, 55.8, 53.5, 52.7, 52.5, 51.9, 47.1, 41.6, 40.9, 39.9, 39.4, 30.1, 28.4, 25.5, 
24.5, 18.7, 12.4. 
IR (KBr) νmax:  3443, 2928, 1655, 1547, 1453, 1385, 1262, 1117. 
HRMS (ESI) m/z calcd for [C 49H65N9O14SNa]
+: 1058.42639 [M+Na]+; found: 1058.42503. 
 
 



































To a solution of 133 (153 mg, 0.15 mmol) in dry THF (5 mL), under nitrogen atmosphere, 
freshly distilled benzyl alcohol (1.52 mL, 14.4 mmol, 100 equiv), and molecular sieves 4 Å 
(300 mg), and Ti(OiPr)4, (50 µL, 0.16 mmol, 1.05 equiv) were added. The suspension was 
stirred at 90 ºC for 20 h, then filtered through a pad of celite and washed with THF. The 
solvent was evaporated under reduced pressure and the crude residue was purified by flash 
chromatography on silica gel (CH2Cl2/ CH3OH, 93/7) to afford 134 as a white solid (159 mg, 
97%). 
Mp: 135-137 °C 
[α]24D = -23.8 (c 0.73, CHCl3)   
1H NMR (400 MHz, CDCl3) δ: 7.96 (m, 2H), 7.66 (br s, 1H), 7.27-7.38 (m, 16H), 6.52 (s, 1H), 
6.27 (s, 3H), 6.10 (d, 1H, J=8.6 Hz), 5.39 (d, 1H, J=15.6 Hz), 5.05-5.11 (m, 1H), 4.95 (d, 1H, 
J=12.4 Hz), 4.58-4.77 (m, 4H), 4.37 (br s, 1H), 3.93-4.06 (m, 4H), 3.82 (s, 3H), 3.69 (m, 1H), 
3.07-3.20 (m, 3H), 2.94 (d, 1H, J=16.1 Hz), 2.60-2.68 (m, 8H), 2.12 (s, 3H), 1.55-1.97 (m, 
3H), 1.39 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ: 173.3, 171.7, 170.9, 170.5, 170.1, 166.3, 166.0, 158.9, 156.9, 
156.6, 138.9, 137.0, 136.4, 135.6, 135.8, 129.4, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5, 
CHAPTER IV              EXPERIMENTAL PART 
 178 
128.2, 125.2, 112.1, 82.1, 67.5, 65.8, 57.5, 55.8, 53.5, 52.5, 51.9, 47.1, 41.7,  40.9, 39.9, 
39.5, 39.4, 29.9, 28.4, 25.5, 24.5, 18.7, 12.4. 
IR (KBr) νmax:  3339, 2940, 1655, 1547, 1259, 1119. 
HRMS (ESI) m/z calcd for [C 55H69N9O14SNa]
+: 1134.45769 [M+Na]+; found: 1134.45891. 
 
 

































Compound 134 (160 mg, 0.14 mmol) was dissolved in methanol (10 mL) and Pd/C (32 mg, 
20% weight) was added. The reaction flask was purged three times with hydrogen, and 
stirring was maintained under hydrogen atmosphere at r.t. overnight.  The mixture was 
filtered trough Celite, and the cake was washed thoroughly with methanol. The filtrate was 
concentrated and dried to give the desired product 135 (124 mg, 100 %) as a white foam, 
that was used without further purification. 
Mp:  180-182 °C 
1H NMR (400 MHz, CD3OD) δ: 7.29-7.39 (m, 5H), 6.67 (s, 1H), 5.23 (d, 1H, J=15.5 Hz), 5.04 
(d, 1H, J=14.8 Hz), 4.45-4.53 (m, 2H), 4.30 (d, 1H, J=15.2 Hz), 4.15 (s, 1H), 3.67-4.08 (m, 
9H), 3.36 (s, 2H), 3.21 (br s, 2H), 2.94 (m, 2H), 2.59-2.69 (m, 8H), 2.13 (s, 3H), 1.82-1.94 (m, 
1H), 1.56-1.75 (m, 3H), 1.45 (s, 9H). 
13C NMR (100 MHz, CD3OD) δ: 173.4, 173.0, 171.0, 170.0, 168.5, 167.5, 166.1, 158.9, 
138.9, 138.5, 136.9, 133.8, 128.9, 128.3, 127.9, 124.7, 111.8, 83.1, 65.9, 58.7, 55.0, 53.3, 
52.1, 49.8, 42.3, 40.6, 38.0, 36.4, 31.7, 29.5, 27.4, 26.0, 23.3, 22.7, 17.8, 11.1. 
IR (KBr) νmax: 3447, 2935, 1657, 1552, 1253, 1157. 
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To a solution of crude 135 (120 mg, 0.135 mmol) in DMF (7.4 mL), under nitrogen 
atmosphere and at 0 ºC, HATU (103 mg, 0.27 mmol, 2 equiv), HOAt (0.54 mL, 0.27 mmol, 2 
equiv) and 2,4,6-collidine (54 µL, 0.4 mmol, 3 equiv) were added. The reaction was stirred at 
0 ºC for 1 h and at r.t. overnight. The mixture was then diluted with EtOAc (100 mL) and the 
organic layer was washed in order with: 1 M KHSO4 (2 × 30 mL), aqueous NaHCO3 (2 × 30 
mL) and brine (2 × 20 mL), dried over Na2SO4 and volatiles were removed under reduced 
pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2/CH3OH, 
90/10) to afford 136 as a white solid (71 mg, 61%). 
Mp:  215-225 °C 
[α]24D = +36.75 (c 0.59, CH3OH)   
1H NMR (400 MHz, CD3OH) δ: 8.72 (t, 1H, J=6.0 Hz), 8.48 (d, 1H, J=3.5 Hz), 8.25 (br s, 1H), 
7.97 (d, 1H, J=8.9 Hz), 7.76 (t, 1H, J=5.2 Hz), 7.27-7.38 (m, 5H), 6.68 (s, 1H), 6.52 (br s, 
1H), 5.11 (d, 1H, J=15.3 Hz), 4.64-4.70 (m, 1H), 4.44 (t, 1H, J=3.6 Hz), 4.30 (d, 2H, J=15.3 
Hz), 4.09-4.15 (m, 2H), 3.95-4.04 (m, 2H), 3.84 (s, 3H), 3.67 (dt, 1H, J1=14.3 Hz, J2=4.1 Hz), 
3.49 (dd, 1H, J1=16.5 Hz, J2=5.1 Hz), 3.14-3.24 (m, 3H), 2.77-2.82 (m, 2H), 2.68 (s, 3H), 2.62 
(s, 3H), 2.54 (d, 1H, J=9.1 Hz), 2.13 (s, 3H), 1.68-1.83 (m, 2H), 1.53-1.68 (m, 2H), 1.45 (s, 
9H).  
13C NMR (100 MHz, CD3OH) δ: 174.0, 172.2, 172.0, 170.8, 170.0, 167.2, 165.7, 158.9, 
157.4, 138.4, 136.9, 136.1, 133.8, 128.9, 128.0, 127.9, 124.7, 111.8, 81.4, 58.5, 55.4, 55.0, 
52.1, 52.0, 43.7, 47.5, 40.4, 39.3, 38.4, 37.2, 27.7, 27.3, 26.0, 23.3, 17.8, 11.1.      
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II.  CHAPTER III  EXPERIMENTAL  PART 
 
MATERIALS AND METHODS : Usual solvents were purchased from commercial sources. 
Dimethylformamide (DMF) was distilled from CaSO4, tetrahydrofurane (THF) was distilled 
from sodium/benzophenone, acetonitrile was distilled from CaCl2, CH2Cl2 was distilled from 
calcium hydride. TLC was performed on silica gel, 60F-254 (0.26 mm thickness) plates. The 
plates were visualized with UV light (254 nm) or with a solution of vanillin in ethanol or with a 
solution of ninhydrin in ethanol. Liquid chromatography was performed on Merck 60 silica gel 
(230-400 mesh). Melting points were determined on a Kofler melting point apparatus. NMR 
spectra were performed on a Bruker AMX 200 (1H, 200 MHz; 13C, 50 MHz), Bruker Advance 
300 (1H, 300 MHz; 13C, 75 MHz) or a Bruker AVANCE 400 (1H, 400 MHz; 13C, 100 MHz). 
Proton chemical shifts are reported in ppm (δ) with the solvent reference relative to 
tetramethylsilane (TMS) employed as the internal standard. The following abbreviations are 
used to describe spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, qt = 
quintuplet, m = multiplet, br = broad signal, dd = doublet of doublet. Carbon chemical shifts 
are reported in ppm (δ) relative to TMS with the respective solvent resonance as the internal 
standard. Infrared spectra were recorded on a Bruker Vector 22 FT-IR spectrometer and 
peaks are reported in cm-1. Mass spectra were obtained using a Bruker Esquire electrospray 
ionization apparatus. Element analyses (C, H, N) were performed on a Perkin-Elmer CHN 
Analyser 2400, by the microanalyses Service of the Faculty of Pharmacy at Châtenay-





GENERAL PROCEDURE A FOR DEPROTECTION REACTIONS: To a solution of the N-Boc-protected 
amino acid or dipeptide in methanol was added a solution of HCl/CH3OH 6N (30 equiv). The 
solution was stirred at r.t. overnight. The solvent was evaporated to afford the corresponding 
hydrochloride salt. 
 
GENERAL PROCEDURE B FOR DEPROTECTION REACTIONS: To a solution of the N-Boc-protected 
amino acid or peptidomimetic in CH2Cl2 (0.13 M) was added an equal volume of TFA and the 
reaction was stirred at r.t. for 3 h. The solvent was evaporated, methanol (3×) was added 
followed by evaporation, and then ether was added and evaporated to afford the 
corresponding trifluoroacetate salt. 
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SYNTHESIS  OF  THE  POLAR  SCAFFOLDS : 
 




To a solution of 2,7-dihydroxylnaphthalene (500 mg, 3.0 mmol) in AcOH (7 mL) at 10−15 ºC, 
Br2 (312 µL, 6.1 mmol, 2 equiv) in AcOH (2.5 mL) was added dropwise at r.t. over 40 min. 
After the addition was complete, the mixture was refluxed during 15 min and after cooled to 
r.t.. Then, H2O (2 mL) and Sn powder (740 mg, 6.3 mmol) were added, and the reaction was 
stirred at 80 ºC for 24 h. The mixture was cooled to r.t., diluted with ice-cold distilled H2O (18 
mL), and extracted with EtOAc (3 × 25 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified 
by flash chromatography on silica gel (cyclohexane/EtOAc, 85/15) to afford product 214 as a 
light pink solid (677 mg, 94%). 
Mp:  184-186 ºC (Lit. 190-191 ºC)15 
1H NMR (300 MHz, DMSO-d6) δ: 10.33 (s, 1H), 9.68 (s, 1H), 7.98 (s, 1H), 7.60 (d, 1H, J=8.7 
Hz), 7.05 (s, 1H), 6.85-6.88 (m, 2H). 
13C NMR (75 MHz, DMSO-d6) δ: 155.9, 151.8, 135.2, 131.4, 128.3, 123.4, 116.3, 108.5, 
108.4, 106.9. 
IR νmax: 3430, 1172. 
MS (APCI Negative)  m/z 238 [M-1]+ 
Anal. Calcd for C 10H7BrO 2: C 50.24, H 2.95; found C 49.89, H 2.82. 
 
 
4-[7-(3-Benzyloxycarbonyl-propoxy)-3-bromo-naphthal en-2-yloxy]-butyric acid benzyl 
ester  (215) 
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To a solution of 214 (676 mg, 2.8 mmol) and potassium carbonate (977 mg, 7.1 mmol, 2.5 
equiv) in DMF (25 mL) was added slowly benzyl 4-bromobutyrate (2.18 g, 8.5 mmol, 3 
equiv), and the reaction was stirred, under argon atmosphere, at r.t. overnight. The solvent 
was evaporated under reduced pressure and the residue was dissolved in EtOAc (70 mL). 
The organic layer was washed with H2O (50 mL), 1 N HCl (40 mL), H2O (50 mL), and brine. 
The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. 
The crude residue was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 
90/10) to afford product 215 as a white solid (1.49 g, 89%). 
Mp:  60-62 ºC 
1H NMR (400 MHz, CDCl3) δ: 7.94 (s, 1H), 7.56 (d, 1H, J=9.5 Hz), 7.31-7.34 (m, 10H), 6.97-
7.01 (m, 3H), 5.15 (s, 4H), 4.16 (t, 2H, J=6.2 Hz), 4.10 (t, 2H, J=6.0 Hz), 2.71 (t, 2H, J=7.3 
Hz), 2.63 (t, 2H, J=7.3 Hz), 2.25 (qt, 2H, J=6.5 Hz), 2.20 (qt, 2H, J=6.5 Hz). 
13C NMR (100 MHz, CDCl3) δ: 173.0, 157.5, 153.2, 135.9, 134.8, 131.9, 128.5, 128.2, 124.9, 
117.2, 110.8, 106.9, 105.9, 67.6, 66.7, 66.3, 30.8, 30.7, 24.6, 24.4. 
IR νmax: 1720, 1159. 
MS (ESI Positive)  m/z 614 [M+23]+ 








A flame-dried schlenk tube was charged with 215 (100 mg, 0.17 mmol), palladium acetate (4 
mg, 17 µmol, 10 mol %), xantphos (20 mg, 34 µmol, 20 mol %), and potassium carbonate 
(467 mg, 3.4 mmol, 20 equiv). The schlenk tube was flushed with argon, and dry dioxane 
(2.3 mL) was added followed by the amine (34 µL, 0.25 mmol, 1.5 equiv). The reaction 
mixture was then stirred, under argon atmosphere, for 15 h at 110 ºC. The mixture was 
cooled to r.t., diluted with EtOAc (30 mL), filtered through a small pad of silica, that was 
thoroughly washed with EtOAc (3 × 20 mL). The filtrate was evaporated under reduced 
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pressure and the residue was purified by flash chromatography on silica gel (CH2Cl2, 100% 
to CH2Cl2/EtOAc, 95/5) to afford the product 216 as a yellow oil (76 mg, 70%). 
1H NMR (400 MHz, CDCl3) δ: 7.49 (d, 1H, J=8.6 Hz), 7.32-7.35 (m, 10H), 6.90-6.96 (m, 3H), 
6.76 (s, 1H), 5.15 (s, 4H), 4.70 (br s, 1H), 4.47 (qt, 1H, J=5.5 Hz), 4.06-4.17 (m, 5H), 3.84-
3.88 (m, 1H), 3.39 (dd, 1H, J1=12.7 Hz, J2=4.8 Hz), 3.33 (dd, 1H, J1=12.7 Hz, J2=5.3 Hz), 
2.63 (t, 4H, J=6.8 Hz), 2.25 (qt, 2H, J=6.5 Hz), 2.18 (qt, 2H, J=6.5 Hz), 1.47 (s, 3H), 1.38 (s, 
3H). 
13C NMR (100 MHz, CDCl3) δ: 173.1, 172.9, 154.6, 147.9, 136.6, 136.0, 135.8, 128.5, 128.2, 
126.8, 125.3, 116.1, 109.4, 106.8, 104.9, 104.2, 74.3, 67.3, 67.1, 66.7, 66.4, 66.3, 46.2, 31.0, 
30.9, 26.8, 25.3, 24.8, 24.6. 
IR νmax: 3423, 1731, 1153. 
MS (ESI Positive)  m/z 643 [M+1]+ 
Anal. Calcd for C 38H43NO8: C 71.12, H 6.75, N 2.18; found C 71.05, H 6.79, N 2.14. 
 
 





A flame-dried schlenk tube was charged with 215 (300 mg, 0.51 mmol), palladium acetate 
(12 mg, 51 µmol, 10 mol %), xantphos (60 mg, 0.10 mmol, 20 mol %), potassium carbonate 
(1.40 g, 10 mmol, 20 equiv), and HCl•H-Gly-OEt (106 mg, 0.76 mmol). The schlenk tube was 
flushed with argon, and dry dioxane (7 mL) was added. The reaction mixture was then 
stirred, under argon atmosphere, for 15 h at 110 ºC. The mixture was cooled to r.t., diluted 
with EtOAc (30 mL), filtered through a small pad of silica, that was thoroughly washed with 
EtOAc (3 × 20 mL). The filtrate was evaporated under reduced pressure and the residue was 
purified by flash chromatography on silica gel (cyclohexane/EtOAc, 75/25) to afford product 
217 as a orange oil (235 mg, 76%). 
1H NMR (300 MHz, CDCl3) δ: 7.40 (d, 1H, J=8.7 Hz), 7.26 (br s, 10H), 6.86-6.88 (m, 2H), 
6.83 (s, 1H), 6.55 (s, 1H), 5.07 (s, 4H), 4.18 (q, 2H, J=6.9 Hz), 4.09 (t, 2H, J=6.0 Hz), 3.99 (t, 
2H, J=6.0 Hz), 3.91 (s, 2H), 2.51-2.59 (m, 4H), 2.07-2.20 (m, 4H), 1.22 (t, 3H, J=6.9 Hz). 
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13C NMR (75 MHz, CDCl3) δ: 173.1, 173.0, 171.0, 154.8, 147.8, 135.9, 135.8, 128.5, 128.2, 
127.0, 125.2, 116.1, 106.9, 105.1, 104.5, 67.1, 66.8, 66.4, 66.3, 61.2, 45.8, 31.0, 29.7, 24.8, 
24.6, 14.2. 
IR νmax: 2942, 1731, 1160. 
MS (ESI Positive)  m/z 636 [M+23]+, 652 [M+39]+ 
 
 
4-[3-Amino-7-(3-benzyloxycarbonyl-propoxy)-naphthal en-2-yloxy]-butyric acid benzyl 




A flame-dried schlenk tube was charged with 215 (100 mg, 0.17 mmol), palladium acetate (4 
mg, 17 µmol, 10 mol %), xantphos (20 mg, 34 µmol, 20 mol %), and potassium carbonate 
(467 mg, 3.4 mmol, 20 equiv). The schlenk tube was flushed with argon, and dry dioxane 
(2.3 mL) was added followed by benzophenone imine (44 µL, 0.25 mmol, 1.5 equiv). The 
reaction mixture was then stirred, under argon atmosphere, for 15 h at 110 ºC. The mixture 
was cooled to r.t., diluted with EtOAc (30 mL), filtered through a small pad of silica, that was 
thoroughly washed with EtOAc (3 × 20 mL). The filtrate was evaporated under reduced 
pressure and the resulting crude residue containing the imine adduct 218 was dissolved in 
dioxane (1.5 mL). To the reaction mixture was added a solution of NaOAc•3H2O (96 mg, 0.71 
mmol, 4.2 equiv) in methanol (7 mL) followed by NH2OH•HCl (38 mg, 0.53 mmol, 3.1 equiv).  
After stirring for 5 h at r.t., the solvent was evaporated under reduced pressure, and the 
crude residue was purified by flash chromatography on silica gel (cyclohexane/EtOAc, 80/20) 
to afford product 219 as a light pink solid (55 mg, 62%). 
Mp:  87-89 ºC 
1H NMR (300 MHz, CDCl3) δ: 7.37 (d, 1H, J=8.7 Hz), 7.26 (br, 10H), 6.91 (s, 1H), 6.83-6.87 
(m, 3H), 5.07 (s, 4H), 4.08 (t, 2H, J=6.0 Hz), 3.99 (t, 2H, J=6.0 Hz), 2.58-2.52 (m, 4H), 2.17 
(qt, 2H, J=7.2 Hz), 2.10 (qt, 2H, J=7.2  Hz). 
13C NMR (75 MHz, CDCl3) δ: 173.2, 173.1, 154.9, 148.2, 136.0, 135.9, 134.9, 129.2, 128.6, 
128.3, 128.2, 126.8, 125.1, 116.3, 109.3, 106.7, 105.4, 67.1, 66.7, 66.5, 66.3, 31.2, 31.0, 
24.8, 24.6. 
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IR νmax: 3367, 1725, 1160. 
MS (APCI Positive)  m/z 528 [M+1]+ 




SYNTHESIS  OF  THE  MOLECULAR  TONGS  ARMS: 
 
2-(2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-met hyl-butyric acid methyl 













To a solution of Boc-L-Leu-OH (4.14 g, 18 mmol) in CH2Cl2 was added NMM (2.4 mL, 21 
mmol, 1.2 equiv) and the mixture was stirred at -10 °C for 30 min. Isobutyl chloroformate (2.6 
mL, 20 mmol, 1.1 equiv) was then added, dropwise, and the resulting mixture was stirred at -
10 °C for 40 min. Finally, a solution of H- L-Val-OMe and NMM (2.4 mL, 22 mmol, 1.2 equiv) 
in CH2Cl2 was added, dropwise, and the reaction mixture was stirred ar r.t. for 24 h. The 
solvent was evaporated and the resulting residue was dissolved in EtOAc (200 mL), washed 
sucessively with: 10% aqueous citric acid (50 mL), H2O (50 mL) and 10% aqueous K2CO3 
(50 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude residue was purified by chromatography on silica gel 
(cyclohexane/EtOAc, 70/30) to afford product 221 as a white solid (4.21 g, 68%). 
1H NMR (300 MHz, CDCl3) δ: 6.53 (d, 1H, J=8.0 Hz), 4.83 (d, 1H, J=7.4 Hz), 4.47 (dd, 1H, 
J1=8.9 Hz, J2=4.9 Hz), 4.05 (m, 1H), 3.67 (s, 3H), 2.10-2.20 (m, 1H), 1.49-1.74 (m, 3H), 1.37 
(s, 9H), 0.80-0.92 (m, 12H). 
13C NMR (75 MHz, CDCl3) δ: 174.7, 157.7, 70.6, 61.8, 54.7, 50.4, 41.7, 28.7, 27.4, 22.4, 
21.7, 16.6. 
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3-Methyl-2-[4-methyl-2-(3-methyl-2-phenoxycarbonyla mino-butyrylamino)-pentanoyl 




Compound 221 (4.52 g, 13 mmol) was deprotected according to general method A. To a 
solution of the corresponding hydrochloride salt in dry CH2Cl2 (70 mL), was added Z-L-Val-
OH (3.95 g, 16 mmol, 1.2 equiv), DIPEA (11.4 mL; 66 mmol, 5 equiv), EDCI (3.77 g; 20 
mmol, 1.5 equiv) and HOBt (2.13 g; 16 mmol, 1.2 equiv). The reaction mixture was stirred, 
under argon, overnight. The solvent was evaporated under reduced pressure and the residue 
was dissolved in EtOAc (200 mL). The organic layer was washed sucessively with: 10% 
aqueous citric acid (50 mL), H2O (100 mL), 10% aqueous K2CO3 (50 mL), and brine (25 mL), 
dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting crude 
residue was purified by flash chromatography on silica gel (cyclohexane /EtOAc, 75/25). 
Product 222 was obtained as a white powder (3.90 g, 64%). 
1H NMR (300 MHz, CDCl3) δ: 7.26-7.32 (m, 5H), 6.62 (d, 1H, J=8.7 Hz), 6.37 (d, 1H, J=7.6 
Hz), 5.41 (d, 1H, J=8.7 Hz), 5.08 (s, 2H), 4.34-4.58 (m, 2H), 3.99 (m, 1H), 3.70 (s, 3H), 1.85 -
2.35 (m, 2H), 1.37 -1.75 (m, 3H), 0.87-1.09 (m, 18H). 
13C NMR (75 MHz, CDCl3) δ: 172.2, 171.7, 171.5, 156.5, 136.3, 128.5-128.0, 67.0, 60.4, 
57.2, 52.1, 51.9, 41.0, 31.2, 24.7, 22.7, 22.3, 19.2, 18.9, 18.0, 17.8. 
IR νmax: 3282, 1736, 1692, 1641, 1537, 1247. 
 
 
2-[2-(2-Amino-3-methyl-butyrylamino)-4-methyl-penta noylamino]-3-methyl-butyric acid 




To a solution of 222 (382 mg, 0.83 mmol) in methanol (15 mL) and HCl/CH3OH 6N (1 mL) 
was added Pd/C (50 mg, 13% weight). The reaction flask was purged three times with 
hydrogen, and stirring was maintained under hydrogen atmosphere at r.t. for 12 h. The 
mixture was filtered through celite, and the cake was washed with methanol (200 mL). The 
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filtrate was concentrated and dried to give the crude product 223 as a white powder (314 mg, 
100%). The crude product was used without further purification in the course of the 
synthesis. 
1H NMR (300 MHz, DMSO-d6) δ: 8.61 (d, 1H, J=8.0 Hz), 8.34 (d, 1H, J=8.1 Hz), 8.24 (s, 3H), 
4.48 (q, 1H, J=6.9 Hz), 4.14 (dd, 1H, J1=8.4 Hz, J2=1.8 Hz), 3.61-3.64 (m, 4H), 2.05 (m, 2H), 
1.65 (m, 1H), 1.46 (m, 2H), 0.66-1.05 (m, 18H). 
13C NMR (75 MHz, DMSO-d6) δ: 172.4, 172.2, 167.9, 57.8, 57.4, 52.1, 51.5, 41.3, 30.3, 30.2, 
24.4, 23.4, 22.3, 19.4, 18.6, 18.2. 
IR νmax: 2962, 1746, 1687, 1637, 1530, 1205. 
 
 




To an ice-cold suspension of 2-methoxybenzoic acid (3.00 g, 20 mmol) in concentrated 
aqueous H2SO4 (36 mL) was added portionwise NH4NO3 (1.74 g, 22 mmol, 1.1 equiv). The 
reaction mixture was stirred at 0°C for 30 min and at r.t. for 3h. H2O (150 mL) was then 
added and the resulting precipitate was filtered. The solid was finally washed with H2O (200 
mL) and dried under vacumn (over P2O5 in a desiccator) to give 224 as a white solid (3.10 g, 
80%). 
Mp:  149-150 °C (Lit. 161-162 °C) 17 
1H NMR (200 MHz, CD3OD) δ: 8.64 (d, 1H, J=2.9 Hz), 8.40 (dd, 1H, J1=9.3 Hz, J2=2.9 Hz), 
7.31 (d, 1H, J=9.3 Hz), 4.02 (s, 3H). 
13C NMR (50 MHz, CD3OD) δ: 165.9, 163.6, 140.3, 129.4, 126.7, 122.8, 112.4, 55.9. 
IR νmax: 3258, 1725, 1611, 1514, 1342, 1177. 
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To a solution of 224 (3.05 g, 15 mmol) in dry CH2Cl2 (70 mL), was added tert-butyl carbazate 
(2.25 g, 17 mmol, 1.1 equiv), DIPEA (8.1 mL; 46 mmol, 3 equiv), EDCI (3.26 g; 17 mmol, 1.1 
equiv) and HOBt (2.30 g; 17 mmol, 1.1 equiv). The reaction mixture was stirred, under argon 
atmosphere, overnight. The solvent was evaporated under reduced pressure and the residue 
was dissolved in EtOAc (200 mL) and the organic layer was washed with: 10% aqueous citric 
acid (50 mL), H2O (100 mL), 10% aqueous K2CO3  (50 mL), and brine (25 mL). The organic 
layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The 
resulting crude residue was purified by flash chromatography on silica gel 
(EtOAc/cyclohexane, 60/40) to afford compound 225 as a white solid (4.10 g, 85%). 
Mp: 113-115 °C 
1H NMR (200 MHz, CDCl3) δ: 9.40 (br s, 1H), 9.07 (d, 1H, J=3.0 Hz), 8.35 (dd, 1H, J1=9.2 
Hz, J2=3.0 Hz), 7.10 (d, 1H, J=9.2 Hz), 6.99 (br s, 1H), 4.12 (s, 3H), 1.51 (s, 9H). 
13C NMR (50 MHz, CDCl3) δ: 162.0, 161.7, 155.1, 141.9, 128.7, 128.5, 120.3, 111.9, 82.0, 
57.2, 28.7. 
IR νmax: 3410, 1741, 1678. 
 
 




To a solution of 225 (2.30 g, 7.4 mmol) in methanol (100 mL) was added Pd/C (460 mg, 20% 
weight). The reaction flask was purged three times with hydrogen, and stirring was 
maintained under hydrogen atmosphere at r.t. for 12 h. The mixture was filtered through 
celite, and the cake was washed with methanol (200 mL). The filtrate was concentrated to 
give 226 as a beige foam (1.97 g, 95%). 
1H NMR (300 MHz, CD3OD) δ: 7.35 (s, 1H), 6.87-6.99 (m, 2H), 3.88 (s, 3H), 1.49 (s, 9H). 
13C NMR (75 MHz, CD3OD) δ: 168.2, 157.8, 152.2, 142.7, 122.5, 122.2, 119.5, 114.7, 81.9, 
57.1, 29.1. 
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A solution of 226 (1.74 g, 6.2 mmol) in dry THF (20 mL) was heated at 60°C and acetic 
anhydride (2.9 mL, 31 mmol, 5 equiv) was then added dropwise. The reaction mixture was 
stirred for 40 min at 60°C. THF was evaporated unde r reduced pressure and the crude 
product was dried under vacuum to yield a white powder (1.97 g, 99%). The crude product 
227 was used without any further purification in the course of the synthesis. 
Mp:  209-211 °C (Lit. 211-213 ºC) 17 
1H NMR (300 MHz, DMSO-d6) δ: 9.93 (s, 1H), 9.62 (s, 1H), 8.92 (s, 1H), 7.89 (s, 1H), 7.75 
(d, 1H, J=8.9 Hz), 7.07 (d, 1H, J=8.9 Hz), 3.83 (s, 3H), 2.01 (s, 3H), 1.42 (s, 9H). 
13C NMR (75 MHz, DMSO-d6) δ: 167.9, 164.9, 155.1, 152.6, 132.4, 123.1, 121.2, 112.2, 
79.0, 55.9, 28.0, 23.7.  
IR νmax: 3275, 1712, 1665, 1596, 1491, 1245, 1163. 








Compound 227 (297 mg, 0.92 mmol) was deprotected according to general procedure B. 
The corresponding trifluoroacetate salt and Boc-L-Val-OH (200 mg, 0.92 mmol, 1 equiv) were 
dissolved in DMF (15 mL). DIPEA (2.0 mL, 12 mmol, 12.5 equiv), HBTU (417 mg, 1.1 mmol, 
1.2 equiv) and HOBt (135 mg, 1.0 mmol, 1.1 equiv) were successively added and the 
reaction mixture was stirred, under argon atmosphere, for 48 h at r.t.. The solvent was 
evaporated under reduced pressure and the resulting residue was dissolved in EtOAc (200 
mL) and the organic layer was washed sucessively with: 10% aqueous citric acid (50 mL), 
10% aqueous K2CO3 (50 mL), H2O (100 mL), dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude product was purified by flash chromatography on silica 
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gel (EtOAc/cyclohexane, 80/20). The solid obtained was recristallyzed from EtOAc/petroleum 
ether to afford product 228 as a white solid (265 mg, 68 %). 
1H NMR (400 MHz, CDCl3) δ: 12.15 (d, 1H, J=7.0 Hz), 11.42 (d, 1H, J=7.0 Hz), 8.82 (s, 1H), 
8.47 (d, 1H, J=7.0 Hz), 8.11 (s, 1H), 7.02 (d, 1H, J=7.0 Hz), 5.60 (d, 1H, J=8.7 Hz), 4.79 (m, 
1H), 4.08 (s, 3H), 2.19 (s, 3H), 2.02 (m, 1H), 1.48 (s, 9H), 0.88 (m, 6H). 
13C NMR (100 MHz, CDCl3) δ: 169.0, 165.8, 158.2, 156.0, 153.6, 133.2, 125.9, 122.8, 117.8, 
112.0, 79.6, 57.1, 56.6, 33.4, 28.5, 24.7, 17.9. 
IR νmax: 3314, 2969, 1712, 1658, 1492, 1245, 1168. 
MS (ESI Positive) m/z 445 [M+23]+  
 
 
(6-[N'-(5-Acetylamino-2-methoxybenzoyl)hydrazino]-5-benz yloxycarbonyl amino-6-oxo 




Compound 227 (479 mg, 1.5 mmol) was deprotected according to general procedure B. The 
corresponding trifluoroacetate salt and Nα-Boc-Nε-Z-L-Lys-OH (563 mg, 1.5 mmol, 1 equiv) 
were dissolved in DMF (15 mL). DIPEA (2.6 mL, 15 mmol, 10 equiv), HBTU (618 mg, 1.6 
mmol, 1.1 equiv) and HOBt (220 mg, 1.6 mmol, 1.1 equiv) were successively added to the 
reaction mixture. The reaction mixture was stirred, under argon atmosphere, for 24 h at r.t.. 
The solvent was evaporated under reduced pressure and the resulting residue was dissolved 
in EtOAc (200 mL). The organic layer was washed sucessively with: 10% aqueous citric acid 
(50 mL), 10% aqueous K2CO3 (50 mL), H2O (100 mL), dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica (EtOAc, 100%). The solid obtained was recristallyzed from 
EtOAc/petroleum ether to afford product 198 as a white solid (635 mg, 73 %). 
Mp:  136-138 °C  
1H NMR (400 MHz, CDCl3) δ: 11.9 (s, 1H), 11.3 (d, 1H, J=7.0 Hz), 8.78 (s, 1H), 8.44 (d, 1H, 
J=9.0 Hz), 7.9 (s, 1H), 7.28 (m, 5H), 6.97 (d, 1H, J=9.0 Hz), 5.64 (d, 1H, J=7.5 Hz), 5.01 (s, 
2H), 4.92 (m, 1H), 4.76 (s, 1H), 4.02 (s, 3H), 3.04 (m, 2H), 2.20 (s, 3H), 1.81 (m, 1H), 1.74 
(m, 1H), 1.46 (s, 9H), 1.35-1.46 (m, 4H). 
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13C NMR (100 MHz, CDCl3) δ: 169.0, 166.3, 158.6, 156.3, 155.6, 153.6, 136.6, 133.1, 128.4, 
128.0, 126.1, 122.5, 117.8, 112.4, 79.8, 66.5, 56.5, 52.0, 40.7, 34.0, 29.5, 28.6, 24.6, 21.9. 
IR νmax: 3312, 1663, 1627, 1530, 1494, 1246, 1168, 1015. 
MS (ESI Positive) m/z 608 [M+Na]+ 
HRMS (ESI) m/z calcd for [C 29H39N5O8Na]
+: 608.2696 [M+Na]+; found: 608.2697. 
Anal. Calcd for C 29H39N5O8: C 59.47, H 6.71, N 11.96; found C 59.33, H 6.75, N 11.74. 
 
 
(6-[N'-(5-Acetylamino-2-methoxybenzoyl)hydrazino]5-amino -6-oxohexyl) carbamic acid 




To a solution of 198 (150 mg, 0.26 mmol) in methanol (15 mL) was added Pd/C (23 mg, 20% 
weight). The reaction flask was purged three times with hydrogen, and stirring was 
maintained under hydrogen atmosphere at r.t. for 12 h. The mixture was filtered through 
celite, and the cake was washed with methanol (200 mL). The filtrate was concentrated and 
dried to give the crude product 230 as a white powder (111 mg, 96%). The crude product 
was used without further purification in the course of the synthesis. 
1H NMR (300 MHz, CDCl3) δ: 9.29 (s, 1H), 8.91 (s, 1H), 8.29 (s, 2H), 7.87 (m, 1H), 6.94 (m, 
1H), 5.65 (m, 1H), 4.67 (m, 2H), 3.94-4.13 (m, 4H), 2.19-2.27 (m, 5H), 1.78 (br, 2H), 1.33-
1.51 (m, 13H). 
13C NMR (75 MHz, CDCl3) δ: 169.2, 169.1, 158.5, 155.6, 153.7, 132.9, 125.9, 122.7, 118.2, 
112.0, 79.9, 56.4, 52.3, 52.2, 50.2, 27.0, 28., 24.4, 22.2. 
IR νmax: 1651, 1512, 1170.  
MS (ESI Positive) m/z 452 [M+1]+  
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To a solution of tert-butyl carbazate (2.55 g, 18 mmol) in CH2Cl2 (20 mL), under argon 
atmosphere and at 0 ºC, was added pyridine (3.4 mL, 42 mmol, 2.2 equiv). After 10 min, a 
solution of phenyl chloroformate (2.6 mL, 21 mmol, 1.1 equiv) in CH2Cl2 (20 mL) was added 
dropwise and the reaction was stirred at 0 ºC for 40 min and at r.t. overnight. After 
evaporation of the solvent and volatiles under reduced pressure, the resulting residue was 
triturated with n-hexane affording product 231 as a white solid (4.65 g, 97%). 
Mp:  134-136 ºC 
1H NMR (300 MHz, CDCl3) δ: 7.14-7.39 (m, 5H), 6.99 (br s, 1H), 6.50 (br s, 1H), 1.49 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ: 155.6, 155.1, 150.6, 129.4, 125.8, 121.4, 82.2, 28.2. 
IR νmax: 3273, 3221, 1756, 1691, 1523, 1486, 1218, 1150. 
MS (ESI Positive)  m/z 275 [M+23]+ 
Anal. Calcd for C 12H16N2O4: C 57.13, H 6.39, N 11.10; found C 57.03, H 6.14, N 10.92. 
 
 




To a solution of 231 (2.50 g, 9.9 mmol) in methanol (40 mL) was added hydrazine 
monohydrate (3.3 g, 64 mmol, 6.5 equiv) and the mixture was stirred at 60 ºC for 1.5 h. After 
evaporation of the solvent, the resulting residue was triturated with petroleum ether. The 
resulting precipitate was recrystallized from EtOAc/petroleum ether, to afford product 232 as 
a white solid (1.35 g, 72%). 
Mp:  138-140 ºC 
1H NMR (300 MHz, DMSO-d6) δ: 8.41 (s, 1H), 7.80 (s, 1H), 7.30 (s, 1H), 4.04 (br s, 2H), 1.38 
(s, 9H). 
13C NMR (75 MHz, DMSO-d6) δ: 159.9, 155.9, 78.7, 28.1. 
IR νmax: 3254, 3254, 3046, 1729, 1649, 1508, 1150. 
MS (ESI Positive)  m/z 213 [M+23]+ 
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To a solution of 232 (625 mg, 3.3 mmol) in THF (50 mL) was added pyridine (678 µL, 8.2 
mmol, 2.5 equiv) and the mixture was stirred until a homogeneous solution was obtained. 
The solution was then cooled to 0 ºC and phenyl chloroformate (458 µL, 3.6 mmol, 1.1 equiv) 
was added. After stirring for 15 min at r.t., the solvent was evaporated under reduced 
pressure and the residue was dissolved in EtOAc (50 mL). The organic layer was washed 
sucessively with: H2O (2 × 25 mL), 5% aqueous citric acid (2 × 20 mL), 10% aqueous K2CO3 
(2 × 20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash chromatography on silica gel (EtOAc/cyclohexane, 80/20) to 
afford product 233 as a white solid (923 mg, 91%). 
Mp:  173-174 ºC 
1H NMR (300 MHz, CDCl3) δ: 7.81 (br s, 2H), 7.68 (br s, 1H), 7.09-7.31 (m, 5H), 6.99 (br s, 
1H), 1.43 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ: 158.7, 156.7, 155.8, 150.6, 129.3, 125.7, 121.4, 82.1, 28.1. 
IR νmax: 3262, 3238, 1712, 1682, 1519, 1489, 1226, 1154. 
MS (ESI Positive)  m/z 333 [M+23]+ 
Anal. Calcd for C 13H18N4O5: C 50.32, H 5.85, N 18.06; found C 50.29, H 5.52, N 17.87. 
 
 
(S)-tert-Butyl  2-(2-(1-amino-3-methyl-1-oxobutan-2-ylcarba moyl)hydrazinecarbonyl) 




Coumpond 233 (273 mg, 0.88 mmol) and HCl•H-L-Val-NH2 (151 mg, 0.97 mmol, 1.1 equiv) 
were dissolved in acetonitrile (17 mL), and triethylamine (741 µL, 5.3 mmol, 6 equiv) was 
successively added to the reaction mixture. The reaction was stirred, under argon 
atmosphere, for 3 days at r.t.. The solvent was evaporated under reduced pressure and the 
resulting residue was purified by flash chromatography on silica gel (EtOAc/CH3OH, 90/10) 
to afford product 236 as a white solid (272 mg, 93%). 
Mp:  154-156 ºC 
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1H NMR (300 MHz, DMSO-d6) δ: 8.61 (br s, 1H), 8.13 (s, 2H), 7.77 (s, 1H), 7.37 (br s, 1H), 
7.08 (s, 1H), 6.05 (d, 1H, J=8.4 Hz), 4.00 (dd, 1H, J1=8.4 Hz, J2=5.1 Hz), 1.95-2.02 (m, 1H), 
1.41 (s, 9H), 0.87 (d, 3H, J=6.6 Hz), 0.82 (d, 3H, J=6.6 Hz). 
13C NMR (75 MHz, DMSO-d6) δ: 173.5, 158.6, 158.1, 155.9, 79.0, 57.5, 30.6, 28.1, 19.3, 
17.4. 
IR νmax: 3259, 2969, 1658, 1529, 1241, 1158. 
MS (ESI Positive)  m/z 355 [M+23]+ 








Coumpond 233 (150 mg, 0.48 mmol) and HCl•NH2CH3 (37 mg, 0.53 mmol, 1.1 equiv) were 
dissolved in acetonitrile (9 mL), and triethylamine (475 µL, 3.4 mmol, 6 equiv) was 
successively added to the reaction mixture. The reaction was stirred, under argon 
atmosphere, for 3 days at r.t.. The resulting precipitate was filtered and washed successively 
with EtOAc, methanol, and ether, to give product 248 as a white solid (84 mg, 70%). 
Mp:  232-234 ºC 
1H NMR (300 MHz, DMSO-d6) δ: 8.54 (br s, 1H), 8.05 (br s, 2H), 7.61 (s, 1H), 6.07 (br s, 1H), 
2.56 (d, 3H, J=4.5 Hz), 1.40 (s, 9H). 
13C NMR (75 MHz, DMSO-d6) δ: 159.1, 158.4, 155.9, 79.0, 28.1, 26.1. 
IR νmax: 3272, 3106, 2936, 1665, 1474, 1159. 
MS (ESI Positive)  m/z 270 [M+23]+ 
Anal. Calcd for C 8H17N5O4: C 38.86, H 6.93, N 28.32; found C 38.89, H 6.76, N 27.97. 
 
 
tert-Butyl 2-(2-(3-methoxy-3-oxopropylcarbamoyl)hydrazi necarbonyl) 
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Compound 233 (400 mg, 1.3 mmol) and HCl•H-β-Ala-OCH3 (198 mg, 1.4 mmol, 1.1 equiv) 
were dissolved in acetonitrile (25 mL), and triethylamine (1.1 mL, 7.7 mmol, 6 equiv) was 
successively added to the reaction mixture. The reaction was stirred, under argon 
atmosphere, for 3 days at r.t.. The solvent was evaporated under reduced pressure and the 
resulting crude residue was triturated with EtOAc. The solid was filtered and washed 
successively with EtOAc, methanol, and ether, to afford product 240 as a white solid (274 
mg, 67%). 
Mp:  122-124 ºC 
1H NMR (300 MHz, DMSO-d6) δ: 8.54 (s, 1H), 8.05 (br s, 2H), 7.68 (s, 1H), 6.20 (br, 1H), 
3.61 (s, 3H), 3.25 (dt, 2H, J1=11.7 Hz, J2=5.7 Hz), 2.45 (t, 2H, J=5.7 Hz), 1.40 (s, 9H). 
13C NMR (75 MHz, DMSO-d6) δ: 172.0, 158.4, 155.9, 79.0, 51.3, 35.2, 34.3, 28.1. 
IR νmax: 3270, 3106, 2936, 1666, 1542, 1161. 
MS (ESI Positive) m/z 342 [M+23]+ 




SYNTHESIS  OF  THE  MOLECULAR  TONGS: 
 




To a solution of 2,7-dihydroxynaphthalene (5.00 g, 30 mmol) and K2CO3 (6.50 g, 47 mmol, 
1.5 equiv) in dry DMF (50 mL) was added, dropwise, ethyl 4-bromobutyrate (4 mL, 27 mmol, 
0.9 equiv) and the reaction mixture was stirred for 24 h at r.t.. The solvent was evaporated 
under reduced pressure and the resulting residue was dissolved in CH2Cl2. The organic layer 
was washed with H2O (5 × 30 mL), dried over Na2SO4, and concentrated in vacuo. The 
resulting crude residue was purified by chromathography on silica gel (petroleum 
ether/EtOAc, 4/1) to afford 242 as white needles (2.80 g, 36%). 
Mp:  91-93 °C  (Lit. 91-93 °C) 18 
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1H NMR (200 MHz, CDCl3) δ: 7.6 (d, 2H, J=8.8 Hz, 2H), 6.9-7.0 (m, 4H), 5.5 (br s, 1H), 4.0-
4.2 (m, 4H), 2.5 (t, 2H, J=7.0 Hz), 2.1 (m, 2H), 1.2 (t, 3H, J=7.1 Hz).  
13C NMR (50 MHz, CDCl3) δ: 174.4, 157.2, 136.3, 129.3, 123.4, 116.2, 115.5, 108.4, 105.8, 
66.7, 60.2, 30.5, 24.6, 14.4. 
IR νmax: 3292, 1699. 
 
 








To a solution of 242 (6.5 g, 24 mmol) and K2CO3 (4.1 g, 29 mmol) in dry CH3CN (70 mL) was 
added benzyl bromide (3.5 mL, 29 mmol, 1 equiv) and the reaction mixture was stirred for 3 
h at reflux and for 24 h at r.t.. The resulting suspension was filtered and the filtrate was 
concentrated under reduced pressure. The resulting residue was dissolved in CH2Cl2 (70 
mL), and the organic layer was washed with H2O (3 × 10 mL), dried over Na2SO4, filtered, 
and concentrated under reduced pressure. The crude product was purified by 
chromatography on silica gel (petroleum ether/EtOAc, 9/1) to give 243 as white crystals (4.98 
g, 60%). 
Mp:  84-85 °C  (Lit. 84-85 ºC) 18 
1H NMR (200 MHz, CDCl3) δ: 69-7.7 (m, 11H), 5.1 (s, 2H), 4.0-4.2 (m, 4H), 2.5 (t, 2H, J=7.2 
Hz), 2.1 (m, 2H), 1.3 (t, 3H, J=7.0 Hz).  
13C NMR (50 MHz, CDCl3) δ: 174.4, 157.2, 136.3, 129.3, 128.0, 123.4, 116.2, 115.5, 108.4, 
105.8, 69.5, 66.7, 60.2, 30.5, 24.6, 14.4.  
IR νmax: 1732,
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A suspension of 243 (0.9 g, 2.5 mmol) in a 10% KOH methanolic solution (25 mL) was stirred 
at reflux for 4 h. The solvent was evaporated and the resulting residue was suspended in 
H2O (10 mL) and the aqueous layer was acidified with HCl 1 N, extracted with CH2Cl2 (2×) 
and the organic layers were dried over MgSO4 and concentrated undewr reduced pressure. 
The crude product was then recrystallized from EtOAc/petroleum ether (85/15) to give 244 as 
white crystals (0.76 g, 92%). 
Mp:  132-134 °C (Lit. 132-134 ºC) 18 
1H NMR (300 MHz, DMSO-d6) δ: 12.19 (s, 1H), 7.73 (dd, 2H, J1=8.9 Hz, J2=3.6 Hz), 7.27-
7.56(m, 6H), 7.20 (d, 1H, J=2.2 Hz), 7.02 (ddd, J1=8.9 Hz, J2=2.4 Hz), 5.2 (s, 2H), 4.08 (t, 
2H, J=6.4 Hz), 2.43 (t, 2H, J=7.3 Hz), 2.01 (qt, 2H, J= 6.8 Hz). 
13C NMR (75 MHz, DMSO-d6) δ: 174.6, 157.4, 157.2, 137.5, 136.1, 129.5, 128.9, 128.2, 
124.3, 116.5, 107.2, 106.7, 69.9, 67.0, 30.6, 24.7. 





















To a solution of 244 (1.24 g, 3.7 mmol), HBTU (1.53 g, 4.0 mmol, 1.1 equiv), and 
triethylamine (0.6 mL, 4.0 mmol, 1.1 equiv) in dry DMF (25 mL) was added H-VLV-OMe 
(1.26 g, 3.7 mmol, 1 equiv) and 0.5 mL of triethylamine and the mixture was stirred for 24 h 
at r.t.. DMF was evaporated under reduced pressure and the resulting residue was dissolved 
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in CH2Cl2, and the organic layer was washed sucessively with: HCl 1 N (30 mL), NaOH 1 N 
(30 mL), and H2O, dried over MgSO4 and evaporated under reduced pressure. The crude 
product was finally recrystallized from EtOAc/MeOH, to afford 245 as a white powder (2.7 g, 
90%). 
Mp:  215-217 ºC 
1H NMR (300 MHz, DMSO-d6) δ: 7.95 (m, 3H), 7.73 (dd, 2H, J1=8.9 Hz, J2=4.0 Hz), 7.32-
7.54 (m, 5H), 7.30 (d, 1H, J=2.4 Hz), 7.17 (d, 1H, J=2.3 Hz), 7.05 (dd, 1H, J1=8.9 Hz, J1=2.5 
Hz), 6.98 (dd, 1H, J1=8.9 Hz, J1=2.5 Hz), 5.20 (s, 2H), 4.35-4.43 (q, 1H, J=7.8 Hz), 4.11-4.23 
(m, 2H), 4.06 (t, 2H, J=6.6 Hz), 3.60 (s, 3H), 2.37 (t, 2H, J=6.9 Hz), 1.92-1.99 (m, 4H), 1.52-
1.69 (m, 1H), 1.45 (t, 2H, J=7.3 Hz), 0.71-0.97 (m, 18). 
13C NMR (75 MHz, DMSO-d6) δ: 172.7, 172.2, 171.4, 157.5, 157.2, 137.5, 136.1, 129.5, 
129.4, 128.9, 128.3, 128.2, 124.3, 116.6, 116.4, 107.2, 106.6, 69.7, 67.4, 58.3, 57.7, 52.1, 
51.3, 41.2, 32.0, 30.7, 30.3, 25.5, 24.5, 23.4, 22.1, 19.6, 19.3, 18.7, 18.6. 
 
 




To a solution of 245 (535 mg, 0.81 mmol) in methanol/DMF (30 mL/40 mL) was added Pd/C 
(80 mg, 20% weight). The reaction flask was flushed three times with hydrogen, and the 
reaction was stirred, under hydrogen atmosphere, for 24 h at r.t.. The mixture was filtered 
through a pad of celite, and the cake was thoroughly washed with methanol (200 mL). The 
filtrate was evaporated under reduced pressure to afford product 246 as a white solid (462 
mg, 100%). The product was used without any further purification in the course of the 
synthesis. 
1H NMR (300 MHz, DMSO-d6) δ: 9.61 (s, 1H), 7.96 (m, 3H), 7.64 (dd, 2H, J1=8.9 Hz, J2=2.7 
Hz), 7.02 (dd, 2H, J1=12.7 Hz, J2=2.1 Hz), 6.88 (dd, 2H, J1=8.8 Hz, J2=2.3 Hz), 4.39 (m, 1H), 
4.16 (m, 2H), 4.03 (t, 2H, J=6.4 Hz), 3.61 (s, 3H), 2.36 (m, 2H), 2.00 (m, 4H), 1.60 (s, 1H), 
1.44 (t, 2H, J=7.1 Hz), 0.7-0.8 (m, 18H). 
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13C NMR (75 MHz, DMSO-d6) δ: 172.7, 172.2, 171.4, 157.3, 156.2, 136.5, 129.4, 123.4, 
116.3, 115.7, 108.5, 105.7, 67.3, 58.2, 57.7, 52.1, 51.3, 41.2, 32.0, 30.7, 30.3, 25.51 (C12), 
24.5, 23.4, 22.1, 19.6, 19.3, 18.7, 18.6. 
IR νmax: 3279, 2957, 1740, 1634, 1542, 1207. 
 
 




To a solution of 4-bromo butyric acid (5.0 g, 30 mmol, 1 equiv) in dry THF (35 mL) was 
added, dropwise, oxalyl chloride and dry DMF (6 drops). The reaction mixture was stirred at 
0 °C for 2 h. The solvent was evaporated and a solu tion of benzyl alcohol (4.6 mL, 45 mmol, 
1.5 equiv) and triethylamine (8.5 mL, 60 mmol, 2 equiv) in CH2Cl2 (45 mL) was added. The 
resulting mixture was then stirred at 0 °C for 8 h.  The solution color was changed from yellow 
to orange. The mixture was washed with H2O (2 × 300 mL) and brine (2 x 50 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. The resulting residue was purified 
by chromatography on silica gel (CH2Cl2/cyclohexane, 70/30), to give the desired compound 
as a colorless oil (6 g, 78%). 
1H NMR (200 MHz, CDCl3) δ: 7.26-7.36 (m, 5H), 5.2 (s, 2H), 3.46 (t, 2H, J=6.4 Hz), 2.6 (t, 
2H, J=7.1 Hz), 2.2 (m, 2H). 
13C NMR (50 MHz, CDCl3) δ: 172.2, 135.8, 128.1, 128.5, 66.2, 32.4-32.5, 27.6. 
IR νmax: 1735. 
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A solution of 246 (900 mg, 1.6 mmol), K2CO3 (391 mg, 2.8 mmol, 1.8 equiv) and benzyl 4-
bromobutyrate (645 mg, 2.5 mmol, 1.6 equiv) in anhydrous DMF (100 mL) was stirred for 24 
h at 50 °C. The solvent was evaporated under reduce d pressure and the resulting residue 
was dissolved in EtOAc (200 mL). The organic layer was washed with H2O (100 mL), HCl 2 
M (70 mL), H2O (50 mL), brine (50 mL), dried over MgSO4, filtered, and concentrated under 
reduced pressure. The crude product was purified by chromatography on silica gel 
(EtOAc/cyclohexane, 6/4) to yield compound 247 as a white solid (950 mg, 81%). 
Mp: 153-154 °C 
1H NMR (300 MHz, DMSO-d6) δ: 7.96 (m, 3H), 7.70 (d, 2H, J=8.5 Hz), 7.34 (m, 5H), 7.17 (br 
s, 2H), 6.93-6.99 (m, 2H), 5.12 (s, 2H), 4.36-4.42 (m, 1H), 4.05-4.20 (m, 6H), 3.60 (s, 3H), 
2.58 (t, 2H, J=7.3 Hz), 2.37 (t, 2H, J=7.3 Hz), 1.94-2.01 (m, 6H), 1.60 (m, 1H), 1.43 (m, 2H), 
0.84 (m, 18H). 
13C NMR (75 MHz, DMSO-d6) δ: 172.9, 172.7, 172.2, 171.4, 157.4, 157.3, 136.6, 136.7, 
129.4, 128.9, 128.4, 124.2, 116.4, 116.3, 106.6, 67.4, 66.9, 66.0, 58.2, 57.7, 52.1, 51.3, 41.2, 
32.0, 30.7, 30.3, 25.5, 24.7, 24.5, 23.4, 22.1, 19.7, 19.3, 18.7, 18.6.  
IR νmax: 3281, 2955, 1744, 1633, 1541, 1209. 
 
 



















To a solution of 247 (929 mg, 1.2 mmol) in DMF (50 mL) was added Pd/C (140 mg, 15% 
weight). The reaction flask was flushed three times with hydrogen, and the reaction was 
stirred, under hydrogen atmosphere, for 24 h at r.t.. The mixture was filtered through a pad of 
Celite, and the cake was thoroughly washed with methanol (200 mL). The filtrate was 
evaporated under reduced pressure to afford product 248 as a white solid (462 mg, 
quantitative yield), which was used without any further purification in the course of the 
synthesis. 
Mp:  192-194°C 
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1H NMR (300 MHz, DMSO-d6) δ: 8.02 (m, 3H), 7.72 (d, 2H, J=8.8 Hz), 7.20 (br s, 2H), 6.98 
(d, 2H, J=8.9 Hz), 4.36-4.42 (m, 1H), 4.01-4.24 (m, 6H), 3.62 (s, 3H), 2.30-2.47 (m, 4H), 
1.88-2.12 (m, 6H), 1.62 (m, 1H), 1.46 (m, 2H), 0.86 (m, 18H).  
13C NMR (75 MHz, DMSO-d6) δ: 172.9, 172.7, 172.2, 171.4, 157.4, 157.3, 136.6, 136.2, 
129.4, 128.9, 128.4, 128.2, 124.2, 116.4, 116.3, 106.6, 67.4, 66.9, 58.2, 57.7, 52.1, 51.3, 









Compound 236 (128 mg, 0.38 mmol) was deprotected according to general procedure B. 
The corresponding trifluoroacetate salt 237 and compound 248 (230 mg, 0.35 mmol) were 
dissolved in DMF. DIPEA (207 µL, 1.2 mmol, 3.5 equiv), HBTU (159 mg, 0.42 mmol, 1.2 
equiv), and HOBt (52 mg, 0.38 mmol, 1.1 equiv) were successively added to the reaction 
mixture that was then stirred, under argon atmosphere, for 24 h at r.t.. The solvent was 
evaporated under reduced pressure to afford a beige oil. Trituration in EtOAc yielded a beige 
solid that was filtered and washed successively with EtOAc, CH2Cl2, distilled H2O, CH3OH, 
and ether. Product 249 was obtained as a white powder (150 mg, 49%). 
Mp:  218-220 ºC 
1H NMR (400 MHz, DMSO-d6) δ: 9.63 (s, 1H), 8.20 (br s, 2H), 7.92-7.97 (m, 3H), 7.78 (s, 
1H), 7.71 (d, 2H, J=9.3 Hz), 7.32 (br s, 1H), 7.17 (s, 2H), 7.05 (s, 1H), 6.98 (br s, 2H), 6.09 
(d, 1H, J=7.2 Hz), 4.36-4.40 (m, 1H), 3.99-4.17 (m, 7H), 3.60 (s, 3H), 2.33-2.37 (m, 4H), 
1.98-2.03 (m, 7H), 1.60 (br, 1H), 1.44 (br, 2H), 0.81-0.85 (m, 24H). 
13C NMR (100 MHz, DMSO-d6) δ: 173.5, 172.2, 171.7, 170.9, 158.3, 158.1, 157.0, 135.7, 
129.0, 123.7, 115.9, 106.2, 66.9, 66.8, 57.8, 57.6, 57.3, 51.6, 50.8, 40.8, 31.6, 30.7, 30.3, 
29.9, 29.7, 25.1, 24.4, 24.1, 23.0, 21.6, 19.3, 19.2, 18.8, 18.2, 18.1, 17.4. 
IR νmax: 3278, 2963, 1632, 1545, 1210. 
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MS (ESI Positive)  m/z 895 [M+23]+, 911 [M+39]+ 








To a solution of 2,7-dihydroxynaphthalene (1.5 g, 9.37 mmol) and potassium carbonate (3.24 
g, 23 mmol, 2.5 equiv) in DMF (60 mL) was slowly added ethyl 4-bromobutyrate (4.0 mL, 28 
mmol, 3 equiv), and the reaction mixture was stirred for 12 h at r.t.. The solvent and volatiles 
were evaporated and the resulting residue was dissolved in CH2Cl2 (100 mL). The organic 
layer was washed with H2O (2 × 50 mL), dried over MgSO4, and the solvent was evaporated. 
The crude product was purified by chromatography on silica gel (cyclohexane/EtOAc, 70/30) 
giving rise to 250 as a white oil (3.15 g, 87%). 
1H NMR (300 MHz, CDCl3) δ: 7.66 (d, 2H, J=8.8 Hz), 6.88-7.11 (m, 4H), 3.98-4.32 (m, 8H), 
2.58 (t, 4H, J=7.3 Hz), 2.10-2.29 (m, 4H), 1.25-1.30 (dt, 6H, J=7.1 Hz). 
13C NMR (75 MHz, CDCl3) δ: 173.6, 157.3, 135.8, 129.0, 124.3, 116.1, 106.0, 66.6, 60.4, 
51.6, 30.8, 24.6. 
IR νmax: 2965, 1729, 1627, 1177. 
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 A solution of ethanol (50 mL) containing 250 (2.76 g, 7.1 mmol) and 10% aqueous KOH (50 
mL) was stirred at reflux for 4 h. The solution was then poured in ice and extracted with 
CH2Cl2 (2 × 50 mL). The aqueous layer was acidified with 10% aqueous HCl and the 
resulting precipitate was filtered and washed with H2O to afford product 251 as a white solid 
(2.29 g, 97%). 
Mp:  158-159°C (Lit. 144 °C) 16 
1H NMR (300 MHz, CDCl3) δ: 7.75 (d, 2H, J=7.0 Hz), 7.25 (d, 2H, J=1.3 Hz), 7.00 (dd, 2H, 
J1=7.0 Hz, J2=7.0 Hz), 4.10 (t, 4H, J=7.0 Hz), 2.50 (t, 4H, J=7.0 Hz), 2.00 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ: 174.1, 157.0 1, 136.0, 129.0, 123.8, 116.1, 106.2, 66.4, 30.2, 
24.2.  
IR νmax: 3209, 1712, 1629, 1209. 
 
 




Compound 236 (301 mg, 0.91 mmol) was deprotected according to general procedure A. 
The corresponding trifluoroacetate salt 237 and compound 251 (137 mg, 0.41 mmol) were 
dissolved in DMF. DIPEA (486 µL, 2.9 mmol, 7 equiv), HBTU (391 mg, 1.0 mmol, 2.5 equiv), 
and HOBt (123 mg, 0.91 mmol, 2.2 equiv) were successively added to the reaction mixture 
that was then stirred, under argon atmosphere, for 48 h at r.t.. The solvent was evaporated 
under reduced pressure to afford a beige oil. Trituration in EtOAc yielded a beige solid that 
was filtered and washed successively with EtOAc, CH2Cl2, H2O, CH3OH, and ether. Product 
252 was obtained as a white powder (174 mg, 56%). 
Mp:  181-185 ºC 
1H NMR (400 MHz, DMSO-d6) δ: 9.63 (s, 2H), 8.20 (br s, 4H), 7.77 (s, 2H), 7.71 (d, 2H, 
J=8.8 Hz), 7.32 (br s, 2H), 7.18 (s, 2H), 7.05 (s, 2H), 6.97 (d, 2H, J=7.6 Hz), 6.08 (d, 2H, 
J=8.4 Hz), 3.97-4.08 (m, 6H), 2.31-2.34 (m, 4H), 1.91-2.03 (m, 6H), 0.85 (d, 6H, J=6.7 Hz), 
0.82 (d, 6H, J=6.7 Hz). 
13C NMR (100 MHz, DMSO-d6) δ: 173.5, 171.8, 158.3, 158.1, 157.0, 135.7, 129.0, 123.7, 
115.9, 106.2, 66.7, 57.6, 30.7, 29.6, 24.4, 19.3, 17.4. 
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IR νmax: 3252, 2967, 1657, 1516, 1211. 
MS (ESI Positive)  m/z 783 [M+23]+, 799 [M+39]+ 








Compound 238 (157 mg, 0.64 mmol) was deprotected according to general procedure A. 
The corresponding trifluoroacetate salt 239 and compound 251 (101 mg, 0.30 mmol) were 
dissolved in DMF. DIPEA (358 µL, 2.1 mmol, 7 equiv), HBTU (287 mg, 0.76 mmol, 2.5 
equiv), and HOBt (90 mg, 0.67 mmol, 2.2 equiv) were successively added to the reaction 
mixture that was then stirred, under argon atmosphere, for 48 h at r.t.. The solvent was 
evaporated under reduced pressure to afford a pale-pink oil. Trituration in EtOAc yielded a 
white solid that was filtered and washed successively with EtOAc, CH2Cl2, distilled H2O, 
CH3CN, acetone, CH3OH, and ether. Product 253 was obtained as a white powder (98 mg, 
55%). 
Mp:  206-210 ºC 
1H NMR (400 MHz, DMSO-d6) δ: 9.59 (s, 2H), 8.14 (br s, 4H), 7.63-7.72 (m, 4H), 7.19 (s, 
2H), 6.96 (s, 2H), 6.09 (br, 2H), 4.08 (br, 4H), 2.57 (s, 6H), 2.33-2.42 (m, 4H), 2.01 (br, 4H). 
13C NMR (100 MHz DMSO-d6) δ: 174.1, 159.2, 158.1, 156.9, 135.7, 128.9, 123.7, 115.9, 
106.1, 66.6, 29.7, 26.2, 24.2. 
IR νmax: 3280, 2947, 1664, 1515, 1210. 







CHAPTER IV              EXPERIMENTAL PART 
 205 




Compound 240 (218 mg, 0.68 mmol) was deprotected according to general procedure A. 
The corresponding trifluoroacetate salt 241 and compound 251 (101 mg, 0.30 mmol) were 
dissolved in DMF. DIPEA (384 µL, 2.3 mmol, 7 equiv), HBTU (308 mg, 0.81 mmol, 2.5 
equiv), and HOBt (97 mg, 0.72 mmol, 2.2 equiv) were successively added to the reaction 
mixture that was then stirred, under argon atmosphere, for 48 h at r.t.. The solvent was 
evaporated under reduced pressure to afford a pale-yellow oil. Trituration in EtOAc yielded a 
pale-grey solid that was filtered and washed successively with EtOAc, CH2Cl2, distilled H2O, 
CH3CN, acetone, CH3OH, and ether. Product 254 was obtained as a pale-grey powder (174 
mg, 73%). 
Mp:  177-187 ºC 
1H NMR (400 MHz, DMSO-d6) δ: 9.60 (s, 2H), 8.14 (br s, 4H), 7.70-7.72 (m, 4H), 7.19 (s, 
2H), 6.97 (d, 2H, J=8.4 Hz), 6.23 (br, 2H), 4.08 (br, 4H), 2.59 (s, 6H), 3.22-3.28 (m, 4H), 
2.43-2.47 (m, 4H), 2.32 (t, 4H, J=7.1 Hz), 2.02 (br, 4H). 
13C NMR (100 MHz, DMSO-d6) δ: 171.9, 158.5, 158.1, 157.0, 135.7, 129.0, 123.7, 115.9, 
106.2, 66.8, 51.3, 35.3, 34.3, 29.7, 24.5. 
IR νmax: 3304, 2947, 1663, 1552, 1208. 
MS (ESI Positive)  m/z 757 [M+23]+ 
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4-(7-(3-Carboxy-propoxy)-3-[(2,2-dimethyl-[1,3]diox olan-4-ylmethyl)-amino]-naphthalen 




To a solution of 216 (282 mg, 0.44 mmol) in CH3OH/EtOAc (20 mL/20 mL) was added Pd/C 
(56 mg, 20% weight). The reaction flask was flushed three times with hydrogen, and the 
reaction was stirred, under hydrogen atmosphere, for 24 h at r.t.. The mixture was filtered 
through a pad of celite, and the cake was thoroughly washed with methanol (200 mL). The 
filtrate was evaporated under reduced pressure to afford product 255 as a beige solid (201 
mg, 99%). 
Mp:  90-92 ºC 
1H NMR (300 MHz, CD3OD) δ: 7.46 (d, 1H, J=9.0 Hz), 7.03 (d, 1H, J=2.1 Hz), 7.02 (s, 1H), 
6.89 (dd, 1H, J1=8.7 Hz, J2=2.4 Hz), 6.79 (s, 1H), 4.45 (qt, 1H, J=5.4 Hz), 4.03-4.17 (m, 5H), 
3.84 (dd, 1H, J1=12.7 Hz, J2=6.2 H), 3.23-3.36 (m, 2H), 2.48-2.53 (m, 4H), 2.16 (qt, 2H, 
J=6.6 Hz), 2.08 (qt, 2H, J=6.6 Hz), 1.46 (s, 3H), 1.36 (s, 3H). 
13C NMR (75 MHz, CD3OD) δ: 175.8, 154.4, 147.8, 136.5, 128.3, 126.3, 125.2, 115.4, 109.0, 
106.4, 104.5, 103.8, 74.2, 66.9, 66.7, 66.5, 45.5, 30.3, 25.7, 24.5, 24.3, 24.0. 
IR νmax: 2918, 1703, 1248. 
MS (APCI Positive)  m/z 462 [M+1]+ 




















Compound 228 (312 mg, 0.72 mmol) was deprotected according to general procedure A. 
The corresponding trifluoroacetate salt 229 and 255 (150 mg, 0.33 mmol) were dissolved in 
DMF. DIPEA (384 µL, 2.3 mmol, 7 equiv), HBTU (308 mg, 0.81 mmol, 2.5 equiv), and HOBt 
(97 mg, 0.72 mmol, 2.2 equiv) were successively added to the reaction mixture that was then 
stirred, under argon atmosphere, for 48 h at r.t.. The solvent was evaporated under reduced 
pressure to afford an orange oil. Trituration in EtOAc yielded a orange solid that was filtered 
and washed successively with EtOAc, CH2Cl2, CH3OH, and ether. Product 256 was obtained 
as a orange powder (174 mg, 50%). 
Mp:  188-194 ºC 
1H NMR (400 MHz, DMSO-d6) δ: 10.33 (s, 1H), 10.32 (s, 1H), 9.93 (s, 4H), 7.94-8.00 (m, 
4H), 7.75 (d, 2H, J=8.7 Hz), 7.48 (d, 1H, J=9.0 Hz), 7.09 (d, 2H, J=9.0 Hz), 7.06 (s, 2H), 6.88 
(dd, 1H, J1=8.8 Hz, J2=1.7 Hz), 6.77 (s, 1H), 5.03 (t, 1H, J=5.0 Hz), 4.31-4.41 (m, 3H), 3.97-
4.08 (m, 5H), 3.84 (s, 6H), 3.75-3.79 (m, 1H), 3.28 (br, 2H), 2.33-2.44 (m, 4H), 2.02 (s, 6H), 
1.97 (br, 6H), 1.39 (s, 3H), 1.29 (s, 3H), 0.95 (d, 6H, J=6.4 Hz), 0.90 (d, 6H, J=6.4 Hz). 
13C NMR (100 MHz, DMSO-d6) δ: 171.6, 169.5, 168.0, 163.3, 153.9, 152.7, 147.6, 136.6, 
132.6, 127.7, 126.5, 124.9, 123.3, 121.3, 121.1, 115.6, 112.4, 106.8, 104.9, 103.1, 73.7, 
67.4, 66.9, 66.8, 56.1, 56.0, 45.6, 31.6, 30.7, 26.7, 25.2, 25.0, 23.8, 19.2, 18.3. 
IR νmax: 3260, 2953, 1604, 1490, 1250. 
MS (ESI Positive)  m/z 1093 [M+23]+ 
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4,4'-(3-(2,3-Dihydroxypropylamino)naphthalene-2,7-d iyl)bis(oxy)bis(N-((S)-1-(2-(5-




Compound 256 (51 mg, 48 µmol) was dissolved in a mixture of 1 M HCl/THF/EtOH (1:1:2, 
v/v/v) that was then stirred for 1 h at 55 ºC. The solvent was evaporated under reduced 
pressure, and the resulting residue was triturated with ether, filtered and washed 
successively with: saturated aqueous NaHCO3, distilled H2O, EtOH, EtOAc, cyclohexane and 
ether. Product 257 was obtained as a orange powder (30 mg, 60%). 
1H NMR (300 MHz,DMSO-d6) δ: 10.33 (s, 2H), 9.94 (s, 4H), 7.93-8.02 (m, 4H), 7.73-7.77 (m, 
2H), 7.47 (d, 1H, J=9.0 Hz), 7.05-7.11 (m, 4H), 6.88-6.92 (m, 1H), 6.73 (s, 1H), 4.31-4.35 (m, 
3H), 3.99-4.09 (m, 5H), 3.84 (s, 6H), 3.81-3.84 (m, 1H), 3.28 (br, 2H), 1.91-2.06 (m, 12H), 
0.95 (d, 6H, J=6.6 Hz), 0.90 (d, 6H, J=6.6 Hz). 
13C NMR (75 MHz, DMSO-d6) δ: 171.7, 169.5, 168.0, 167.9, 163.3, 152.7, 149.1, 137.0, 
135.0, 132.6, 131.6, 128.9, 128.0, 124.8, 123.3, 121.3, 121.2, 114.6, 112.4, 106.8, 103.9, 
103.2, 69.5, 67.3, 66.5, 64.3, 56.1, 53.7, 31.5, 30.7, 30.4, 25.0, 23.8, 19.2, 18.3. 
IR νmax: 3271, 2936, 1641, 1490, 1249. 
MS (ESI Positive)  m/z 1053 [M+23]+, 1069 [M+39]+ 
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Compound 255 (71 mg, 0.15 mmol) and 230 (152 mg, 0.34 mmol, 2.2 equiv) were dissolved 
in DMF. DIPEA (129 µL, 0.77 mmol, 5 equiv), HBTU (145 mg, 0.38 mmol, 2.5 equiv), and 
HOBt (46 mg, 0.34 mmol, 2.2 equiv) were successively added to the reaction mixture that 
was then stirred, under argon atmosphere, for 48 h at r.t.. The solvent was evaporated under 
reduced pressure and the residue was dissolved in EtOAc (200 mL). The organic layer was 
washed with H2O (100 mL), 10% aqueous citric acid (50 mL), 10% aqueous K2CO3 (50 mL), 
H2O (100 mL), dried over Na2SO4 and concentrated under reduced pressure. The crude 
residue was then purified by flash chromatography on silica gel (CH2Cl2/CH3OH, 90/10) to 
afford product 258 as a light pink powder (119 mg, 59%). 
Mp:  160-170 ºC 
1H NMR (400 MHz, CDCl3) δ: 11.99 (br s, 2H), 11.34 (s, 2H), 8.93 (s, 2H), 8.43 (s, 2H), 7.97 
(s, 1H), 7.95 (s, 1H), 7.42 (d, 1H, J=8.3 Hz), 6.82-7.00 (m, 5H), 6.70 (s, 1H), 5.89 (br s, 1H), 
5.63-5.70 (m, 3H), 4.92 (br, 2H), 4.45 (br, 1H), 3.81-4.13 (m, 12H), 3.28-3.48 (m, 3H), 3.03-
3.10 (m, 4H), 2.04-2.28 (m, 14H), 1.62-1.79 (m, 4H), 1.19-1.46 (m, 32H). 
13C NMR (100 MHz, CDCl3) δ: 172.1, 172.0, 169.2, 169.1, 166.3, 155.6, 154.6, 153.6, 148.0, 
136.3, 133.2, 128.4, 126.9, 126.2, 126.1, 125.1, 122.6, 117.8, 116.0, 112.1, 109.5, 107.0, 
105.4, 104.4, 79.8, 74.2, 74.1, 67.2, 67.1, 66.7, 56.6, 52.1, 46.5, 39.3, 34.2, 32.8, 32.6, 29.7, 
29.3, 28.4, 26.9, 25.2, 25.1, 24.9, 24.6, 22.2. 
IR νmax: 3309, 2926, 1643, 1492, 1248. 
MS (ESI Positive)  m/z 1351 [M+23]+ 
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Compound 258 (23 mg, 17 µmol) was dissolved in methanol (1.5 mL) and p-TsOH•H2O (5.5 
mg, 29 µmol, 1.7 equiv) was added. The mixture was then stirred for 3 h at 50 ºC. The 
solvent was evaporated under reduced pressure, and the resulting crude residue was 
purified by flash chromatography on silica gel (CH2Cl2/CH3OH, 80/20) to afford product 259 
as a light pink powder (6 mg, 30%). 
MS (ESI Positive)  m/z 1289 [M+1]+ 
 
 




To a solution of 219 (156 mg, 0.30 mmol) in CH3OH/EtOAc (5 mL/5 mL) was added Pd/C (31 
mg, 20% weight). The reaction flask was flushed three times with hydrogen, and the reaction 
was stirred, under hydrogen atmosphere, for 24 h at r.t.. The mixture was filtered through a 
pad of celite, and the cake was thoroughly washed with methanol (200 mL). The filtrate was 
evaporated under reduced pressure to afford product 260 as a light-pink solid (102 mg, 
99%). 
Mp:  144-146 ºC 
1H NMR (300 MHz, CD3OD) δ: 7.40 (d, 1H, J=9.0 Hz), 7.04 (s, 2H), 7.00 (s, 1H), 6.88 (dd, 
1H, J1=8.7 Hz, J2=2.1 Hz), 4.03-4.17 (m, 5H), 2.48-2.57 (m, 4H), 2.17 (qt, 2H, J=6.6 Hz), 
2.08 (qt, 2H, J=6.5 Hz), 1.23 (br s, 2H). 
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13C NMR (75 MHz, CD3OD) δ: 177.3, 177.2, 156.4, 150.1, 136.1, 131.2, 127.8, 126.6, 117.2, 
111.3, 107.8, 106.6, 68.5, 68.1, 31.9, 31.6, 26.0, 25.9. 
IR νmax: 2923, 1714, 1253. 








Compound 228 (275 mg, 0.65 mmol) was deprotected according to general procedure A. 
The corresponding trifluoroacetate salt 229 and compound 260 (103 mg, 0.30 mmol) were 
dissolved in DMF. DIPEA (394 µL, 2.1 mmol, 7 equiv), HBTU (281 mg, 0.74 mmol, 2.5 
equiv), and HOBt (88 mg, 0.65 mmol, 2.2 equiv) were successively added to the reaction 
mixture that was then stirred, under argon atmosphere, for 48 h at r.t.. The solvent was 
evaporated under reduced pressure to afford an orange oil. Trituration in EtOAc yielded a 
orange solid that was filtered and washed successively with EtOAc, CH2Cl2, CH3OH, and 
ether. Product 261 was obtained as a brick colour powder (192 mg, 68%). 
Mp:  208-214 ºC 
1H NMR (400 MHz, DMSO-d6) δ: 10.31 (s, 2H), 9.92 (s, 4H), 7.92-8.01 (m, 4H), 7.75 (d, 2H, 
J=7.2 Hz), 7.38 (d, 1H, J=8.3 Hz), 7.09 (d, 2H, J=8.1 Hz), 7.03 (s, 2H), 6.86 (s, 2H), 4.94 (br 
s, 2H), 4.33 (d, 2H, J=6.7 Hz), 3.96-4.08 (m, 4H), 3.84 (s, 6H), 2.37-2.42 (m, 4H), 2.01 (br, 
12H), 0.95 (s, 6H), 0.90 (s, 6H). 
13C NMR (100 MHz, DMSO-d6) δ: 171.8, 171.7, 169.5, 168.0, 163.3, 157.3, 152.6, 148.0, 
136.3, 132.6, 128.0, 126.0, 124.8, 123.3, 121.3, 121.1, 115.6, 112.4, 107.0, 106.7, 105.1, 
67.1, 66.9, 56.1, 56.0, 31.7, 31.6, 30.8, 30.7, 25.1, 23.8, 19.2, 18.3. 
IR νmax: 3258, 1607, 1491, 1250. 
MS (ESI Positive)  m/z 979 [M+23]+ 
Anal. Calcd for C 48H61N9O12•2.5 H2O: C 57.58, H 6.66, N 12.60; found C 57.94, H 6.32, N 
12.26. 
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Figure I. COSY  spectra of compound 92 (concentration 5 mM) in CDCl3 at 25 °C. 























Figure II. NOESY spectra of compound 92 (concentration 5 mM) in CDCl3 at 25 °C, d8 = 800 ms. 
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Figure V. 1H-NMR spectra of compound 93 (concentration 2 mM) in CDCl3 at 25 °C. 
 






















Figure VI. COSY spectra of compound 93 (concentration 2 mM) in CDCl3 at 25 °C. 
 
 






















Figure VII. NOESY spectra of compound 93 (concentration 2 mM) in CDCl3 at 25 °C, d8 = 800 ms. 







































y = -0,0053x + 8,8951
R2 = 0,9696
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NH1 7.81 -7.6 8.21 -4.6 -0.07 300 
NH2 7.03 -8.2 7.21 -5.3 0.53 160 
NH3 6.28 -9.1 6.61 -15.5 1.25 < 10 
NH4 8.10 -4.1 8.18 -2.7 0.03 960 
NH5 5.41 -1.8 6.40 -2.3 ≥ 0.7 -g 
 
a) Concentration 0.5 mM in CDCl3; b) Concentration 2.0 mM in CDCl3; c) at 298 K; d) determined 
between 238 and 288 K; e) measured in CDCl3/CH3OH 4/1; f) measured in CDCl3/CD3OD 4/1; g) not 
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Figure X. COSY spectra of compound 94 (concentration 2 mM) in CDCl3 at 25 °C. 





















Figure XI. NOESY spectra of compound 94 (concentration 2 mM) in CDCl3 at 25 °C, d8 = 800 ms. 
NOESY data collected with a noesytp pulse program with 1024 data points in F2 and 256 data points in 
F2. 
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y = -0,0143x + 11,496
R2 = 0,9951













































δa,b ( ppm) ∆δ/∆T a,c (ppb/K) 
NH1 6.47 -2.5 
NH2 7.71 -8.3 
NH3 7.21 -14.3 
NH4 7.14 -16.0 
NH5 7.77 -6.8 
NH6 5.27 -4.8 
  
a) Concentration 2.0 mM in CDCl3; b) at 298 K; c) determined  
between 258 and 298 K. 
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Figure XIV. 1H-NMR spectra of compound 95 (concentration 2 mM) in 5% CD3OH-CDCl3 at 25 °C. 













































































Figure XVII. ROESY spectra of compound 95 (concentration 2 mM) in DMSO-d6 at 25 °C, p15 = 400 
ms. ROESY data collected with a roesytp pulse program with 1024 data points in F2 and 256 data 




























Figure XVIII. ROESY spectra of compound 95 (concentration 2 mM) in 5% CD3OH-CDCl3 at 25 °C, p15 
= 400 ms. ROESY data collected with a roesytp pulse program with 4096 data points in F2 and 256 
data points in F2. 
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Figure XX. COSY spectra of compound 96 (concentration 2 mM) in DMSO-d6 at 25 °C. 
 























Figure XXI. ROESY spectra of compound 96 (concentration 2 mM) in DMSO-d6 at 25 °C, p15 = 400 
ms. ROESY data collected with a roesytp pulse program with 1024 data points in F2 and 256 data 
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e,f δe,f (ppm) 3JNHCHαe,f 
NH1 6.99 -8.0 5.7 5.6 7.83 5.6 
NH2 8.24 -2.5 7.7 7.4 8.19 7.9 
NH3 7.61 -15.5 8.0 8.1 8.29 7.2 
NH4 7.68 -16.5 -g -g 8.28 -g 
NH5 7.97 -1.3 -g -g 8.25 -g 
NH6 7.42 -8.5 8.0 7.8 8.18 7.8 
NH7 5.76 -6.0 6.8 9.1 7.96 8.9 
 
a) Concentration 2.0 mM in 5% CD3OH-CDCl3; b) at 288 K; c) determined between 248 and 288 K; 
d) at 278 K; e) Concentration 2.0 mM in DMSO-d6; f) at 298 K; g) broad signal. 
 
 
 
